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ABSTRACT 
 
 
Tolerance blocks the expression of autoantibodies, whereas autoimmunity 
promotes it.  How tolerance breaks and autoantibody production begins, thus, are crucial 
questions for the understanding and treatment of autoimmune diseases.  Evidence 
implicates cell death and autoantigen modifications in the initiation of autoimmune 
reactions.  One form of neutrophil cell death deserves attention because it occurs as a 
consequence of neutrophil activation, requires the post-translational modification of 
histones and results in the extracellular release of chromatin.  The extracellular chromatin 
incorporates histones in which arginines have been converted to citrullines by 
peptidylarginine deiminase IV (PAD4) creating structures that capture or “trap” bacterial 
pathogens. Neutrophil extracellular traps (NETs), as these structures are known, generate 
an extracellular complex of deiminated histones and bacterial cell adjuvants.  The 
complex of bacterial antigens and deiminated chromatin may be internalized by host 
phagocytes during inflammatory conditions, as arise during bacterial infections or 
chronic autoinflammatory disorders.  The uptake and processing of deiminated chromatin 
together with bacterial adjuvants by phagocytes may induce the presentation of modified 
histone epitopes and co-stimulation, thus yielding a powerful stimulus to break tolerance.   
 
To test the hypothesis that NETs can lead to autoimmunity, we measured 
autoantibodies to deiminated histones in human autoimmune disorders.  We detected 
autoantibodies to deiminated histones in Felty’s syndrome (FS) patients, whereas 
autoantibodies from Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis 
(RA) patients did not distinguish deiminated from non-deiminated histones.  FS 
autoantibodies colocalized with deiminated histone H3 in LPS-treated neutrophils 
suggesting activated neutrophils as the source of autoantigens. In addition, we identified 
and characterized deimination of linker histone H1 and found rare autoantibodies to 
deiminated H1 in SLE and Sjogren’s syndrome patients.  We also studied sera of 
autoimmune lupus prone mice to determine if they would recognize deiminated histones 
and found that deimination represses binding of murine lupus autoantibodies to histones.  
The inability of immunoglobin from sera of lupus mice to recognize deiminated histones 
suggests the presence of effective tolerance to NET components released during innate 
neutrophil response to infections.  Our finding of antibodies to deiminated histones in 
Felty’s syndrome supports the idea that tolerance to deiminated histones is compromised 
only in exceptional circumstances.  Understanding the tolerance mechanism to 
deiminated histones and how they are compromised in patients could be useful to design 
strategies for the prevention and treatment of many autoimmune disorders.  
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CHAPTER 1.    INTRODUCTION 
 
 
Autoimmunity 
 
In 1901 Erhlich coined the term “Horror Autotoxicus” to explain “the 
unwillingness of the organism to endanger itself by formation of toxic autoantibodies”.  
He found that immunizing goats with their own red blood cells (RBCs) did not lead to 
any antibody formation (1).  Erhlich postulated that autoimmune diseases cannot occur 
and lack of immune response against self antigens came to be known as ‘tolerance’.  
However, the first autoimmune disorder was reported in 1904, when Donath and 
Landsteiner demonstrated that toxic autoantibodies destroy self RBCs in Paroxysmal 
Cold Hemoglobinuria (PCH) (2).  For the next 50 years, the study of autoimmune 
diseases progressed slowly until Rose and Roitt nearly simultaneously published separate 
reports on autoimmune thyroiditis.  Rose and Witebsky published evidence for the 
experimental induction of autoimmune thyroiditis in rabbits (3, 4).  About the same time, 
Roitt published a report on thyroid-reacting autoantibodies in Hashimoto’s patients (5).  
Identification of Hashimoto’s thyroiditis as an autoimmune condition led to acceptance to 
the concept of autoimmunity and opened up the search for others.  
 
The acceptance of autoimmunity forced scientists to look at the immune system in 
a new light.  Burnet explained that immune response (antibody production) results after 
engagement and expansion of clones from a cell with a single specificity (Clonal 
Selection) (6) and tried to explain tolerance as a result of “deletion” of self reactive 
clones from the B cell repertoire.  He postulated that autoimmunity results from the 
escape of “forbidden” self reacting clones.  Cloning of B cells of healthy individuals 
revealed that about 76% of early immature B cells express self reactive antibody 
receptors (7).  Self reactivity of B cell receptors (BCR) progressively decreased as B cell 
development progressed.  The first check point against self reactivity was observed 
during the transition of immature B cells to mature B cells as the frequency of self 
reactive antibodies produced falls to about 40% in B cells newly emigrated from the bone 
marrow (7).  Another checkpoint for getting rid of self reacting specificities was found 
during the maturation of newly emigrant B cells to peripheral naïve B cells (7).  In 
patients with SLE, about 25-50% of naïve B cells express self-recognizing BCR in 
contrast to about 5-20% of B cells from healthy individuals (8).  Though these 
observations tried to explain autoimmunity on the basis of escape of self reacting B cells, 
more questions than answers ensued.  What role do self-reactive naïve B cells play in 
healthy individuals?  In what way are these cells different in healthy individuals and 
autoimmune patients?  How are the cells bearing self-reactive receptors kept in check in 
healthy individuals?  It follows that various mechanisms contribute to keep the self-
reactive lymphocytes in a state of non-responsiveness called “anergy”.  Engagement of 
lymphocyte receptors by self-antigens without receiving a second signal (from an 
activated helper T cells or CD80/86 expressed on APC) promotes desensitization of 
receptor for subsequent re-exposure to antigen.  Chronic engagement of BCR with self-
antigen results in low calcium influx and activation of inhibitory signaling that prevents 
activation of B cells (9, 10).  Survival and proliferation of B cells on receptor engagement 
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is dependent on B cell activating factor (BAFF; also known as BLyS) and self-reacting B 
cells have a higher threshold for BAFF signaling and so they are outcompeted by naïve B 
cells for survival in lymphoid follicles (11).  Many more mechanisms for maintaining 
peripheral tolerance have been found (12-14) and force us to think about other 
mechanisms by which autoimmune disorders arise.  What conditions favor the 
engagement and activation of self-reactive B cells leading to the initiation of autoimmune 
diseases?  Presently, we have some knowledge about factors that contribute to 
autoimmunity, yet understanding how autoimmune responses are initiated and 
perpetuated is far from clear. 
 
Owing to the self perpetuating nature of autoimmunity in which the targeted 
antigen cannot be cleared from the body, autoimmune responses are extremely 
destructive.  The autoimmune disorders cause extensive morbidity and can sometimes 
become life threatening.  The chronic morbidity of autoimmune diseases hampers the 
normal lifestyle and productivity of millions of affected people.  In the past hundred 
years, ever since the discovery of the first autoimmune condition, many more disease 
states have been identified that have an autoimmune component.  
 
 
Types of Autoimmune Disorders 
 
Presently, there are around 80 autoimmune diseases known in humans (15).  The 
prevalence of autoimmune disorders is estimated to be about 5% in the world population 
(16, 17).  The current classification of autoimmune disorders is based on the organs 
involved, the type of lesion, the morbidity and also the type of autoimmune process 
involved.  Broadly, autoimmune disorders are grouped into organ-specific or systemic 
autoimmune disorders.  In organ-specific disorders, the autoimmune immune response is 
directed against an antigen that is localized to one particular organ.  The classical 
example of such an organ-specific autoimmune disorder is Hashimoto’s thyroiditis in 
which the thyroid gland gradually becomes dysfunctional.  Autoantibodies against 
thyroid-specific antigens, thyroid peroxidase, thyroglobulin and thyroid stimulating 
hormone (TSH) receptor, are found in patients with Hashimoto’s thyroiditis.  
Autoantibodies mediate the destruction of the thyroid resulting in hypothyroidism.  Other 
organ-specific autoimmune disorders include type 1 Diabetes Mellitus (T1D), Graves’ 
disease and Autoimmune Hemolytic Anemia.  
 
In systemic autoimmunity, the autoimmune response is directed against a target 
antigen that is widespread in its distribution.  Systemic lupus erythematosus (SLE) is a 
prototype of systemic autoimmunity and is characterized by autoantibodies against 
double stranded deoxyribonucleic acid (dsDNA), histones and a variety of other nuclear 
antigens that are found in every tissue of the body.  The main organ systems involved in 
SLE are the kidneys, heart, joints, skin, lung, blood vessels and the nervous system.  
Other systemic autoimmune disorders are Rheumatoid Arthritis (RA), Sjogren’s 
syndrome (SS) and Dermatomyositis.  The development of organ-specific or systemic 
autoimmunity depends on the autoantigens targeted by the immune system and their 
distribution within the body.  In some autoimmune conditions, the cells bearing the 
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targeted antigen are distributed to all parts of the body by the circulation leading to 
widespread disease manifestations.  Classic examples of such autoimmune conditions are 
the small vessel vasculitides that involve neutrophil antigens and are characterized by the 
presence of anti-neutrophilic cytoplasmic antibodies (ANCA).  Three subtypes of small 
vessel vasculitides are Wegener’s granulomatosis (WG), Churg-Strauss syndrome (CSS) 
and microscopic polyangiitis (MPA).  All three of them are characterized by severe 
inflammation and granuloma formation in the kidney, lungs, upper respiratory tract, 
gastrointestinal tract and skin. 
 
In order to provide effective clinical treatment to millions of patients with 
autoimmune diseases, it is necessary to understand how and when some self antigens 
become targets of the immune response.  A better insight into what drives a particular 
autoimmune process will help in preventing autoimmune conditions and guide the 
development of new treatments. 
 
 
Proposed Mechanisms for Autoimmunity 
 
Autoimmunity has a complex etiology.  Genetics and environmental factors play 
roles in the engagement, activation and proliferation of self-antigen specific lymphocytes 
resulting in autoimmunity.  Several examples of genetic defects predisposing to 
autoimmunity have been described.  For example, the src-family tyrosine kinase lyn, 
which is associated with membrane immunoglobulin (Ig), is essential for B cell signaling, 
and defects in lyn signaling may result in B cell activation by self-antigens and 
autoimmunity (18).  T cells express an inhibitory receptor, cytotoxic T-lymphocyte 
antigen (CTLA4) that competes with CD28 for binding to CD80/86 molecules and 
transmits inhibitory signals (19).  Polymorphisms in CTLA4 gene were found to be 
associated with Grave’s disease as well as T1D (20).  In one mouse model of T1D a 
variation of CTLA4 mRNA splicing resulting in a molecule with reduced ability to 
interact with CD80/CD86 ligands were found (20).  With development of new biological 
techniques for studying autoimmunity, the following mechanisms have been proposed to 
influence initiation of autoimmunity. 
 
 
Genetic Predisposition 
 
Genetic predisposition plays an important role in the development of autoimmune 
disorders.  Multiple polymorphisms in major histocompability complex (MHC) genes, 
the most extensively studied region of human genome, have been found associated with 
autoimmune disorders.  In human genes encoding MHC molecules are located on the 
short arm of chromosome 6 (21).  MHC gene loci are segregated into 3 different classes, 
with Class 1 including genes for human leukocyte antigens (HLA) A, B and C.  Class II 
MHC consists of genes for heterodimeric HLA-DR, DP and DQ molecules.  Many other 
gene products including complement components (eg C4), tumor necrosis factor alpha 
(TNF-α) and heat shock protein 70 (hsp70) are grouped together in MHC Class III (22).  
With genes involved in signaling, cell death and antigen processing and presentation 
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closely clustered in one small region of the genome, polymorphisms in MHC molecules 
influence immunoreactivity against many self antigens.  As early as the seventh decade of 
the 20th century, association of HLA-B27 with ankylosing spondyloarthopathy (AS) was 
established (23, 24).  The  association of HLA-B27 or its subtypes with AS holds true 
worldwide with higher prevalence of AS in populations with higher frequency of HLA-
B27 (25).  Even after this close association between AS and HLA-B27, a genetic study 
found that only 16% of identical twins with HLA-B27 positive genotype developed AS 
(26).  More recently, it was found that susceptibility to AS is not limited to HLA-B27 
haplotypes, but extends to other Class I and Class II MHC molecules including A2, A9, 
Bw and DR1/DR2 (27).  Thus a genetic component is found in almost all patients with 
AS, although the HLA haplotype is not the only contributor to the development of AS 
because about 90% of HLA-B27 positive individuals remain free of the disease (27).  
This suggests that there must be an environmental trigger for AS development.  
Nevertheless, the association of AS and HLA-B27 provide a classic example of one 
genetic trait conferring susceptibility to disease. 
 
Genetic contributions to autoimmune susceptibility have been identified in almost 
all known autoimmune conditions.  Recent studies have shown that certain HLA-DR2 
and DR3 Class II haplotypes contribute to development of SLE (28).  MHC associated 
risk factors for SLE are not limited to Class II haplotypes but extend to involve the Class 
III region also particularly in superkiller viralicidic activity 2-like (SKIV2L), tumor 
necrosis factor (TNF) and complement component C4 gene loci regions (29, 30).  
Genetic as well as animal model studies establish that HLA antigens, particularly HLA-
DR and DQ also contribute to autoimmune susceptibility in RA and Type 1 diabetes (31-
33). 
 
Advanced genetic studies in recent years have located several polymorphisms in 
genes outside the MHC cluster that are associated with increased incidence of 
autoimmunity.  Linkage analysis studies identified polymorphisms associated with signal 
transducer and activator of transcription 4 (STAT4) in RA and SLE (34), and nucleotide 
binding and oligomerization domain 2 (NOD2) in Crohn’s disease (35, 36).  Genome-
wide association studies, possible after the complete sequencing of human genome, 
further enhanced the number of genes associated with autoimmune conditions.  Many of 
these genes are involved in signaling pathways of T cell (PTPN22)(37) and B cell 
(BANK1, BLK)(38-40) development, or in co-stimulation signaling during antigen 
presentation (CTLA4, CD40)(41-43).  Polymorphisms in genes involved in interferon 
production (IRF5, IRF8, IRAK1, and STAT4)(44, 45) and cell to cell communication 
(IL-2, IL-12A, IL-23R) (46) may influence T and B cell interaction with self-antigens in 
various ways and thus be associated with autoimmune disorders.  Even though many 
genetic polymorphisms and mutations have been found to associate with autoimmune 
disorders, the impact of any one genetic factor on the development of autoimmunity is 
very modest.  Only a few conditions, such as autoimmune lymphoproliferative syndrome 
due to mutations in fas (CD95 or Apo 1) and autoimmune polyglandular endocrinopathy 
with candidiasis and ectodermal dysplasia (APECED) that occur due a mutation in the 
Autoimmune Regulator (AIRE) gene, are examples of autoimmune disorders arising due 
to direct consequence of genetic defects (47, 48).  Most of the genetic factors provide 
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additional susceptibility in the run up to full blown autoimmune disorders, but their 
contribution to initiation of autoimmunity remains unsubstantiated.  Involvement of 
multiple genetic components in individual autoimmune disorders and also of one genetic 
polymorphism in multiple autoimmune conditions points to an input from multiple genes 
toward the susceptibility to autoimmunity. 
 
Mouse models of autoimmune disorders have contributed to the understanding of 
the complex genetic contribution to autoimmune disorders.  Clear evidence of genetic 
involvement in autoimmune diseases came from the observation that mice of a certain 
genetic background, such as MRL/lpr, (NZB x NZW) F1 and NZM2410 develop 
autoimmune conditions mimicking human disease.  Study of such mice that 
spontaneously develop autoimmunity narrowed the boundary of genetic intervals that 
contribute to breaking of tolerance in these animal models of SLE.  By backcrossing 
NZM2410 mice to C57BL/6 mice 3 genetic intervals named Sle1, Sle2 and Sle3 were 
identified that contribute to disease susceptibility (49).  By segregating these 
susceptibility loci on a non-autoimmune background important insights in the 
mechanisms by which they promote autoimmunity was gained.  It was found that Sle1 
locus predisposes for autoantibody production against nuclear antigens (49, 50).  Genes 
in the Sle2 interval lower the activation threshold of B cells, resulting in a higher 
production of polyclonal IgM, but not of IgG antibodies (49, 51).  B cells from mice 
harboring the Sle2 locus were hyperresponsive to antigen challenge suggesting that this 
locus may contain a gene that reduces the threshold for B cell activation (51).  While Sle1 
and Sle2 loci influenced the effector B and T cells, the Sle3 locus on chromosome 7 
predisposed to autoimmunity by increasing antigen presentation by dendritic cells (52). 
The antigen presenting cells from mice bearing the Sle3 locus, were more efficient at 
presenting antigens to T cells and releasing more proinflammatory cytokines as compared 
to APCs from normal mice (53).  Though these congenic mice models have helped in 
understanding the role each of these genetic intervals play in autoimmunity, the actual 
process by which autoimmunity is initiated is far from clear. 
  
One problem in understanding the mechanisms of autoimmunity as a result of 
only genetic contribution is that at times one gene may predispose to many autoimmune 
conditions: PTPN22, a gene involved in B and T cell signaling is associated with 
autoimmune thyroiditis, RA, SLE and T1D (54).  STAT4 which regulates INF gamma 
production is involved both in SLE and RA (55).  Different manifestations of a single 
gene defect point to additional factors involved in the etiology of autoimmune disorders 
over and above the genetic elements that predispose to autoimmunity.  Though an 
underlying genetic background favors the development of autoimmunity, disease 
manifestations may differ as they reflect differences in the underlying mechanisms of 
autoimmunity.  These observations coupled with the fact that not every individual 
inheriting disease associated genotypes eventually develops autoimmunity suggest that 
multiple factors, in addition to genetics, are involved in the initiation and progression of 
an autoimmune response.  Presently, it is believed that different genetic factors lower the 
threshold of an individual for breaking tolerance but the initiation of an autoimmune 
response needs an additional trigger.  It is obvious that in addition to predisposing genetic 
factors, environmental influences contribute to overt autoimmunity. 
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Environmental Factors in Autoimmunity 
 
Several environmental toxins and infectious agents are associated with 
autoimmune disorders.  Classical involvement of infections in initiating an autoimmune 
response is seen in rheumatic fever associated carditis and Guillian-Barre Syndrome 
(GBS) associated polyneuropathy (56).  In rheumatic fever, the immune response against 
the M protein of  Streptococcus pyogenes cross reacts with myosin from cardiac 
myocytes, thus leading to myocarditis (57, 58).  A common event that preceeds GBS is 
infectious diarrhea caused by Campylobacter jejuni, suggesting infection with C.jejuni as 
a predisposing condition for GBS.  Viral infections as well as vaccination against 
influenza virus have also precipitated GBS, clearly pointing to the role of infections in 
initiating this autoimmune myelitis (59).  Definite mechanisms by which infections result 
in GBS are not known, but it is assumed that immune response against a pathogen later 
re-directs itself against antigens on gangliocytes.  This type of cross reactivity is similar 
to the crossreactivity shown by M protein of S. pyogenes and antigens on cardiac 
myocytes in rheumatic fever.  The cross reactivity is thought to arise from “molecular 
mimicry” between antigens expressed on pathogen and host tissue.  Several other 
infections agents are thought to promote autoimmunity.  Epstein-Barr virus (EBV) is 
associated with systemic lupus and in a study it was noticed that SLE patients develop 
antibodies to EBV protein EBNA-1 prior to developing autoantibodies (60).  It is found 
that antibodies to EBNA-1 cross react with self-antigen Ro, one of the many autoantigens 
targeted by autoantibodies (61).  Molecular mimicry has been postulated to be a 
mechanism by which infections can cause autoimmune diseases (62, 63). 
 
The environment may influence autoimmunity in ways other than infections.  
Exposure to chemical substances can also promote autoimmunity.  Mice exposed to 
environmental toxins such as mercury or demethylating agents, procainamide or 
hydralazine develop an autoimmune response similar to that seen in SLE.  The 
“molecular mimicry” hypothesis does not provide an explanation for chemical-induced 
autoimmunity and the mechanism remains poorly understood.  One possible explanation 
is that chemicals induce covalent modifications in the host antigens that cause the 
immune system to recognize modified self antigens in a manner such that an immune 
response occurs. 
 
 
Post Translational Modification of Proteins: Generation of “Neo-epitopes” 
 
Post translational modifications (PTM) play an important role in various cellular 
functions ranging from cell division to cell death by rapidly altering protein structure, 
function and interactions with other proteins.  While doing so PTMs might also change 
the way the immune system recognizes a particular protein by generating “Neo-
Epitopes”.  A neo-epitope is a portion of a protein that gets modified in a manner such 
that recognition by a lymphocyte antigen receptor is also altered.  PTMs are one way neo-
epitope can arise.  Tolerance to neo-epitopes has not been established during lymphocyte 
development.  Such “neo-epitopes” may activate lymphocytes in a similar manner as 
foreign antigens. 
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A variety of PTM including phosphorylation, acetylation, glycosylation, 
methylation and deimination have been identified on autoantigens (64, 65).  Importantly, 
several of these modified autoantigens are preferentially processed, presented and 
recognized by the immune system contributing to the development of autoimmunity (66, 
67).  PTMs associated with apoptotic cell death increase the immunogenicity of self 
antigens and predispose to autoimmunity.  Examples of apoptosis-related PTMs include 
phosphorylation, acetylation, ubiquitination and transgluamination of histones (68).  
Phosphorylation of small nuclear ribonucleoprotein (snRNP) (U1-70K) and acetylation of 
histone H4 (H4-8K) cause enhanced immunoreactivity with systemic lupus sera (69, 70).  
PTMs contributing to autoimmune disease are not limited to nuclear self-antigens.  
Hydroxylation and glycosylation of collagen result in severe disease manifestations in a 
collagen-induced mouse model of arthritis (71, 72).  In addition, deiminated proteins are 
targets of autoantibodies in RA (73).  The high specificity and sensitivity of anti-
deiminated protein antibodies in RA led to the development of several diagnostic kits 
(74).  Although the preferential recognition of PTMs by autoimmune sera supports the 
“neo-epitope” theory for initiation of autoimmunity, the lack of reactivity to these PTM 
in control subjects argues for effective tolerance mechanisms.  So how and when these 
PTM affect the development of autoimmune disorders is still an open question. 
 
 
Cell Death, Exposure of Hidden Antigens and Defective Clearance 
 
The involvement of dead cell remnants in the etiology of autoimmunity was 
reported in 1943 by Hargraves et al. who showed that dead polymorphonuclear (PMN) 
leucocytes are responsible for the LE cell phenomenon (75).  They found that PMNs 
from the bone marrow of SLE patients have phagocytosed free nuclear material that 
appeared to be partially “lysed,” “digested” or “decondensed”.  This was in contrast to 
the phagocytosis of nuclear material observed in the “Tart” cells from healthy individuals 
that retain all the characteristic of nuclear staining.  The degenerated nuclear material of 
LE cells attracted PMNs, to form rosettes.  They also observed that the chemotactic 
attractiveness of the nuclear material was lost once it was been engulfed by the PMNs.  
These were the first observations to suggest that the exposure of nuclear remnants and 
defective clearance may constitute mechanisms for the development of autoimmunity.  
Haserick and Bortz found that a plasma factor, immunoglobulin, was responsible for the 
LE cell phenomenon (76).  This heralded the discovery of a plethora of autoantibodies 
against the nucleus and its components (anti nuclear, anti-DNA and anti histone 
autoantibodies) that are found commonly in SLE patients.  Although, the mechanism for 
the induction of these autoantibodies is not completely understood, there is evidence that 
membrane disintegration following cell death might make these autoantigens accessible 
(77-81).  In accordance with this view, increased apoptotic rates for lymphocytes were 
observed in patients with SLE and other autoimmune disorders (82).  This raises 
important questions like whether it is the excessive cell death in SLE which predisposes 
for autoimmunity.  Or is the increased apoptosis seen in SLE patients a consequence of 
an underlying autoimmune disease process? 
 
Evidence so far suggests that both of the above possibilities are true to some 
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extent.  Apoptotic mechanisms not only expose nuclear and other potential autoantigens 
but also enhance the immunogenicity of these autoantigens by subjecting them to various 
PTMs and enzyme action (83-85).  Caspases, the main effectors for apoptosis, also 
facilitate the translocation of nuclear autoantigens to cytoplasm by cleaving the nuclear 
localizing signal of various proteins (86) and allow the development of apoptotic surface 
blebs by activating ROCK1 kinase (81, 87, 88).  With these studies, it became clear that 
apoptotic cells are involved in making nuclear autoantigens available to react with B cells 
or other APC.  This however doesn’t explain the mechanism for the initiation of the 
autoimmune response.  A big question remains: if potential autoantigens are expressed on 
cells undergoing apoptosis then why do not all individuals develop an autoimmune 
response at some point of time? 
 
Excessive cell death or defects in the clearance of dead cells also predispose to 
autoimmunity, as implied by studies of knock-out mice lacking genes involved in 
clearance or regulation of apoptosis (89).  One of the first clues indicating that 
autoimmunity arises from clearance defects was provided by C1q deficient mice that 
developed autoimmunity resembling SLE, including immune complex deposition and 
accumulation of apoptotic bodies in the glomeruli (90).  Similarly, animals defective for 
other molecules involved in the clearance of dead cells such as Mer tyrosine kinase (91, 
92) or milk fat globule E8 (MFG-E8) (93) developed high titres of autoantibodies and 
glomerulonephritis.  Clearance defects are also found in SLE patients.  Macrophages 
derived from circulating monocytes of SLE patients are small, have impaired function 
and die earlier than those derived from control subjects (94).  Nuclear remnants of dead 
cells were also found to be associated with follicular dendritic cells (FDC) in the 
germinal center in patients with SLE (95).  This highlights the defective clearance 
mechanisms that are prevalent in SLE patients, and links them to the persistent anti-
nuclear B cell activation that characterizes SLE. 
 
Though it became clear that effective clearance of dead cells is necessary for 
avoiding autoimmunity, researchers soon discovered that an absence of factors involved 
in clearing dead cells does not always lead to autoimmunity.  The strongest association 
between autoimmunity and dead cell clearance is observed in C1q deficiency.  Yet, a 
specific mixed genetic background - (129/O1a X C57BL/6)F2 was needed in C1q 
knockout mice to develop autoimmunity (90).  This may be due to the redundancy of 
mechanisms involved in clearing dead cells and may suggest that additional mechanisms 
are involved in developing the manifestations of an autoimmune phenotype.  Dead cell 
membranes lose their phospholipid asymmetry leading to the exposure of anionic 
phospholipids such as phosphotidylserine (PS).  The exposed PS can be recognized by a 
number of phagocytic scavenger receptors (96) as well as many freely circulating 
opsonins like T-cell immunoglobulin mucin (Tim-1, Tim-4) (97), MFG-E8 (98) and 
Protein S (99).  This redundancy means that the deficiency of one component of a 
clearance system can be tolerated well.  Also apart from specialized phagocytic cells, 
such as macrophages, dead cells can be taken up and cleared by epithelial, endothelial 
and fibroblastic cells (100-105). 
 
The role of apoptosis in the initiation of autoimmunity came into question when it 
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was found that apoptotic cells promote secretion of anti-inflammatory factors such as IL-
10 and TGF-β from resident dendritic cells. This increases the rate of dead cell clearance 
while maintaining immune unresponsiveness (106, 107).  Moreover, macrophages 
encountering apoptotic cells respond in an anti-inflammatory and immunosuppressive 
way (108, 109).  Apoptotic cells inhibit the activation of macrophages by inducing 
production of TGF-β, prostaglandin E2 (PGE2) and platelet activating factor (PAF) 
(109).  While mechanisms involved in all anti-inflammatory mediator release are not 
fully understood, TGF-β secretion appears to depend on PS recognition (110).  In 
addition to the indirect suppression of macrophage activation by TGF-β and IL-10, direct 
recognition of apoptotic cells by the c-mer proto-oncogene receptor tyrosine kinase (Mer-
TK) inhibits toll like receptors (TLR) signaling by upregulating the production of 
suppressor of cytokine synthesis (SOCS) proteins (111).  Moreover, monocytes incubated 
with apoptotic cells produced IL-10 in response to lipopolysaccharide (LPS) treatment 
indicating the dominant immunosuppression mediated by apoptotic cells (112).  
Apoptotic cells also suppress TNF-α secretion by epithelial cells in response to LPS 
(104).  The immunosuppression by apoptotic cells can be mediated by a rapid 
transcriptional repression of inflammatory cytokines (113, 114) as well as by the 
inhibition of extracellular signal-regulated kinases 1 and 2 (ERK1/2) (115). 
 
These observations, together with the fact that apoptosis is an ongoing process 
that is essential in development, raised the possibility that different cell death pathways 
elicit varied responses from the immune system.  In support of this, it was shown that 
necrotic cells induce the production of proinflammatory cytokines by engaging TLRs 
(116).  The plasma membrane damage in necrotic cells results in leakage of molecules 
that can be recognized by pattern recognition receptors (PRR).  Many of these “danger” 
molecules (e.g. HMGB1) are capable of promoting inflammation by engaging TLRs 
(117).  The involvement of these endogenous molecules supports the danger model of 
immune activation (118).  Necrosis occurs commonly as a consequence of an external 
insult such as infections.  The danger molecules, together with pathogen associated 
molecular patterns (PAMPs) associated with infectious agents are capable of stimulating 
the production of proinflammatory molecules.  Thus, innate immune responses provide 
suitable conditions for initiation of an adaptive immune response.  It is likely that the 
presence of self antigens in proinflammatory conditions, such as arise during infection, 
may predispose for the development of adaptive autoimmunity. 
 
 
Autoimmunity: Interplay of Innate and Adaptive Immunity 
 
Autoimmunity by definition is the immune response against self antigens that are 
recognized as if they were “foreign”.  In understanding autoimmunity a lot can be 
inferred from the way the immune system reacts against infectious agents.  After an 
infectious agent has breached the cellular integrity of host, the damaged cells of the host 
alarm the locally residing macrophages to a foreign intrusion.  Soluble (complement, 
IgM), cell surface expressed (TLR 1,2,4,5 &6), endosomal (TLR 7,8,&9),  and 
cytoplasmic (NOD like receptors) PRRs recognize PAMPs that are evolutionarily 
conserved on infectious agents and prepare for a response against invading agent.  The 
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response usually consist of local infiltration by cells of innate immune system that are 
capable of responding to infection as well as preparing for the presentation of foreign 
antigens to the adaptive immune system for a vigorous and more focused response. 
 
 
Immune Response to Infectious Agents and Lessons for Autoimmunity 
 
As soon as the infectious agent or host cell damage is identified, surrounding 
endothelial and stromal cells release numerous cytokines such as IL-1β, IL-8, IL-18, 
IL-25, IL-33 (119) as well as several alarmins such as HMGB1, heat shock protein (HSP)  
and uric acid (120, 121) that activate locally residing macrophages, recruit monocytes 
and neutrophils from intravascular space into the extravascular site of inflammation and 
promote activation of B and T cells.  Macrophages and monocytic cells recruited at the 
site of infection are capable recognizing PAMPs and and are primed to phagocytose and 
kill extracellular pathogens.  If infection cannot be brought under control by these 
mechanisms, these cells also promote processing and presentation of antigens to T cells 
that influx into the site of inflammation.  Antigens from previously unencountered 
pathogens are engaged by B and T cells with assistance initially from macrophages and 
later by dendritic cells (122).  T cells so activated further help antigen specific B cells to 
differentiate into antibody producing plasma cells and long lived memory B cells 
completing the recruitment of the adaptive arm of immunity to fight invading infection 
(123).  If B and T cells have responded to the pathogen earlier and have generated 
memory cells, an effective adaptive immunity mounts quickly.  In this manner, the innate 
immune system not only fights against the invading pathogen, but also facilitates the 
activation of the adaptive arm of immunity (124). 
 
What lessons can be learnt from pathogen-immune system interactions that can 
help us understand autoimmunity?  It can be easily deduced that adaptive autoimmune 
immune responses in a local inflammatory environment will follow an activation course 
potentially involving autoantigens that will be similar to that against foreign infectious 
agents.  After encountering antigens B cells undergo somatic hypermutations and affinity 
maturation so as to produce more specific antibody response (125).  Similarly, antibodies 
from patients with autoimmune diseases show characteristics of hypermutation and 
affinity maturation suggesting that autoimmunity is an antigen driven process (126).  
Two fundamental differences that separate autoantigens from antigens of foreign 
infectious agents are “inaccessibility” as most autoantigens are within membrane 
compartments and “lack of inflammation” at least in the initial phase.  In circumstances 
such as cell death there is large expression of hidden autoantigens that can be equated to 
the initial inoculation by an invading pathogen.  If activation of innate immune response 
occurs simultaneously the result can be development of autoimmune response against 
self-antigens. 
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Successful Adaptive Immune Response Requires Contribution from Innate 
Immunity 
 
Previously considered as two separate branches of immunity, it is now evident 
that innate and adaptive components of immune system interact and intricately influence 
the activation of each other so as to offer comprehensive protection against foreign 
antigens.  Various PRRs on cells of the innate immune system (e.g. dendritic cells, 
macrophages) are instrumental in directing the T cell responses by increasing the 
presentation of peptide MHC complex as well as upregulation of co-stimulatory 
molecules (127, 128).  Engagement of BCR with an antigen together with the interaction 
of its CD40 molecules with CD40L expressed on activated CD4+ helper T cells promotes 
B cell clonal expansion and differentiation into short lived plasma cells. B cell interaction 
with helper T cells also promotes class switch recombination of BCR receptor and 
affinity maturation, migration, and transition into memory cells and long lived plasma 
cells (129).  The role of innate immunity in facilitating B cell immunity against antigen 
does not stop to just promoting helper T cell activation.  Certain populations of dendritic 
cells (CD11clo ) promote activation and proliferation of Marginal Zone B cells (MZ B 
cells) and B1 B cells against antigens in a T cell independent manner(130).  
T independent B cell responses are mediated by the release of BAFF and a proliferation 
inducing ligand (APRIL) secreted by activated dendritic cells, macrophages and 
neutrophils (130, 131).  It is not just the innate immune system that feeds into the 
adaptive immune system.  Antigen specific antibodies from B cells promote clearance of 
opsonized antigens through Fc receptor mediated phagocytosis (132).  Also activated 
T cells secrete cytokines that promote activation and maturation of macrophages and 
dendritic cells. 
 
 
Components of Innate Immunity Involved in Autoimmunity and Tolerance 
 
Processing and presentation of antigens are not limited to foreign or infectious 
agents.  Dendritic cells were found to take up and process self antigens, especially from 
dying cells (133-135).  Then how is tolerance maintained against self antigens?  It 
follows that in the absence of inflammation uptake of self antigens, mostly from 
apoptotic cells, is done without maturation of dendritic cells.  These immature dendritic 
cells express low levels of MHC-peptide complex and are devoid of co-stimulatory 
molecules (136).  In case of infectious agents, engagement of TLRs by PAMP of 
infectious agents induces maturation of dendritic cells (136).  Maturation of dendritic 
cells results in increased secretion of inflammatory chemokines (137), cytokines (138) as 
well as several growth factors (IL-2) needed for T cell maturation (139).  Formation of 
peptide-MHC complexes is increased (140) along with the expression of co-stimulatory 
molecules that results in T cell activation.  Interaction of self-antigens with  immature 
dendritic cells devoid of co-stimulatory signals results in deletion or anergy of self 
specific T cells (141, 142).  Are mature dentritic cells that express co-stimulatory 
molecules capable of initiating an immune response against self antigens?  With an 
elegant study, Probst et al found that presentation of LCMV derived peptides by steady 
state immature dendritic cells induced T cell anergy whereas those presented by mature 
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and activated dendritic cells promoted an immune response (143).  This supports the idea 
of PAMP or endogenous TLR ligand engagement by dendritic cells promoting 
autoimmune T cell response against self-antigen.  Though specific challenge of mice 
transgenic for ovalbumin expression in pancreas with various TLR ligands failed to 
induce autoimmunity (144) indicating that perhaps local inflammatory environment is 
needed for successful presentation of self-antigens. 
 
Both murine and human B cells express TLRs including TLR1, TLR2, TLR7, 
TLR9 and TLR10 (145) which can be activated by various PAMPs and even with some 
endogenous ligands.  B1 and MZ B cells are particularly responsive to TLR mediated 
maturation, proliferation and differentiation into plasma cells that is independent of T cell 
help (146).  Nuclear autoantigens associated with RNA or DNA can activate autoreactive 
B cells by TLR7/TLR9 engagement by providing the required second signal after BCR 
engagement and so promoting autoantibody production without T cell help (147, 148).  
An example of this can be seen in activation of rheumatoid factor producing B cells with 
endogenous DNA of immune complexes acting through simultaneous BCR and TLR 
engagement (148).  Thus, activation of innate immunity can promote autoimmune 
responses from B cells by direct activation of TLRs expressed on B cells or indirectly by 
promoting activation of APCs.  Infections increase host cell death and promote activation 
of innate immune system by engaging various PRRs and thus provide a unique example 
by which activation of innate immunity can proceed to development of autoimmunity.  
Several endogenous TLR ligands like fibrinogen, hyaluronate, heat shock proteins and 
modified low density lipoproteins have been identified as capable of activating B cells by 
engaging TLR receptors (149). 
 
 
Infections Generate an Environment Suitable for Autoimmunity 
 
For a long time, infections have been thought to contribute to the development of 
autoimmunity. Many autoimmune conditions like GBS or autoimmune carditis arise after 
a bout with infection. In many chronic autoimmune conditions such as SLE and RA, 
infections cause flairs and worsening of symptoms.  There are multiple mechanisms by 
which infectious agents may contribute to autoimmunity. 
 
 
Molecular Mimicry 
 
Molecular mimicry suggests that some pathogens carry epitopes similar to host 
molecules and that these may be responsible for the development of autoimmunity.  The 
similarity in amino acid sequence or structure between host and infectious molecules can 
cause the immune response against infectious agent to cross react with self.  Molecular 
mimicry, as a mechanism of autoimmunity is most studied in cardiac autoimmune 
conditions.  Acute cardiomyopathy of rheumatic fever after group A streptococcal 
pharyngitis is a classical example of molecular mimicry related autoimmunity.  
Monoclonal antibodies developed from the B cells of patients with acute rheumatic fever 
with streptococcal pharyngitis cross react with both streptococcal M protein and also with 
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cardiac myosin (150).  CD4+ and CD8+ T cells isolated from a patient with rheumatic 
carditis have shown cross reactivity to both recombinant myosin M protein and human 
cardiac myosin, laminin and tropomyosin (151).  Molecular mimicry is also seen between 
Coxsackievirus B (CVB) and cardiac myosin (152).  It was suggested that the immune 
response arising against CVB3 virus cross reacts to myosin to cause myocarditis (153).  
In another example of molecular mimicry being involved in the development of an 
autoimmune disease in humans, it was found that LPS derived from C.jejuni serotypes 
that predispose to GBS resembles human ganglioside structure (154, 155).  Immunization 
of rabbits with C. jejuni LPS caused development of flaccid paralysis similar to that seen 
in human GBS patients.  Affected rabbits also developed antibodies against GM1 
ganglioside (156).  Though many such examples of cross reactivity between infectious 
agents and host tissue exist, molecular mimicry fails to provide an easy explanation for 
the development of autoimmunity.  The majority of individuals who get infected with C. 
jejuni do not develop flaccid paralysis.  Therefore, multiple factors from both host and 
infectious agents must be responsible for determining whether an episode of infection 
will result in autoimmunity. 
 
 
Bystander Activation and Epitope Spreading 
 
Immature APCs maintain peripheral tolerance by continuously presenting self 
antigens to naïve T cells in absence of costimulatory molecules (157).  Such engagement 
without costimulatory signalling results in T cell anergy.  In an inflammatory 
environment, APCs upregulate CD80/CD86 costimulatory molecules while presenting 
foreign derived peptides to antigen specific T cells.  APCs also secrete generous amounts 
of cytokines (IL-2, TNF-α and IL-6) which can activate nearby naïve T cells with other 
antigen specificities independent of TCR engagement in a phenomenon called “bystander 
activation” (158, 159). 
 
Self reactive T cells thus can get activated to respond against self antigens in an 
inflammatory environment.  Good examples of bystander activation leading to 
autoimmune disorders are provided by T1D and Multiple Sclerosis (MS).  In both these 
diseases the concordance rates in monozygotic twins are approximately 40%, indicating 
an environmental link to the development of autoimmunity (160-162).  Rubella, mumps, 
CVB4 and Cytomegalovirus (CMV) infections are found to associate with T1D and 
antibodies against pancreatic islets are found in rubella (163) and CMV (164) infected 
patients.  Many children get rubella and mumps early in life and protective antibodies 
against the two persists nearly for life.  As the majority of these kids do not develop 
diabetes, molecular mimicry by itself does not explain the association between these viral 
infections and T1D.  Though the exact mechanism by which different viruses can cause 
T1D is not fully understood, bystander activation of self-reactive T cell clones is likely to 
be involved.  One study found that preexisting autoreactive T cells are needed for 
acceleration of disease in the CVB4-infected NOD mouse, thus implying that the 
accelerated disease manifestation is the effect of bystander activation rather than CVB4 
infection induced direct damage of the pancreas (165).  Viral (and many bacterial) 
components can induce the release of inflammatory cytokines and up regulation of MHC 
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class I and class II molecules on cells.  In Theiler’s murine encephalomyelitis virus 
(TMEV) induced model of MS, the reactivity against myelin epitopes does not arise due 
to molecular mimicry between the virus and myelin sheath.  Instead, there is a temporal 
progression of anti-myelin reactivity from an immunodominant myelin epitope to other 
myelin components and blocking of costimulatory B7 CD27 prevents the onset of chronic 
autoimmune demyelination (166).  The TMEV model of MS also gives a good example 
of epitope spreading, where the immune response slowly progresses from 
immunodominant epitope of myelin to other non immunodominant components.  
Persistance of viral RNA during this time suggests bystander activation as mechanism 
responsible for initiation of antimyelin autoimmunity. 
 
 
Cryptic Antigens and Epitopes 
 
Self antigens commonly associated with autoimmune disorders are usually hidden 
inside cell membranes.  Most notable of these are the nuclear antigens.  This has led to 
the hypothesis that autoimmunity arises when these membrane bound or cryptic antigens 
become exposed to circulating T/B cells.  Cell death provides circumstances where 
nuclear antigens become exposed at the cell surface (80).  Infections cause massive cell 
death as well as result in the influx of neutrophils, monocytes and lymphocytes.  Thus 
infections provide an environment where self ignorant, non-tolerant immune cells can be 
activated while encountering cryptic self antigens.  While this seems a simple and likely 
explanation for the initiation of autoimmunity against organ specific or cell sequestered 
cryptic self antigens, it has been found that organisms have mechanisms to avoid 
“immunological ignorance” during T cell development (167).  With the mediation of 
AIRE (autoimmune regulator of gene expression) in the thymus, several organ specific 
antigens are expressed in the medullary region of thymus so that even organ-specific self 
reactive T cells can be eliminated from the peripheral repertoire (167).  This greatly 
decreases and often eliminates the risk of autoimmunity towards self antigens expressed 
in organ specific locations.  Because self reactive T cells are known to exist in the 
periphery, it can be assumed that infections can still contribute to the development of 
autoimmunity by inducing cell death and providing an excess of cryptic self-antigens. 
 
Crypticity is not only associated with antigens, but also with certain epitopes 
within self antigens.  Certain (cryptic) portions of an antigen are not recognized by T 
cells, whereas other immunodominant portions are easily recognized.  This is clearly 
evident from studies of proteolipid protein (PLP), an autoantigen in MS.  Epitope 
mapping studies using overlapping peptides and PLP-specific T cells from MS patients 
revealed two immunodominant peptides (p30-49, p180-199) such that T cell lines 
generated using these two peptides responded well to intact PLP.  However, other T cells 
responded to different PLP peptides (p80-99, p90-109, p170-189, p260-276) but not to 
intact PLP (168).  Even in the case of acetylcholine receptor (AChR), three peptides 
(p75-115, p138-167 and p309-344) generated T cell lines but these T cells did not 
respond to either full length or fragments of the AChR alpha chain.  Interestingly one 
p309-344 specific T cell line responded to a trypsin treated AChR fragment (p256-366) 
but not to the untreated fragment (169).  This gives an example of how differential 
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processing of antigen by proteases can unmask cryptic epitopes on self antigens and 
influence the generation of immune response against self antigens.  These studies 
however don’t implicate cryptic epitopes in the etiology of autoimmune disease, as 
proliferation of T cells in response to peptides can be viewed as an in vitro artifact.  
Evidence that cryptic epitopes are important in manifestation of autoimmune diseases 
comes from Lewis rat models of uveoretinitis where disease can be induced by 
immunizing rats with bovine interphotoreceptor retinoid binding protein (IRBP).  Apart 
from the full protein, the disease was also induced by immunizing rats with cryptic 
peptides (170) or by transferring cryptic epitope-specific T cells (171).  The importance 
of antigen processing by APC in the response against cryptic peptides became evident as 
T cells lines against one of the epitopes (p1158-1180) responded to IRBP treated with 
endopeptidases but not against intact IRBP.  Effect of antigen processing or presentation 
on generation of cryptic peptides involved in autoimmunity is also observed when 
myocarditis resulted in Lewis rats by immunization with trypsin-digested but not intact, 
untreated porcine cardiac myosin (172). 
 
Immunization of B10.BR mice with cryptic epitopes (p26-40, p56-70) from the D 
protein of small nuclear ribonucleoprotein (snRNP) induced a lupus like syndrome (173).  
Similarly a cryptic peptide (p104-117) from myelin proteolipid protein was able to induce 
experimental autoimmune encephalomyelitis (EAE) in SJL/J mice when used as an 
immunogen (174).  Also T cells specific to p104-117 of PLP were able to introduce 
disease when adoptively transferred to naïve mice.  Splenocytes from SJL/J mice 
immunized with whole PLP did not proliferate when incubated with the cryptic p104-117 
peptide (174) indicating that this epitope does not result from processing of the native 
protein by APCs.  The ability of cryptic p104-117 peptide to induce splenocyte 
proliferation in an antigen specific manner, when immunized in SJL/J mice, suggests that 
lymphocytes recognizing such self-antigen cryptic epitopes may be a part of the normal 
repertoire.  Events, such as infection or injury, can lead to the unmasking of these cryptic 
epitopes for antigen processing and presentation to such self reactive lymphocytes.  
Unmasking of cryptic epitopes may occur as a direct consequence of infection as several 
infectious agents carry unique proteases.  Alternatively, the host response to infection 
may activate many proteases.  For example, neutrophils enter infected tissues and release 
primary, secretory and azurophilic granules rich in various proteases (Elastase, PR3 and 
Cathepsin G).  They also kill microorganisms by a burst of reactive oxygen species which 
can unmask cryptic epitopes by introducing non specific nicks in host proteins. 
Moreover, neutrophil activation results in PTM of host proteins that can unmask cryptic 
epitopes or generate “neo-epitopes”.  Thus, in addition to direct involvement of infectious 
agents, innate host responses, such as neutrophil activation, provide conditions for the 
activation of self reactive lymphocytes, possibly initiating autoimmune disorders. 
 
 
Neutrophils: First Line of Defense against Infections 
 
Neutrophils are the first cells to be recruited to the site of inflammation and in 
most instances neutrophil responses are sufficient to clear pathogens.  Being the frontline 
warriors against infection, neutrophils are the most numerous and most reactive immune 
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cells in the body.  They form about 60-70% of circulating immune cells in human blood 
and they enter sites of inflammation in great numbers.  Neutrophils employ numerous 
mechanisms to capture and kill microorganisms.  They can either ingest a pathogen to kill 
it by phagocytosis or can release granules with various toxic substances for extracellular 
killing. 
 
 
Neutrophil Engagement of Infectious Agents: Mechanisms and Consequenses 
 
The primary role of neutrophils is to engage and eliminate invading microbial 
agents.  For this, they employ many effective mechanisms.  Neutrophils granules can be 
discharged as soon as an invading infectious agent is identified.  The first of these 
granules to be emptied are the peroxidase negative gelatinase granules (secondary 
granules) that contain a variety of matrix metalloprotinases (MMP8, MMP9, MMP25).  
These proteases degrade surrounding laminins, collagen, proteoglycans and fibronectin.  
Matrix metalloproteinase action is important in degrading the surrounding tissue and 
facilitating more neutrophil recruitment.  Proteases also help in collapsing the blood and 
lymphatic vessels, thus blocking the escape routes for the bacteria and preventing further 
colonization.  Secondary granules contain a variety of antimicrobial (lactoferrin, 
lipocalin, lysozymes) and chemotactic substances such as cathelicidin-LL37. While 
lactoferrin and lipocalin starve the bacteria for iron, lysozyme and LL37 are microbicidal 
in their own right. 
 
Depending on the infectious agent involved and severity of infection, release of 
gelatinase granules is followed by the release of peroxidase-positive azurophilic 
(primary) granules.  The azurophilic granules contain potent serine proteases: cathepsin 
G, neutrophil elastase, protease 3 along with azurocidin/CAP37 and myeloperoxidase 
(MPO) (175, 176).  Azurocidin/CAP37, a homologue of serine proteases is potently 
bactericidal but lacks protease activity (177).  Azurocidin is also chemoattractant to 
moncytes and macrophages and helps in their recruitment at the site of inflammation 
(178).  MPO is involved in the production of numerous reactive oxygen species (ROS), 
mainly hypochlorous acid, which can react with amines to form bactericidal chloramines 
(179).  The importance of ROS production by neutrophils for the elimination of 
infections is evident from the fact that the absence of ROS production is associated with 
high morbidity from severe infection (180).  Azurophilic granules also contain a LPS 
binding bactericidal permeability increasing protein (BPI) that provides potent 
bactericidal activity against Gram-negative bacteria (181). 
 
Initially thought to form part of the innate arm of immunity, it is now understood 
that neutrophils play an important role in shaping the adaptive immune response against 
invading microorganisms.  Being the first cells to arrive at the site of infection, 
neutrophils modulate different aspect of the immune response for effective clearance of 
infection.  There is evidence that other than mounting their own robust effector 
mechanisms against infectious agents, neutrophils play a role in recruitment, activation 
and programming of APCs (182).  Apart from secreting chemoattractant chemokines, 
neutrophils also recruit APCs with protease specific mechanisms that are unique only to 
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neutrophils (183).  Cathepsin G, a protease present in neutrophil granules mediates 
proteolytic activation of prochemerin to chemerin, a substance that specifically attracts 
APCs by engaging its ChemR23 receptor (184).  Neutrophils also influence 
differentiation of dendritic cells to activated macrophages by secreting chemokines. The 
ability of dendritic cells to secrete IL-12 and TNF-alpha was severely curtailed in 
neutrophil depleted mice infected with Toxoplasma gondi (182).  Other than secretion of 
cytokines, IL-12 and TNF-alpha by activated neutrophils, direct engagement of DC-
specific, C type lectin, DC-SIGN with Mac-1 integrin of activated neutrophils induce 
maturation of DC which in turn is important for inducing T cell activation and 
proliferation (185).  In addition, neutrophils can directly promote the proliferation and 
maturation of B and T cells by secreting TNF-related ligand B-lymphocyte stimulator 
(BLyS) (186) and interferon-gamma (187). 
 
 
Neutrophils as Antigen Presenting Cells 
 
In addition to creating an environment favorable for activation of B and 
T lymphocytes, neutrophils also function as APCs in certain conditions. Treatment of 
neutrophil cultures with GM-CSF, INF-gamma and IL-3 induces the expression of MHC 
class II molecules (188, 189).  Neutrophils cultured with GM-CSF showed de novo 
synthesis of MHC class II molecules, along with CD80 and CD86.  When incubated with 
staphylococcus enterotoxin and tetanus toxoid along with T cells, these neutrophils 
induced production of IL-2 and proliferation of T cells in a MHC class II restricted 
manner (190).  In vivo expression of MHC class II and costimulatory molecules (CD80 
and CD86) were found on neutrophils from patients with Wegener’s granulomatosis 
(191, 192) and also from neutrophils recovered from the inflamed joints of RA patients 
(193).  Neutrophils from normal healthy donors did not show constitutive expression of 
MHC class II or co stimulatory molecules, but their expression could be induced when 
neutrophils were cultured with T cells or T cell derived cytokines or with GM-CSF (192).  
These examples provide evidence that neutrophils and T cells can cooperate to manifest 
an adaptive immune response against microbial and perhaps against self antigens too. 
 
 
Neutrophil Extracellular Traps: Unique Mechanism to Counter Infections 
 
Fully differentiated neutrophils in circulation have two different fates - either to 
undergo apoptosis in the absence of any stimuli or to migrate to the site of an active 
infection and participate in microbial killing.  Phagocytosis of microbes by activated 
neutrophils is a known and well studied mechanism.  Recently, it was observed that other 
than phagocytosis, neutrophils kill microorganisms by releasing chromatin and granular 
proteins to engage the microbes (194).  These extracellar “traps” of chromatin are named 
neutrophil extracellular traps (NETs) and contain proteins from both primary azurophilic 
granules (myeloperoxidase, elastase and cathepsin G) and secondary granules 
(lactorferrin and gelatinase) (194).  DNA and histones form the meshwork of NETs and 
bind to Gram-positive and Gram-negative bacteria (194) as well as fungi (195).  NET 
formation is now considered a unique form of programmed cell death, one that is 
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different from both apoptosis and necrosis (196).  Unlike in apoptosis, during the early 
stages of NET formation, phosphatidylserine (PS) does not relocalize to the outside of 
plasma membrane, DNA is not condensed or fragmented (at least initially) and caspases 
are not  activated.  Necrosis differs from NET formation in keeping the nuclear and 
cytoplasmic compartments separate with no appreciable changes in chromatin structure.  
In contrast, NET formation progresses through distinct phases, where first 
heterochromatin decondenses followed by a disintegration of nuclear membranes 
allowing mixing of nuclear and cytoplasmic contents, and finally release of a chromatin 
meshwork interlaced with cytoplasmic granular proteins from the cell (196). 
 
The ability of neutrophils to deploy NETs is supported by the cytoskeleton in 
neutrophils, as demonstrated by a reduction in NET formation following exposure to 
agents that depolymerzise actin and microtubule filaments (197).  Apart from 
cytoskeleton elements, NET formation is also dependent on ROS production by 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (196, 198).  Oxidative 
burst is needed for NET release, as neutrophils from patients deficient in functional 
NADPH oxidase subunits (who suffer from chronic granulomatous disease, CGD) are 
unable to form NETs (196).  Recently, it was discovered that Rac2, a GTPase known to 
interact with NADPH oxidase is needed to make NETs (199).  Also involved in NET 
formation are two proteases, neutrophil elastase and myeloperoxidase (200, 201), that 
degrade specific histones and allow chromatin release. 
 
NET formation seems to be a late attempt by neutrophils to clear bacteria, as 
treating neutrophils with DNase affects the ability of neutrophils to eliminate bacteria at 
later time points (> 2 hours) (196).  At earlier time points, DNase-treated and untreated 
neutrophils are equally potent in clearing bacteria, suggesting that phagocytosis is the 
primary mechanism employed by neutrophils.  Apart from being morphologically unique 
NET formation is also associated with a unique biochemical process -deimination of 
histone arginine residues to citrulline (202).  Exposure of neutrophils to inflammatory 
stimuli induces activation of peptidylarginine deiminase IV (PAD4), the enzyme that 
deiminates arginine residues on histones to citrullines (202).  Activation of other PAD 
isoforms in higher vertebrates is associated with physiological growth processes.  
Deimination of histones during neutrophil activation in response to inflammatory stimuli 
or infectious agents provides a unique example of self protein deimination in response to 
external factors.  The mechanism and regulation of NET formation is not fully 
understood, but the hypercitrullination (deimination) of histones is presumed to play a 
role in the decondensation of chromatin for extracellular release (203).  It is likely that 
the conversion of positively charged arginines to neutral citrullines reduces the 
interactions between histones and negatively charged DNA.  Does deimination of 
histones facilitate NET formation?  NET formation requires rapid decondensation of 
chromatin (194).  The linker histone H1 keeps the chromatin compact. Deimination of 
core histones is known at present.  Whether deimination occurs in linker histone H1, a 
histone subtype responsible for maintaining the higher order structure of chromatin is still 
to be determined (see Chapter 3). 
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Deimination: a Post Translational Modification during Neutrophil Activation 
 
During neutrophil activation, deimination of histones occurs as a result of the 
action of PAD4. This enzyme belongs to a family of highly conserved, Ca++ dependent 
enzymes known as peptidylarginine deiminases (PAD) (204, 205).  Deimination of 
proteins is notable because it transforms a positively charged amino acid (arginine) to a 
neutral amino acid (citrulline) resulting in a net loss of one positive charge per 
transformed residue.  So deimination changes not only the primary sequence of a protein 
is but also the net charge on the protein.  During this reaction, the guanidino group of 
arginine is attacked by the Cys residue of a PAD enzyme resulting in the formation of a 
tetrahedral adducts.  A nucleophilic attack by a water molecule then cleaves the adduct to 
form a keto group of citrulline while releasing ammonia and regenerating the Cys residue 
of the enzyme (206, 207).  The net result is the conversion of arginine to citrulline with a 
mass shift of +1 Da.  PAD4 is the only member of this family that has a nuclear 
localization signal and is therefore responsible for deimination of histone and other 
nucleroproteins during neutrophil activation.  Other members of the PAD family, 
PAD1-3 and PAD6 have other tissue localization and substrate specificities. 
 
 
Physiological Effects of Protein Deimination 
 
Deimination of proteins changes their primary, secondary or tertiary structure and 
also influences protein-protein interactions.  Deimination may result in a loss of ordered 
structure and denaturation of proteins (208).  Deimination by causing loss of basic 
residues and alterations in charge distribution results in loss of ionic interactions and 
breaking of hydrogen bonds.  In general, deimination results in a less compact 
configuration of proteins.  In epidermis keratin (K1 and K10), filaggrin and trichohalin 
are known to undergo deimination (209, 210).  After undergoing deimination, 
profilaggrin acquires an open configuration that is more accessible to the neutral protease 
calpain.  Cleaved filaggrin units are osmotically active, contributing to hydration of the 
skin (211).  Deimination further causes small filaggrin units to bind keratin more 
efficiently by lowering their isoelectric point and thus providing strength to the epidermis 
(211).  During early postnatal life, deiminated myelin basic protein binds less tightly to 
gangliosides and thus provides the plasticity needed for brain development (212).  
Without deimination development of nerve and hydration of skin suffers.  Also, without 
deiminating histones, neutrophils do not make NETs efficiently resulting in defective 
bacterial clearance (203, 213).  These examples illustrate the important role deimination 
plays in the development of nerves, maintenance of skin characteristics and neutrophil 
function. 
 
 
Deiminated Proteins and Autoimmunity  
 
Interest in deimination as a PTM that enhances and promotes autoimmunity 
started when it was discovered that previously known anti-keratin antibodies associated 
with rheumatoid arthritis actually recognize deiminated filaggrin (214).  Later, 
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autoantibodies against several other deiminated proteins were identified in RA patients.  
These were directed against deiminated fibrin, vimentin and collagen.  Many of these 
deiminated proteins were identified in the synovial joints of RA patients (215, 216).  
Detection of anti- deiminated protein antibodies paved the way for the development of 
kits used for diagnosing RA with very high sensitivity and specificity (217-219).  
Antibodies to deiminated proteins can be identified in the sera of RA patients even before 
the onset of disease and have been associated with severe erosive arthritis (220, 221).  All 
these findings suggest that deimination plays an important role in the etiology of RA. 
 
In addition to RA, deimination seems important for the etiology of multiple 
sclerosis (MS).  A higher percent of deiminated MBP is found in the nerves of children 
that decreases with age (212).  Deimination of myelin basic protein (MBP) found in adult 
MS patients is comparable to early post natal levels (212).  T cells that interact with 
deiminated MBP were recognized in MS patients (222) as well as in mouse models of 
MS (223).  When tested, deiminated peptides of MBP induced more severe disease in 
EAE models of MS than unmodified peptides (223). 
 
How can peptides with one modified residue make such an impact in inducing 
autoimmune disorders?  Perhaps deimination of arginine results in generation of “neo-
epitopes” influencing antigen processing, presentation or recognition.  Studies have 
shown that positively charged P4 pockets of certain MHC class II molecules (of HLA DR 
β-chain) can interact with citrullines better than arginine for antigen presentation (224).  
Individuals which share a common epitope (EQKRAA) in the third hypervariable region 
of the DRB chain of MHC molecules share increased susceptibility to RA (225, 226).  
The genetic risk for RA is not limited to MHC haplotypes bearing the shared epitope but 
extends to include additional MHC alleles and genes outside MHC region (227).  A 
genetic study of Japanese patient population found that certain haplotypes of PAD4 
associate with an increased susceptibility for RA (228).  The study revealed that the 
mRNA of RA susceptible PAD4 haplotypes is 4-5 time more stable than the mRNA of 
non-susceptible haplotypes (228).  Increased mRNA stability of PAD4 may result in 
more extensive deimination of proteins due to higher expression of PAD4.  Other 
evidence which points to the role of PAD4 induced deimination in RA includes the 
presence of anti-PAD4 antibodies in anti CCP positive RA patients (229) and 
colocalization of PAD4 and deiminated proteins in RA synovial tissue (230, 231).  Also 
patients with anti-PAD4 autoantibodies have a severe RA phenotype (232).  Certainly 
autoantibodies against deiminated proteins play a role in destruction of synovial tissues 
and joints, but how these autoantibodies arise is not yet known. 
 
 
Neutrophil Activation: Confluence of Factors for Initiation of Autoimmunity 
against Deiminated Histones? 
 
The following factors are implicated in predisposing to autoimmunity: 1. Genetic 
background influencing immune signaling, antigen processing and presentation; 2. 
Excessive cell death; 3. Defects in clearance of dead cells; 4. environmental agents 
particularly infections and chemical pollutants; 5. Exposure of membrane bound antigens 
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and 6; Post translational modifications generating ‘neo-epitopes’.  Autoimmunity is a 
multifactorial event and neutrophil activation can bring majority of above mentioned 
factors together resulting in autoimmunity in susceptible individuals.  In addition to 
phagocytic response to clear infections, neutrophils employ NETs with extruded 
chromatin laced with deiminated histones to contain infectious agents.  Death of 
neutrophils during NET formation adds to increased cell death seen during infection and 
may overwhelm local clearance mechanisms.  NETs also cause contact activation of 
plasma kallikrein (PK) of intrinsic coagulation pathway (233).  On one hand this results 
in coagulation of clotting factors thereby augmenting microbial trapping while on the 
other hand it results in the release of bradykinin, a potent proinflammatory peptide (234).  
This along with the inflammatory cytokines released by neutrophils, resident 
macrophages and epithelial cells generates a highly proinflammatory microenvironment.  
Thus, neutrophil activation and NET formation increase the local concentration of 
chemotactic and stimulatory cytokines that further enhance the infiltration of B and T 
lymphocytes at the site of infection.  Adjuvant effects of bacterial products such as LPS 
can only increase the risk of initiating an unwanted immune response against NET 
associated proteins. 
 
Autoantibody targets on neutrophils were identified in SLE, small vessel 
vasculitides and many of these targeted antigens are integral components of NETs (235-
238).  Autoantibodies have been identified against neutrophil proteases- neutrophil 
elastase, cathepsin G and proteinase 3 (PR3) (235, 236) as well as other bactericidal 
substances, such as defensins and the LL-37 peptide (239, 240).  In SLE patients 
neutrophils are reported to have increased propensity to make NETs (241).  These 
patients also have increased serum levels of NETs and associated granular proteins (242)  
as well as autoantibodies against them (243).  Both levels of NET associated granular 
proteins and autoantibodies against them correlate well with the severity of disease.  
Released NETcomponents in SLE patients causes direct endothelial damage as well as 
contributes to the production of type 1 IFNs from plasmacytoid dentritic cells (240, 242).  
The fact that anti-DNA autoantibodies of lupus patients protect NETs from being 
degraded by nucleases only adds to the persistence of NETs further amplifying the 
damage (243). 
 
Two major components of NETs are DNA and core histones that constitute about 
70% of NET associated proteins (244).  Histones are also well known autoantigens in 
diseases like lupus (245) and Felty’s Syndrome (246).  Of the 4 core histones present in 
NETs, 3 (H2A, H3 and H4) are known substrates of PAD4.  The fact that autoantibodies 
are found against all major NET components and that histones in NETs undergo 
deimination, a PTM that changes recognition of self antigens in a manner to initiate an 
autoimmune response, made us think that autoantibodies against deiminated histones 
should also arise in susceptible individuals.  Therefore, we began this study to find 
neutrophil involvement in autoimmune diseases. 
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Aims and Objectives 
 
Infections have long been suspected to play a role in the etiology of autoimmune 
disorders.  Though the role of infections in the initiation of autoimmune disease is not 
clear, evidence of flares in autoimmune disease during episodes of infection support their 
involvement in autoimmunity.  Infections provide a unique confluence of events which 
may promote initiation of an autoimmune response.  First, infection can cause massive 
recruitment and activation of neutrophils.  Second, deimination a PTM known to alter 
self antigens to “neo-epitope” is associated with neutrophil activation.  Third, NET 
formation brings deiminated histones to the outside from the confines of cellular 
membranes and exposes them directly to the antigen presenting cells.  Fourth, the 
adjuvant effect of the trapped microbial components increases the efficiency of antigen 
processing and presentation.  Fifth, a variety of cytokines and chemokines released from 
the activated neutrophils, macrophages and APCs at the site of infection recruits T and B 
cells, some of which may be capable of binding to deiminated histones if central 
tolerance against deiminated histone “neo-epitopes” is not established previously.  Sixth, 
the lack of any known mechanism for reversing deimination combined with the fact that 
deiminated histones are embedded into exposed NETs encapsulating pathogen increases 
the possibility that deiminated proteins persist in an environment suitable for recognition 
by lymphocytes.  Keeping these points in mind we formed our hypothesis that PTM, 
particularly those that are introduced in a pro-inflammatory context (deimination), 
are responsible for breaking tolerance. 
 
In this study our main objective was to determine if deiminated histones are 
targets in autoimmune diseases.  In the chapters to follow we provide evidence for 
autoimmune response against deiminated histones in patients with Felty’s syndrome (FS) 
but not in SLE, RA and small vessel vasculitides (Chapter 1).  Next, we identify linker 
histone H1 as a new substrate of PAD4, provide evidence for deiminated H1 being an 
autoantigen in SLE and map citrullines on H1 subtypes expressed in neutrophils (Chapter 
2).  Finally, we describe profound B cell tolerance to deiminated histone seen in both 
non-autoimmune and autoimmune prone mice (Chapter 3). 
 
 
Significance 
 
Mechanisms involved in the breaking of tolerance to self antigens and initiation of 
autoimmune disorders are multifactorial.  Environment and infections seem to influence 
the development and progression of autoimmune disorders.  Autoimmune disorders flair 
during infection indicating direct role for infectious agents in the disease progression.  
Mechanisms like molecular mimicry of host antigens by microbial proteins have been 
identified as directly contributing to autoimmunity.  Though a direct contribution by 
infections to autoimmunity has been established in some cases, in this study we looked 
for evidence for indirect contribution of infections in breaking tolerance.  We focused on 
how an immune response (neutrophil activation) initiated to fight infections may 
contribute to the initiation of autoimmune response.  We found evidence for the presence 
of autoantibodies against deiminated histones in a subset of patients with FS, SLE and 
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RA.  In contrast, autoantibodies from patients with vasculities preferentially bound to 
non-deiminated histones over deiminated histones suggesting that different circumstances 
or genetic differences can skew the autoimmune response to one form of histones.  
Preferrential binding of anti-deiminated histone autoantibody containing sera to activated 
neutrophils and the specific recognition of deiminated histones in activated neutrophil 
lysates suggest involvement of neutrophils as source of deiminated histones to drive 
autoimmune reaction. 
 
In order to test the contribution of deimination in initiating an immune response 
against self-antigens, we immunized BALB/c mice with deiminated histones. Our results 
show that though deiminated histones are able to induce proliferation of deiminated 
histone specific T cells, B cell tolerance to deiminated histones is similar to that against 
non-deiminated histones.  In mice with defective tolerance against histones (NZB X 
NZW, NZM2410 and SLE congenic mice derived from them), we found that 
spontaneously arising autoantibodies preferred non-deiminated histones over deiminated 
histones. This suggests that B cell tolerance to deiminated histones is actively maintained 
even in autoimmune prone mice. On futher investigation we found the presence of 
deiminated histones in the spleen of autoimmune mice and conclude that deiminated 
histones, probably from activated neutrophils, are trapped in the reticulo-endothelial 
system of spleen (247) and help in maintaining peripheral tolerance against deiminated 
histones even when tolerance to non-deiminated histones is compromised. 
 
Alternatively, the preference of B cell response for non-deiminated histones over 
deiminated histones may be due to differences in processing and presentation of the two 
antigens.  Proteolytic processing of proteins is a prerequisite for MHC loading.  Though 
many proteases of the lysosomal compartment have overlapping activity, certain 
proteases are specific for digesting and presenting specific proteins.  For example, tetanus 
toxin C fragment (TTCF) is specifically cleaved by asparaginyl endopeptidase (248).   
Consequently, APCs treated with inhibitors of asparaginyl endopeptidase, and not other 
protease inhibitors, have reduced presentation of TTCF antigen (248).  With regard to 
deiminated histones, cleavage by neutrophil proteases may shift position relative to non-
deiminated histones.  Neutrophils express cathepsin H (249), a lysosomal cysteine 
proteinase involed in antigen presentation (250).  Cathepsin H recognizes arginine as its 
major cleavage site.  Neutrophils also express trypsin, a protease that cleaves proteins at 
carboxy terminal of arginine. Thus, by deiminating arginine to citrulline, the loss of a 
cleavage site on histones may result in different peptide fragments.  Because histones are 
abundant self proteins, it is not surprising that they are presented in MHC.  Thus, an 
arginine containing peptide from histone H2A (RIIPRHLQL) has been identified as a 
natural endogenous ligand for HLA-G (MHC-1) (251).  Deimination may change 
presentation of this or similar histone peptides by MHC.  Differences in presentation may 
influence T cell central tolerance and B or T cell activation in the periphery.  As 
splenocytes from (NZB X NZW) F1 mice proliferated in response to both deiminated and 
non-deiminated histones, we suggest that MHC presentation of deiminated histones is 
intact in lupus prone autoimmune mice.  Therefore, the preference of IgG binding for 
non-deiminated histones may be due to the presence of a B cell tolerance mechanism to 
deiminated histones.  
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Our finding that autoantibodies to deiminated histones are present in humans with 
FS represents the first instance where a product of the innate immune system is directly 
targeted by an autoimmune response.  Lack of autoantibodies against deiminated histones 
in patients with vasculitis indicate that different genetic predisposition or environmental 
circumstances determines whether an autoimmune response against deiminated histone 
will be initiated or not.  Our observation in autoimmune mice that peripheral tolerance to 
deiminated histones is intact and separate from tolerance against non-deiminated histones 
also points to the fact that different factors, both genetic and environmental, will 
determine whether an autoimmune response will be initiated against either self-antigens.  
Understanding tolerance against deiminated histones in autoimmune lupus prone mice 
may increase the possibility of tolerance being manipulated in ways so as to to put an 
autoimmune disease into long term remission. 
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CHAPTER 2.     FELTY’S SYNDROME AUTOANTIBODIES BIND TO 
DEIMINATED HISTONES AND NEUTROPHIL EXTRACELLULAR 
TRAPS* 
 
 
Summary 
 
To test the hypothesis that autoantigen modifications by peptidylarginine 
deiminase IV (PAD4) increase immunoreactivity, sera from patients with systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), Felty’s syndrome (FS), and ANCA-
associated vasculitides (AAV), along with non-autoimmune controls, were tested for 
binding to activated neutrophils, deiminated histones, and neutrophil extracellular traps 
(NETs).  IgG binding to LPS-activated neutrophils was assessed by confocal microscopy, 
and binding to in vitro deiminated histones was measured by ELISA and Western blot.  
In addition, we quantitated histone deimination in freshly isolated neutrophils from the 
blood of patients.  Increased IgG reactivity with activated neutrophils, particularly NETs, 
was paralleled by preferential ELISA binding to deiminated histones over non-
deiminated histones in a majority of FS but only rare SLE and RA sera.  Immunoblotting 
revealed autoantibody preference for deiminated histones H3, H4 and H2A in most FS 
and a subset of SLE and RA patients.  In patients with AAV, serum IgG preferentially 
bound non-deiminated histones over deiminated histones.  Increased levels of deiminated 
histones were detected in neutrophils of RA patients.  Circulating autoantibodies in 
Felty’s are preferentially directed against PAD4-deiminated histones and bind to 
activated neutrophils and NETs.  Thus, increased reactivity to modified autoantigens in 
FS implies a direct contribution of neutrophil activation and the production of 
NET-associated nuclear autoantigens in the initiation or progression of FS. 
 
 
Introduction 
 
Autoimmune disorders such as systemic lupus erythematosus (SLE) or 
rheumatoid arthritis (RA) may progress slowly and follow a chronic path with gradual 
worsening of disease manifestations (252, 253).  In other individuals, sudden flares of 
more intense disease manifestations may interrupt lengthy periods of symptom 
quiescence.  One notable example of worsening in a chronically progressing disorder is 
provided by Felty’s syndrome (FS), a variant of RA that is defined by arthritis involving 
axial joints, enlargement of the spleen, and a decline in neutrophil numbers (254).  The 
decrease in neutrophil numbers is thought to be due to excessive activation of mature 
neutrophils and their clearance in the patient’s spleen.  Felty’s usually arises in 1-3% of 
RA patients after 10 to 15 years of fairly typical symptoms (254). 
 
 
 
* Adapted with permission. Dwivedi, N., J. Upadhyay, I. Neeli, S. Khan, D. Pattanaik, L. 
Myers, et al. 2011. Felty's syndrome autoantibodies bind to deiminated histones and 
neutrophil extracellular traps. Arthritis Rheum (In Press). 
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In an alternative view, FS does not arise as chronic progression of RA.  Instead, 
Felty’s may be closely related to a T-cell form of large granular lymphocyte leukemia 
(LGL) with which it shares its defining clinical features and an oligoclonal CD8+ T cell 
expansion (255).  Due to the neutropenia, FS patients experience an elevated risk of 
infections.  The factors determining the course of disease in any given patient are largely 
unknown.  A prevalent finding is that autoimmune disorders may worsen in parallel with 
various types of infections (256), although it is difficult to separate environmental effects 
from underlying genetic and stochastic contributions. 
 
Just how infections may affect autoimmune reactivity and potentially lead to 
sudden flares in the presentation of autoimmune disorders is not established.  One 
possibility is that, as result of infection, the number of apoptotic cells could transiently 
rise because diverse pathogens induce apoptosis in infected cells (257).  The increased 
numbers of apoptotic cells may exceed the clearance capacity of tissue-resident 
scavenger cells and lead to the stimulation of the immune system with antigens from the 
apoptotic cells (105, 258).  This proposed mechanism is consistent with the increased risk 
of autoimmunity arising from genetic defects in serum factors that recognize and bind 
apoptotic cells or defects in phagocyte receptors that function in uptake and clearance of 
apoptotic cells (258).  Whether inefficient clearance of cells that die from other forms of 
cell death also increases the risk of autoimmunity has been less thoroughly tested. 
 
An alternative form of cell death that is induced during an infection is “NETosis”.  
NETosis received its name from neutrophil extracellular chromatin traps (NETs) that are 
released in response to infectious agents ranging from bacteria to fungi (194).  Once at 
the site of an infection, neutrophils deploy extracellular chromatin that is studded with 
additional bactericidal granule components and may serve to immobilize and destroy 
microbes (244, 259).  The release of NETs is induced by a wide range of inflammatory 
stimuli (202) and depends on signals from the cell surface and the participation of the 
cytoskeleton (197).  Autoantibodies to NET components, including lactoferrin, lysozyme 
and elastase (260, 261), arise in autoimmune disorders, suggesting that NETs should be 
viewed as possible stimuli for such antibodies.  Nevertheless, conclusive evidence linking 
NETs to the induction of autoantibodies is lacking. 
 
Core histones in NETs contain arginines that are converted to citrullines (202) by 
peptidylarginine deiminase 4 (PAD4), a post-translational modification (PTM) that is 
essential for NET release (213).  PAD4 acts on various autoantigens (210, 262-266), such 
that antibody reactivity against citrulline-containing peptides has proven useful in the 
diagnosis of autoimmunity.  In RA, autoantibodies react with a peptide of filaggrin, 
provided it contains citrulline (267), and anti-cyclic-citrullinated-peptide (anti-CCP) 
autoreactivity constitutes a reliable marker for this condition (217). 
 
Because histones are the major substrates of PAD4 (268), and because anti-
histone antibodies are produced in SLE (245), RA (269) and FS (246), we hypothesized 
that, if NETs are the source of the autoantigens, autoantibodies from patients with these 
disorders might bind deiminated histones with preference over non-deiminated histones.  
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Our results with FS sera support this hypothesis:  By immunofluorescence, ELISA, and 
Western blotting, we found preferential binding to deiminated histones H3, H4, H2A or 
H1.  In comparison, only few RA and SLE sera showed preferential binding to 
deiminated histones.  A control group of patients with anti-neutrophil cytoplasmic 
autoantibody (ANCA)-associated vasculitides (AAV) expressed antibodies with 
preference for non-deiminated histones over deiminated histones.  We propose that 
activated neutrophils contribute as sources of deiminated autoantigens to the pathogenesis 
of FS. 
 
 
Patients and Methods 
 
 
Patient Sera 
 
Sera were collected at the University of Lubeck, the Hospital for Special Surgery, 
from UTHSC, and from the Veterans’ Administration RA (VARA) serum repository 
(270) and used in accord with IRB approvals from each of the participating institutions.  
All patients fulfilled the American College of Rheumatology classification criteria for 
RA (271) or SLE (272) or ANCA vasculitis (273).  Felty’s syndrome was clinically 
defined by the coexistence of RA, chronic neutropenia (<2000/l), and splenomegaly 
(254), except that VARA participants were classified as having FS based on the 
determination of an International Statistical Classification of Disease (ICD-9) code 
corresponding to this disorder (714.1). 
 
 
Neutrophil Isolation and Stimulation 
 
Neutrophils were isolated from healthy donor blood (Key Biologics, Memphis, 
TN), or from patients with RA or FS, as described (202).  Briefly, neutrophils were 
enriched using dextran sedimentation, recovered by isolymph density gradient (Gallard-
Schlesinger, Plainview, N.Y, USA), and suspended in PBS (without Ca++/Mg++) with 
0.1% glucose and 0.5% heat-inactivated human serum.  Neutrophils were stimulated with 
100 ng of LPS/ml of HBSS or PBS, 2mM Ca++, for 2 hours, and lysed in 2% SDS, 5% 
2-mercaptoethanol and 10% glycerol in 62.5mM Tris, pH 6.8.  Alternatively, 
autoimmune or control sera were diluted to 2 g/ml of IgG and used in place of LPS. 
 
 
Confocal Microscopy 
 
Purified neutrophils were allowed to settle onto poly-L-lysine-coated glass 
coverslips and examined as described (202).  Cells were treated with LPS (100 ng/ml) for 
1 hour at 37°C, rinsed with ice-cold HBSS, and fixed with 4 % paraformaldehyde in 
HBSS.  Coverslips were incubated with patient serum (10 g/ml IgG) or rabbit anti-
citrullinated histone H3 Abs (Abcam, Cambridge, MA, Cat # ab5103) at 1:100 dilution 
for 1 hour.  Antibody binding was detected with goat anti-human IgG-AF647 or goat 
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anti-rabbit IgG-AF488 and Sytox orange (all from Invitrogen) and analyzed by confocal 
microscopy. 
 
 
ELISA 
 
Calf thymus histones or recombinant human histone H3.3 (Millipore Corp., 
Billerica, MA), were incubated with 0.2 µM recombinant PAD4 to completion of 
reaction as described (274).  Flat bottom, 96 well microtiter plates (Immulon 4HBX) 
were coated with 5 µg/mL of deiminated or non-deiminated histones.  As control, 
recombinant PAD4 was added to histones in the presence of EDTA to test whether 
binding to PAD4 confounded our ELISA readings.  Blank values were determined from 
plates incubated with coating buffer.  Plates were blocked with 2.5% BSA in PBS, and 
sera were serially diluted from 20 g/ml of IgG and incubated for 2 hour.  Binding was 
quantified using goat anti-human IgG alkaline phosphatase (Southern Biotech, 
Birmingham, AL) after addition of phosphatase substrate (Sigma) and measurement of 
optical density.  ANCA were detected by immunofluorescence or capture ELISA, as 
described (275).  Anti-citrullinated protein antibodies (ACPA) were measured by anti-
citrullinated vimentin or anti-CCP ELISA, according to manufacturers’ instructions. 
 
 
Western Blot 
 
Proteins were resolved by 15% SDS-PAGE and transferred to nitrocellulose.  
Membranes were blocked in 5% BSA, 0.1% Tween 20 in TBS and incubated with patient 
sera at 5 µg/ml of IgG in TBS containing 2.5% BSA, 1% NP-40 and 0.1% SDS for 2 
hours.  Anti-human IgG–HRP was used for chemiluminescence development with 
“Western Lightning” substrate (PerkinElmer). 
 
 
Statistical Analysis  
 
We used an unpaired, two-tailed t test to evaluate whether FS IgG had greater 
preference for deiminated histones than IgG from other experimental groups.  
Chemiluminescence images of Western blots were scanned and the differences in binding 
between different sera were evaluated by paired permutation test, as described in the 
results.  The relative abundance of deiminated histones in neutrophils ex vivo was 
determined by dividing the intensity of binding to deiminated histone H3 by the total H3 
binding intensity.  The statistical differences between the groups were computed by 
Mann-Whitney (Wilcoxon) Rank test. 
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Results 
 
 
Characteristics of Patient Populations 
 
To analyze potential mechanisms that induce autoreactivity, we collected sera 
from 32 patients with SLE, 37 with RA, 23 with FS, 55 with small vessel vasculitides, 
along with 10 healthy controls.  Patient data are given in Table 2-1.  Despite the fact that 
SLE, RA and FS primarily affect women, patients included 67 females and 76 males who 
ranged from 13 to 88 years of age (avg. 62).  The male predominance is because 34 of the 
FS and RA samples were from the VARA repository which contains mostly male 
patients.  Disease was active in 52 of 60 RA and FS patients, whereas 22 of the SLE 
patients had inactive disease.  In addition, our study also included 32 males and 23 
females with active vasculitis, including 25 patients with WG, 15 with MPA and 15 with 
CSS.   Most patients were treated with combinations of azathiopine, prednisolone, 
methotrexate and endoxan, and 10 RA or FS patients were on anti-TNF therapy (Table  
2-1).  Clinical assays were performed to assess the levels of anti-citrullinated protein 
antibodies (ACPA or anti-CCP).  Most (17 of 23) FS patients and (22 of 37) RA patients 
had antibodies to citrullinated antigens, an indication of more rapidly progressing 
arthritis.  In contrast, 24 WG patients and 14 MPA patients contained ANCA that 
predominantly bound PR3 or MPO respectively (Table 2-1).  The clinical usefulness of 
these assays was recently evaluated (275, 276). 
 
 
Neutrophil Activation Increases Autoantibody Reactivity 
 
Neutrophils respond to bacterial breakdown products, such as LPS, and other pro-
inflammatory stimuli by releasing granule enzymes and casting chromatin NETs (244, 
259).  These complex morphological and enzymatic reactions could potentially affect 
autoantibody binding.  To test whether neutrophil activation increases autoantibody 
reactivity, we prepared neutrophils from healthy donors, exposed them to LPS or left 
them untreated, and measured binding of IgG from SLE, RA, and FS patients.  Bound 
IgG was detected with fluorescent rabbit anti-human IgG antibodies and visualized 
relative to DNA (Figure 2-1).  Control serum IgG did not detectably bind to unstimulated 
neutrophils or to activated neutrophils (Figure 2-1B).  In contrast, IgG from FS, SLE and 
RA patients reacted strongly to LPS-activated neutrophils (Figure 2-1D, F, H, J, L and 
N), yet binding to unstimulated neutrophils remained low.  
 
Binding of patient IgG to NETs was particularly striking.  FS2 IgG binding 
largely overlapped with NET chromatin (Figure 2-1D), and IgG binding closely matched 
the lace-like distribution of dispersed nuclear DNA.  A similar pattern of IgG binding 
was observed with the FS3 serum (Figure 2-1F).  The binding of RA3 and RA4 IgG was 
focused into domains that mostly coincided with the location of DNA, although certain 
patches of chromatin remained unbound (Figure 2-1H and J).  Binding of SLE6 IgG was 
observed in close association with NETs and it extensively overlapped with the 
extracellular chromatin (Figure 2-1L), as did SLE7 IgG, whose binding closely matched  
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Table 2-1: Characteristics of patients   
 
Parameters SLE RA FS WG MPA CSS Non-AI 
Patients (n) 32 37 23 25 15 15 10 
Male (n) 3 18 17 16 7 9 8 
Female (n) 29 19 6 9 8 6 2 
Mean Age (yrs) 35.2 64.9 70.3 54.7 67.4 60.7 36.2 
Active Disease 10 31 21 25* 15 15 - 
pANCA(α-MPO) +ve 1 1 - 2 14 - - 
cANCA (α-PR3) +ve - 1 1 23 - - - 
ACPA +ve 2 22 17 1 - - - 
Azathiopine 9 - - 2 3 1 - 
Prednisolone 26 24 8 24 12 14 - 
Methotrexate 1 25 12 9 3 2 - 
Endoxan 2 - - 9 5 8 - 
Hydroxychloroquine 17 - - - - - - 
Mycophenlate 9 - - - - - - 
Anti-TNF - 4 6 - - - - 
* Sera from the WG patients were also tested in the inactive phase of disease.  
(Abbreviations: SLE, Systemic Lupus Erythematosus; RA, Rheumatoid Arthritis; FS, 
Felty’s Syndrome; WG, Wegener’s Granulomatosis; MPA, Microscopic Polyangiitis; 
CSS, Churg-Strauss Syndrome; Non-AI, Non-Autoimmune.)  
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Figure 2-1: Binding of autoimmune sera to activated neutrophils 
Autoimmune or control IgG bound to unstimulated or LPS-stimulated neutrophils (A-N).  
Representative sera shown are:  Control serum (CS; panels A and B), FS2 (C and D), FS3 
(E and F), RA3 (G and H), RA4 (I and J), SLE6 (K and L), SLE7 (M and N).  Stimulated 
neutrophils, having released NETs, react more strongly with autoimmune IgG.  
Anti-human IgG alone did not bind (O).  Stimulated neutrophils reacted with anti-
deiminated histone H3 (green fluorescence in P).  Anti-IgG binding is displayed in red 
and DNA in blue. 
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the distribution of NET DNA (Figure 2-1H).  The pattern of patient IgG binding 
resembled, in most instances, the distribution of deiminated histone H3 (Figure 2-1P).  
The congruent distributions of IgG immunoreactivity and of deiminated H3 suggested 
that, at least in part, immunoreactivity may be enhanced by histone deimination. 
 
 
Preferential Antibody Binding to Deiminated Histones in ELISA   
 
Previous reports had indicated that neutrophils efficiently deiminate core histones 
(268).  Our own data confirmed that core histones are the major substrates of PAD4 
deimination in activated neutrophils (Figure 2-2), although a number of other proteins 
also are PAD4 substrates.  To directly assess whether deiminated histones are preferred 
targets for FS, RA, or SLE patient autoantibodies, we deiminated histones in vitro and 
measured IgG binding by ELISA. 
 
Binding curves were determined for 23 FS, 37 RA and 32 SLE sera.  Figure  
2-3A-D shows representative curves.  Five of six FS sera showed IgG binding to histones 
in ELISA, and, for each of those 5 sera, binding to deiminated histones exceeded binding 
to non-deiminated histones by 2 to 10-fold (Figure 2-3A).  The sixth sample showed 
negligible binding.  In contrast, RA sera bound less avidly to histones and, except for 
one, the sera showed little to no preference for deiminated histones (Figure 2-3B).  
Histone binding was most pronounced with SLE sera, yet except for one serum (triangles 
in Figure 2-3C), the binding to deiminated and non-deiminated histones was comparable.  
In the exceptional serum, IgG binding to deiminated histones was more than 30-fold 
stronger than to non-deiminated histones.  Control (Non-AI) sera showed very little to no 
binding to either type of histone (Figure 2-3D).  LG2-2, a mouse monoclonal anti-H2B 
(277), gave equivalent binding to either substrate, thus indicating equal coating of plates 
with deiminated and non-deiminated histones (Figure 2-3E).  
  
We subtracted the binding to non-deiminated histones from the binding to 
deiminated histones at 6.6 g/ml IgG (in the linear range of titration curves), in order to 
determine the relative binding preference for deiminated histones (Figure 2-3F).  This 
measure indicated that FS sera were unique among the sera tested, in that binding to 
deiminated histones was generally higher than binding to non-deiminated histones.  The 
SLE group had one serum with greatly enhanced preference for deiminated histones, and 
other sera that bound with only low relative preference to deiminated histones.  IgG from 
RA sera showed only slightly higher binding to histones than control sera and only two 
sera bound preferentially to deiminated histones in ELISA.  These data indicate that FS 
patients differ significantly from RA and SLE patients in their preferential antibody 
binding to deiminated histones. 
 
 
Autoantibodies Distinguish between Different Deiminated Histones 
 
The ELISA with total histones revealed binding preferences that were robust and 
directed at native antigens.  However, the ELISA may not have detected subtle  
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Figure 2-2: Neutrophil substrates of PAD4 
Neutrophil extracts were probed for citrulline by Western blot.  Lanes 1 and 2:  
Neutrophils treated with or without calcium ionophore.  Lanes 3, 4 and 5: Freeze thaw 
lysates of neutrophils maintained in the absence of Ca++ (Lane 3), in the presence of 
2mM Ca++ (Lane 4), or in the presence of 2mM Ca++ with added Cl-amidine, a PAD4 
inhibitor.  Arrows indicate putative core histone bands that exceed multiple other 
deiminated proteins in staining intensity. 
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Figure 2-3: Serum IgG binding to deiminated or non-deiminated histones 
Sera from FS (A), RA (B), or SLE patients (C) and controls (D) were tested for binding 
to deiminated (red) and non-deiminated histones (blue) and OD values were plotted.  
Mouse anti-histone H2B (LG2-2) was used as standard (E).  Differences in binding were 
computed for each serum (F).  Different symbols represent different sera.  Brackets in 
panels B and C identify sera with the greatest preference for deiminated histones.  
Asterisks indicate statistical significance between groups (FS vs. RA: p = 0.017; FS vs. 
SLE: p = 0.042; and FS vs. Non AI: p = 0.047).   
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preferences directed at individual histones.  To determine which histones are 
preferentially bound by autoantibodies, we separated deiminated and non-deiminated 
histones by SDS-PAGE and probed them with patient and control sera (Figure 2-4).  As 
shown by Coomassie Blue staining, both types of histones were present in equivalent 
amounts.  Moreover, the faster mobility of the deiminated histones and their 
immunochemical reaction pattern indicated that, as expected, three core histone contained 
citrullines. 
 
The majority of FS sera and a minority of the RA and SLE sera (some, e.g. RA1, 
quite weakly) bound with preference to one or more deiminated histones (Figure 2-4).  
Most of the samples that scored positive for antibodies to deiminated histones bound 
deiminated H3, although preferential reactivities to deiminated H2A (FS2) or H4 (SLE8) 
were also observed.  Preferential binding to citrulline-containing epitopes from different 
core histones demonstrates that flanking sequences contribute to antibody binding. 
 
Preferential binding to deiminated over non-deiminated histone H3 was 
confirmed by probing multiple gels and quantifying the statistical significance of binding 
(Table 2-2).  In short, chemiluminescence images of Western blots were scanned and 
analyzed using Photoshop imaging software.  Western blots were repeated at least 4 times 
for each patient serum. Different exposures were developed in order to establish the 
saturation range of the x-ray film.  Films were scanned under constant settings of 
brightness/contrast in all cases.  Band intensities were converted to numerical values 
using the histogram function of Photoshop.  These numerical values were used to 
compare binding to the following pairs of histones: deiminated vs. non-deiminated H3, 
and deiminated H3 vs. deiminated H4.  P values were computed to ascertain differences 
in Ab binding to different proteins by paired permutation (exact) test using R Software 
(online at http://www.R-project.org).  Since permutation tests are based on randomly 
generated permutations, the p values for each data set were computed 100 times and the 
means of all the p values were tabulated. Differences were taken as significant if the p 
value was less than 0.01. 
 
Interestingly, four sera (FS2, RA8, SLE5 and SLE6) preferentially bound to a 
deiminated protein migrating near 35 kD.  The anti-citrulline antibody (Anti-Cit) detected 
a band migrating near 35 kD, the approximate size of linker histone H1, suggesting that 
histone H1 is recognized by a variety of patient sera.  Although it will be necessary to 
conclusively demonstrate that H1 is a substrate for PAD4, the possibility is intriguing 
because H1 controls the higher order structure of chromatin.  The analysis of patient sera 
by Western blot confirmed the striking preference of FS antibodies for deiminated 
histones and identified histone epitopes that may be particularly autoreactive. 
 
 
Autoantibodies from ANCA-associated Vasculitides Prefer Non-deiminated 
Histones 
 
As a control, we analyzed anti-histone autoantibodies in autoimmune disorders 
characterized by anti-neutrophil immunoreactivity.  Wegener’s granulomatosis (WG), 
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Figure 2-4: Autoantibodies distinguish different histones 
(A) Representative SLE, RA, and FS sera exhibit different preferences for individual 
deiminated or non-deiminated histones.  Deiminated (left lanes) or non-deiminated 
histones (right lanes) were resolved on SDS-PAGE and stained (Coomassie) or reacted 
with anti-citrulline (Anti-Cit) on blots.  Binding of IgG from autoimmune patients (FS, 
RA or SLE) to histones was detected by Western blot.  (B)  AAV sera preferentially 
recognize non-deiminated histones. Western blots were performed with sera (2 MPA, 2 
CSS and 3 WG) that bound histones.  FS2 serum was used as positive control.  Increased 
binding to individual histones is marked by symbols.  Filled symbols indicate preference 
for deiminated histones, open symbols preference for non-deiminated histones.  Circles 
denote histone H3, squares H2A, up triangles H4, and down triangles histone H1. 
 
  
A
B
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Table 2-2: Statistical analysis of IgG binding to histones 
 
Disease Patient (n) 
p Value 
Cit H3 and H3 Cit H3 and Cit H4 
Control CN 8 0.055015 0.14042 
     
Felty FS1 8 0.00783 0.00775 
 FS2 10 0.001745 0.00189 
 FS3 9 0.003945 0.003785 
 FS4 8 0.007955 0.00749 
 FS5 8 0.00777 0.007805 
 FS6 NA NA NA 
     
RA RA1 9 0.003885 0.00387 
 RA2 11 0.000865 0.00094 
 RA3 10 0.45125 0.51419 
 RA4 9 0.003635 0.00374 
 RA5 11 0.40277 0.002895 
 RA6 10 0.00185 0.031205 
 RA7 9 0.78527 0.38305 
 RA8 8 0.60146 0.007595 
 RA9 11 0.022915 0.000885 
 RA10 NA NA NA 
     
SLE SLE1 9 0.00419 0.0039 
 SLE2 8 0.09374 0.054245 
 SLE3 9 0.16782 0.00758 
 SLE4 NA NA NA 
 SLE5 8 0.007865 0.00782 
 SLE6 8 0.007935 0.00807 
 SLE7 9 0.015795 0.00378 
 SLE8 11 0.1299 0.004625 
 SLE9 8 0.03158 0.03125 
 SLE10  NA NA 
Paired permutation test was used to calculate p values for the identity in binding to 
deiminated and unmodified histones.  Comparisons were made between deiminated H3 
and unmodified H3, and between deiminated H3 and deiminated H4.  Values of less than 
0.01 were considered significant (bold).  The number of observations is indicated by (n). 
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microscopic polyangitis (MPA) and Churg Strauss syndrome (CSS) constitute a group of 
vasculitis disorders associated with ANCA (278).  The characteristics of 25 patients with 
WG, 15 patients with MPA and 15 patients with CSS vasculitis, including their 
autoantibody profiles and therapy, are shown in Table 2-1.  By ELISA, only 7 AAV 
patient sera bound to histones (data not shown).  When those sera were tested by Western 
blot, all 7 AAV sera preferentially bound non-deiminated histones over deiminated 
histones (Figure 2-4).  As before, the FS2 serum preferentially bound deiminated 
histones.  These results showed that AAV patients overall have a low incidence of anti-
histone autoantibodies and that binding of those antibodies is inhibited by deimination. 
 
 
LPS Stimulation of Neutrophils Generates Preferred Histone Autoepitopes 
 
The preceding experiments demonstrated that in vitro deimination of histones 
with PAD4 affects autoreactive IgG binding.  To test whether neutrophil activation also 
generates autoepitopes that mediate autoreactive IgG binding, we exposed neutrophils to 
LPS for 2 hours and probed blots of neutrophil lysates with FS2 and a control antiserum 
(Figure 2-5).  Indeed, the FS2 antibodies showed preferential binding to a protein 
migrating with the expected mobility of deiminated histone H3, providing evidence that 
the relevant FS2 IgG histone autoepitopes are generated by neutrophil exposure to 
inflammatory stimuli.  In addition, other proteins were immunoreactive, and LPS 
stimulation broadly increased the binding of FS2 IgG to cell extracts (Figure 2-5A).  
These results were consistent with the induction of immunoreactive epitopes by PAD4 
activation in neutrophils. 
 
 
Deimination Is Responsible for Preferential Histone Binding 
 
Histones accept numerous post-translational modifications (PTM) that, in various 
combinations, constitute a “histone code” (279).  In order to exclude possible 
contributions of other PTM to the preferential binding of autoantibodies, we used histone 
H3.3 produced in E. coli and thus devoid of eukaryotic PTM.  We deiminated H3.3 with 
PAD4 in vitro.  In parallel, we deiminated BSA to test IgG cross-reactivity with 
citrullines in an unrelated polypeptide. 
 
By Western blotting, FS2 IgG bound with strong preference to the deiminated 
histone H3.3 over the non-deiminated histone.  This result indicated that citrulline is a 
major determinant of FS2 IgG binding.  Furthermore, a low level of binding to 
deiminated BSA was also observed (Figure 2-5B), suggesting that binding can 
accomodate some degree of heterogeneity in flanking sequences. 
 
To localize FS2 IgG binding relative to deiminated histone H3, we stimulated 
neutrophils with LPS on coverslips and incubated them with FS2 serum dilutions and 
rabbit anti-deiminated histone H3.  Binding was visualized with anti-human IgG and anti-
rabbit IgG antibodies (red vs. green in Figure 2-5C).  The FS and rabbit antibodies were 
detected along NET chromatin that was visualized with Sytox orange.  The extent of  
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Figure 2-5: FS2 IgG prefer activated neutrophils, deiminated recombinant 
histone H3.3, and NETs 
(A) Equal amounts of proteins from unstimulated (U) or LPS-stimulated (S) neutrophils 
were stained by Coomasie, or probed with FS2, or control sera.  Protein of histone H3 
mass (arrow) was more reactive with FS2 IgG following LPS treatment.  Control serum 
(CS) did not bind.  (B) Non-deiminated (H) or deiminated (C) H3.3 and BSA were 
probed on Western with FS2 IgG.  LPS-stimulated neutrophils were reacted with FS2 (C) 
or control sera (D).  IgG binding is shown in red, DNA in blue and Anti-Cit H3 in green. 
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colocalization between the antibodies and DNA was nearly complete, revealing clusters 
of FS2 IgG along the extended NET chromatin fibers (bottom left of Figure 2-5C).  This 
confirmed that FS2 serum contains antibodies that recognize deiminated H3 and other, 
more discontinuously arranged NET components.  FS2 IgG also bound neutrophils prior 
to the release of nuclear chromatin, suggesting that autoantigen PTM occur in 
cytoplasmic foci of LPS-activated neutrophils. 
 
 
Circulating Neutrophils from RA Patients Show Spontaneous Activation 
 
To assess histone deimination in circulating neutrophils from RA, FS and control 
subjects, we isolated neutrophils and probed them for deiminated histone H3 by Western 
blot.  Deiminated H3 signal intensities were normalized relative to total H3.  The relative 
intensities showed a 2.9-fold higher level of H3 deimination in RA neutrophils over 
controls (Figure 2-6A; p<0.008).  The increased levels of deiminated histones in  
circulating neutrophils from RA patients suggest a greater degree of PAD4 activation.  In 
contrast, we observed no significant increase in histone deimination in FS over control 
neutrophils (p>0.1).   
 
To explore whether sera from FS, RA or SLE patients contain substances that 
activate neutrophils, we incubated neutrophils from healthy donors with 2 g/ml of 
patient sera and observed histone H3 deimination at 2 hours of incubation.  Both SLE and 
FS sera induced H3 deimination, suggesting the presence of immune complexes or 
cytokines that activate neutrophils, whereas RA sera were inactive as inducers of PAD4 
in neutrophils (Figure 2-6B).  Control sera showed low or undetectable H3 deimination.    
 
 
Discussion 
 
Autoantibodies target diverse PTM in autoantigens (67, 280-282), yet few PTM 
are uniquely associated with infections and inflammation.  The exception is histone 
deimination by PAD4.  A variety of inflammatory stimuli induce histone deimination in 
neutrophils, whereas apoptosis suppresses deimination (202).  Here, we demonstrate that 
autoantibodies to deiminated histones are prevalent in patients with FS.  In contrast, 
autoantibodies to deiminated histones are rare in RA and SLE, and absent from patients 
with ANCA-associated vasculitides.  Our results thus suggest that inflammatory 
activation of neutrophils plays a central role in the induction of FS.   
 
Our observations match findings of others that NET components are antigens in 
autoimmunity.  Autoantibodies from patients with systemic autoimmunity recognize 
innate immune defense proteins that associate with NETs.  This is the case for the granule 
proteases elastase, cathepsin G and proteinase 3 (235, 236, 238) as well as for various 
bactericidal peptides that are stored in granules and co-purify with NETs, such as 
neutrophil defensins and the LL37 peptide (239, 240).  PAD4, the enzyme responsible for 
histone deimination, is an autoantigen in RA patients (283) and anti-PAD4 antibodies 
precede development of clinical disease and predict its severity (284).  In turn, a growing  
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Figure 2-6: Deiminated histone H3 in circulating neutrophils and neutrophil 
stimulation by autoimmune sera   
Neutrophil lysates were prepared from freshly isolated neutrophils from RA, FS and 
control subjects.  H3 deimination was determined by rabbit anti-deiminated histone H3 
and normalized for total H3.  The normalized amounts of deiminated H3 were plotted 
relative to the controls (set to 1).  Horizontal lines represent the mean (thick line) and 
standard deviation (thin lines) for the groups. The difference between the RA and control 
groups was statistically significant (p value =0.008) but not the difference between the FS 
and control groups (p >0.1).  (B) Neutrophils were stimulated by autoimmune sera 
diluted to 2 µg/ml of IgG and analyzed for histone H3 deimination (dH3).  The blot was 
stripped and reprobed with rabbit anti-total H3.    
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number of PAD4 substrates have been recognized as targets of autoantibodies.  These 
include deiminated vimentin (264) and proteins of the extracellular matrix (210, 263, 
266), suggesting that PAD4 is active both inside and outside of cells. 
 
How PAD4 may act on extracellular substrates became clear when it was 
discovered that PAD4 activation is part of the innate immune response to infections 
(202).  Neutrophils release nuclear chromatin and associated enzymes in response to an 
encounter with pathogens (194, 244).  The externalized chromatin entangles pathogens  
and thus becomes linked to potent adjuvants that may stimulate adaptive immunity (285).  
Clearly, uptake and presentation of “NET-ted” pathogens juxtaposes microbial antigens 
and NET autoantigens, including DNA and histones.  Upon pathogen uptake and 
processing, self and foreign antigens may be presented to T cells.  The identification of 
autoantibodies to deiminated histones strongly suggests that NETs provide a source of 
autoantigens in vivo.  Identification of autoantibodies to deiminated histones and other 
NET components (244, 260, 261) implicates NETs as the stimulus for autoantibody 
production and suggests a link between infections or inflammation and the development 
of autoreactivity.   
 
To directly examine the availability of autoantigens in vivo, we quantified 
deiminated histone H3 in freshly isolated blood neutrophils from RA, FS and control 
subjects by Western blot.  We observed nearly 3-fold higher levels of deiminated histones 
in RA patients relative to controls (Figure 2-6A), suggesting ongoing spontaneous 
activation of circulating neutrophils.  In FS, deiminated histones were not significantly 
elevated relative to controls.  Because FS exhibits spontaneous activation and accelerated 
clearance of circulating neutrophils, our observation may be skewed by the fact that an 
elevated proportion of circulating neutrophils in FS is comprised of immature 
(PAD4-negative) neutrophils (286).  Thus, the deiminated histones that were detected in 
FS neutrophils may have been derived from a small fraction of total neutrophils that 
expressed sufficiently high levels of PAD4.  The observation of a potent neutrophil-
stimulating activity in FS and SLE sera (Figure 2-6B) supports this conclusion.  
Together, these results suggest the depletion of mature neutrophils from FS patients and 
the chronic generation of neutrophil-derived autoantigens.   
 
In certain forms of vasculitis, neutrophils are hyperactivated and serum levels of 
neutrophil granule components are elevated in parallel with more advanced disease (287).  
In addition, the severity of lupus correlates with the levels of autoantibodies to the NETs’ 
structural scaffold, DNA (243).  Other studies directly point to neutrophil activation as a 
key factor in the stimulation of autoantibodies.  Notably, SLE patients’ neutrophils show 
an exacerbated response to autoantibody complexes and are more prone to NET release 
(241).  One interesting aspect of these and our studies is that reactivities to different NET 
antigens correlate with different disease manifestations.  Just as PR3-ANCA 
predominantly occur in WG and MPO-ANCA in MPA (288), the anti-deiminated histone 
autoantibodies associate selectively with FS.  We interpret the rare development of anti-
deiminated histone antibodies in RA as indication that tolerance to histones remains 
active and resilient even after development of clinical disease.  Tolerance to deiminated 
histones may only be broken after strong stimulation of adaptive immunity by unique 
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epitopes that drive both B and T cell expansion.   
 
In closing, we propose that anti-deiminated histone autoantibodies are markers 
deserving particular attention in patients with severe inflammation and chronic activation 
of neutrophils who may be at risk of progressing to more severe disease.  Chronic 
presentation of deiminated antigens may, over time, lead to the development of antigen-
specific responses that target the modified antigen determinants and contribute to the 
development of other clinical features of FS.  The data presented in this study allow us to 
propose a model of FS pathogenesis that is based on the biological properties of 
neutrophils, the disease manifestations of FS, and our data on the high incidence of 
autoantibodies to deiminated histones.  In FS, pre-existing arthritis and an increased 
incidence of infections may stimulate a neutrophil response that includes histone 
deimination and the expulsion of chromatin from the cell.  NETs containing deiminated 
histones, in complex with bacterial adjuvants, are the most likely antigenic trigger to 
account for the production of autoantibodies to the modified histones.  These 
autoantibodies or their immune complexes may further stimulate neutrophils, thus 
completing a self-sustaining cycle that drives depletion of mature neutrophils. 
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CHAPTER 3.    AUTOANTIBODY RECOGNITION OF CITRULLINE IN THE 
GLOBULAR DOMAIN OF LINKER HISTONE H1 
 
 
Summary 
 
B cells producing anti-nuclear autoantibodies require a source of antigens. 
Extracellular chromatin, released from activated neutrophils at sites of inflammation, may 
provide access to nuclear autoantigens. Deimination, a posttranslational modification of 
arginine to citrulline by PAD4, plays an important role in neutrophil chromatin release, 
and deiminated histones thus represent a mark of inflammation. Here, we identified 
autoantibodies in sera from systemic lupus erythematosus and Sjögren’s syndrome 
patients that preferentially bound deiminated histone H1.2 over the unmodified H1.2.  
One serum bound epitope included a citrulline located at a highly conserved position in 
the H1.2 globular domain.  We inventoried H1 histone subtypes in human neutrophils by 
RNA expression and by mass spectrometry.  We mapped citrullines by liquid 
chromatography and tandem mass spectrometry.  The data indicate that deimination of 
linker histones generates H1 isoforms with enhanced autoimmune potential. 
 
 
Introduction 
 
Autoantibodies in systemic autoimmune disorders such as systemic lupus 
erythematosus (SLE), Sjögren’s disease, or scleroderma often target nuclear antigens 
such as DNA and histones(289-291).  How such antigens engage B cells and induce 
autoantibodies remained unclear until circumstances were uncovered in which chromatin 
antigens become accessible at the cell surface (77, 292) .  Immunochemical analysis of 
apoptotic cells revealed that nuclear fragments bleb from the plasma membrane, thus 
exposing DNA and core histones to the external milieu (293).  When clearance of 
apoptotic cells is inefficient, apoptotic blebs may supply nuclear antigens to B cells 
(105).  However, autoantibodies to the linker histone H1 represented an exception to this 
pathway.  Anti-H1 bound to early apoptotic cells but the binding to surface blebs was 
undetectable (293).  This observation raised the question whether different circumstances 
are necessary for the exposure of H1 to the extracellular space.  
 
In viable cells, the H1 linker histones bind DNA at the entry and exit points of the 
nucleosome core particle, thereby determining the trajectory of linker DNA that connects 
neighboring nucleosomes (294).  By controlling the stacking of adjacent nucleosomes, 
H1 modulates overall features of the chromatin fiber.  In addition, H1 histones control 
access to internucleosomal DNA, thus contributing to the regulation of gene expression 
(295).  The involvement of H1 in the control of higher-order chromatin structure and 
gene transcription is reflected in the expression of multiple, structurally diverse and cell-
type-specific isoforms of H1(296). 
 
The capacity of H1 histones for chromatin condensation is modulated by a 
repertoire of post-translational modifications (PTM) that fine-tune H1 affinity for DNA 
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and mediate H1 interactions with other proteins (297).  Multiple H1 serine and threonine 
phosphorylation events correlate with mitotic chromosome condensation (298) , whereas 
individual H1 PTM affect the interactions between H1 and RNA polymerases near active 
genes (299).  Additional PTM in H1, including lysine methylation and acetylation, are 
known but their functions have not been as thoroughly examined (297).  
 
A remarkable histone PTM that is induced in neutrophil granulocytes in response 
to inflammatory stimuli is the conversion of specific arginines to citrullines (202, 203).  
The conversion is mediated by peptidylarginine deiminase (PAD4) (300, 301), an 
enzyme that is required for the release of neutrophil extracellular traps (NETs) (213, 
302).  NETs consist of chromatin fibers that associate with components of the 
neutrophils’ vast armamentarium of bactericidal substances (244).  NETs presumably 
serve to enmesh bacteria and yeast pathogens and surround them with compounds that 
reduce their viability (194).  Neutrophils from mice deficient in PAD4 are unable to 
produce NETs and, as consequence, the animals suffer more serious bacterial infections 
(213).  Although core histones are prominent components of NETs, it has been 
controversial whether H1 histones associate with NETs (194, 244).  
 
Recently, we observed that certain human autoimmune sera contain 
autoantibodies to deiminated core and linker histones (303).  Therefore, we screened 
additional autoimmune sera and identified autoantibodies that recognize the deiminated 
human H1.2 histone.  We used the antibodies to map the reactive H1 epitope and we 
surveyed expression of H1 subtypes in neutrophils by RNA expression, H1 purification 
and mass spectrometry.  Purified H1 were subjected to LysC protease cleavage and 
citrulline mapping by MS/MS.  We observed H1 deimination in activated neutrophils and 
increased immunoreactivity of one H1-reactive serum with activated neutrophils and 
NETs.  The data argue that neutrophil activation and NET chromatin release provide 
circumstances for H1 extracellular release and stimulation of H1-reactive B cells.  This 
observation, along with other published studies, suggests that NETs are a source of 
nuclear antigens that could stimulate autoreactive B cells.  
 
 
Materials and Methods 
 
 
Patient Serum Samples   
 
Serum samples were collected at Institut de Biologie Moléculaire et Cellulaire; 
Strasbourg, France and the University of Lubeck, Germany. In all, 24 SLE, 20 Sjögren’s 
Syndrome, 20 Scleroderma and 20 RA serum samples were tested.  All patients fulfilled 
the American College of Rheumatology classification criteria for SLE (272), SS (304) 
and Scl (305).   This study was done in accordance with the IRB approvals from the 
University of Tennessee, US, Institut de Biologie Moléculaire et Cellulaire; Strasbourg, 
France and the University of Lubeck, Germany. 
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In-vitro Deimination of Recombinant H1.2  
 
Recombinant human histone H1.2 (Axxora) , were dissolved in PAD4 reaction 
buffer (100mM HEPES, 100mM NaCl, 10mM CaCl2, 0.1mM EDTA and 2mM 
Dithiothreitol)  to a final concentration of 0.1 mM.  The reaction mixture was incubated 
for 10 min at 37°C and then recombinant PAD4 was added to a final concentration of 0.2 
µM (274).  Deimination was tested by Western blot using antibody to chemically 
modified citrullines (Millipore) as per manufacturer’s instructions. 
 
 
Western Blot 
 
For Western blot analysis, proteins were resolved on 15% SDS-PAGE and 
transferred to nitrocellulose as previously described (303).  Membranes were blocked in 
5% BSA, 0.1% Tween 20 in TBS overnight at 4°C.  Next day, the membranes were 
incubated with patient sera at 5 µg/ml of IgG in TBS containing 2.5% BSA, 1% NP-40 
and 0.1% SDS using pre-blocked polyethylene pouches.  After 2 h of incubation, 
membranes were washed with 1% NP-40 in TBS.  Anti-human IgG –HRP was used for 
detection at 1:40,000 in 0.05% Tween 20 in TBS for 1 h and blots were developed using 
“Western Lightning” chemiluminescence reagent (PerkinElmer).  For Western blots of 
human neutrophil extracts, cell lysates were prepared as described (202).  Protein 
concentration of lysates was measured in a Nanodrop 1000 spectrophotometer (Thermo 
Scientific, Wilmington, Del., USA) and equal loading of the samples was confirmed by 
Coomassie blue staining.  For competition assay, synthetic peptides, competitor 1 
(KKAGGTP-Cit-KASGPPVS) with arginine 32 of H1.2 replaced with citrulline, and 
competitor 2 (KAVAASKE-Cit-SGVSLAA) with arginine 53 of H1.2 replaced with 
citrulline were kind gift from Dr. Jean-Paul Briand of Institut de Biologie Moléculaire et 
Cellulaire, Strasbourg, France. The peptides were incubated for 1h with a dilution of 
SLE6 serum (5ug/ml of IgG) before the mixture was used for a Western blot.  
 
 
Preparation of Protease Digested Peptides 
 
Approximately 1.5 µg of the recombinant Histone H1.2 was desalted using a 3000 
kDa MW cut-off centrifugal filter device (Millipore) according to the manufacturer’s 
instructions.  Protease digestion of H1.2 was performed overnight at 37°C with 50ng of 
LysC and the digestion was stopped with the addition of TFA (1%, v/v). The solution 
was dried in a Vacufuge Concentrator (Eppendorf, Westbury, NY, USA), and the dried 
pellet was reconstituted in 20 ul of 0.1% TFA solution.  The lysC digested peptides were 
loaded on a C18 Ziptip column (Millipore), washed with 0.1% TFA and eluted with 10 µl 
of a 50% acetonitrile solution.  The eluant was near-dried in a vacufuge, and the residue 
was reconstituted in 4 µl of a 0.1% formic acid solution.  Two µl of that solution were 
used for the LC/MSMS analysis. 
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Liquid Chromatography-Mass Spectrometry and Database Search 
 
The H1.2 peptides were resolved by HPLC by a gradient elution in which the 
buffer changed from solvent A (0.1% formic acid solution) to solvent B (0.1% formic 
acid in 90% methanol solution).  Peptide masses were determined by using a Q-TOF 
mass spectrometer in a positive-ion mode.  The nano electrospray ionization source 
temperature was set at 90ºC with capillary and cone voltage set to 3.0 kV and 30V 
respectively.  Mass calibrations were done using polyalanine (Michrom Bioresources 
Inc., Auburn, CA, USA).  Double- and triple-charged precursor ions with a count ≥ 20 
were selected to perform MSMS.  MSMS scans (5 second) were followed by an MS scan 
(1 second).  Masslynx software (version 3.5) was used to process the chromatographic 
and mass spectrometric data.  To identify proteins, Swissprot and NCBInr databases were 
searched using Bioworks (version 3.2; Thermo-Fisher) and Mascot (web-version) 
software.  The precursor ion (MS) and product-ion (MSMS) mass-error tolerances were 
both set to 0.1 Da. The modification of arginine was set to 0.98 Da because the 
monoisotopic mass difference between citrulline (C6H13N3O3) and arginine (C6H14N4O2) 
is 0.98 Da. 
 
 
RNA Extraction and Microarray Analysis 
 
Total mRNA was isolated from neutrophils using RNeasy Mini Kit (Qiagen) as 
suggested by the manufacturer. Genomic DNA was eliminated by RNase-free DNase I 
(Qiagen) digestion during the isolation procedure. Isolated total RNA was analyzed on an 
Agilent 2100 Bioanalyzer using RNA 6000 Pico Labchip Kit (Agilent Technologies). 
Reverse transcription to cDNA was performed at 50°C for 1 h followed by 85°C for 5 
min with Transcriptor First Strand cDNA Synthesis Kit (Roche) using random hexamer 
and anchored-oligo (dT) primers (Roche). RNA quantitations were performed using the 
Whole-Transcript Human Gene 1.0 ST array (Affymetrix).    
 
 
Neutrophil Isolation and Stimulation 
 
Neutrophils were isolated from healthy donor blood purchased from Keybiologics 
(Memphis, TN) and used in accordance with protocols approved by the Institutional 
Review Board (IRB), University of Tennessee.  Neutrophils were isolated as described 
(202).  Briefly, neutrophils were enriched using dextran sedimentation and recovered 
from an isolymph density gradient (Gallard-Schlesinger, Plainview, N.Y, USA) under 
endotoxin-free conditions.  Erythrocytes were lysed in ice-cold, hypotonic buffer (0.2% 
NaCl) for 30 s, and lysis was stopped by adding hypertonic saline (1.6% NaCl).  
Neutrophils were suspended in HBSS (without Ca++ or Mg++) with 0.1% glucose and 
0.5% heat-inactivated human serum or in HBSS with 0.5% heat-inactivated human serum 
at a final concentration of 2 X 106 neutrophils/ml.  Neutrophils were stimulated with 
ionophore in HBBS containing 2mM Ca++ at 37°C for 2 h.  Following incubations, 
neutrophils were pelleted and lysed in SDS-lysis buffer (2% SDS in 62.5mM Tris, pH 
6.8, supplemented with 5% 2-ME and 10% glycerol).   
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Linker Histone H1 Extraction and Purification 
 
Perchloric acid extraction of H1 was performed as described earlier (297). 
Briefly, 50 million neutrophils were resuspended in 0.5ml of 5% HClO4 and subjected to 
three cycles of freezing (in mix of dry ice and methanol), thawing at 37°C and vortexing 
(10 s).  The final suspension was centrifuged at 15,000 × g for 10 min. The clear 
supernatants were mixed with an equal volume of ice-cold 66% (v/v) CCl3COOH. The 
linker histones were precipitated for 30 min on ice and collected by centrifugation at 
15,000 × g for 10 min. The pellets were washed with 0.2% HCl in acetone, then twice 
with pure acetone, and vacuum-dried.  The dried pellets were reconstituted in high salt 
buffer (25mM HEPES pH 7.6 with 550mM NaCl, 12.5mM MgCl2 and 0.1mM EDTA). 
 
 
Confocal Microscopy  
 
Neutrophils were isolated as described above and allowed to settle for 30 min 
onto a poly-L-lysine coated glass coverslips as described (202). Cells were treated with 
LPS (100 ng/ml) for 1 h at 37°C.  Coverslips were washed with ice cold HBSS, cells 
were fixed with 4 % paraformaldehyde in HBSS for 15 min at room temperature and 
incubated overnight with blocking buffer (HBSS with 10% FBS, 1% BSA, 0.05% Tween 
20 and 2mM EDTA) at 4°C.  The coverslips were washed with wash buffer (HBSS with 
3% FBS) and incubated with patient serum (20 µg/ml IgG) or rabbit Abs that bind 
citrullines in the N terminus of histone H3 (Abcam, Cat # ab5103; 1:100 dilution) in 
wash buffer at 4°C for 1 h.  Coverslips were washed and incubated with AF647-
conjugated goat anti-human IgG, AF488-conjugated goat anti-rabbit IgG and Sytox 
Orange (all from Invitrogen) for 30 min at 4°C.  Coverslips were washed and mounted on 
glass slides using mounting media (wash buffer with 50% glycerol) and analyzed by 
confocal microscopy. 
 
 
Results 
 
 
Identification of Autoantibodies to Deiminated H1.2 
 
Previously, we identified autoantibodies to deiminated core and linker histones 
(303).  Because deimination of linker histones has not been characterized, we screened 24 
additional SLE sera, 20 Sjögren’s syndrome sera, 20 scleroderma sera, and 20 
rheumatoid arthritis sera for antibodies with preference for deiminated H1 histones 
(representative results are shown in Figure 3-1A).  As antigen, we used recombinant 
human H1.2 that was treated with PAD4 in vitro or left untreated.  In all, 72 sera 
contained anti-H1 antibodies, as assessed by Western blot, and 4 sera bound deiminated 
H1.2 with at least 2-fold preference over non-deiminated H1.2.  However, the vast 
majority of patient sera showed comparable binding to either form of H1.2 and no serum 
showed a bias toward the non-deiminated H1.2.  We may have missed some 
autoantibodies to deiminated linker histones because we did not measure binding to all  
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Figure 3-1: Preferential binding of autoimmune sera to deiminated H1.2 
Equal amounts of non-deiminated (H) and deiminated (C) H1.2 were blotted on 
nitrocellulose and probed with sera from systemic lupus erythematosus, Sjögren’s 
syndrome, scleroderma and rheumatoid arthritis patients.  Five representative blots from 
each set are shown.  The ratio of binding to deiminated vs. non-deiminated H1.2 (C/H) 
was calculated with ImageJ software and values are listed below each blot.   Two sera 
each of SLE and Sjögren’s syndrome showed a greater than 2.0 binding preference for 
deiminated H1.2 (A).  Equal amounts of non-deiminated (H) and deiminated (C) H1.2 
and BSA were analyzed by coomassie staining or probed with SLE6 serum. Preferential 
binding of SLE6 to deiminated H1.2 over non-deiminated H1.2 and no detectable binding 
to deiminated BSA reveal the contribution of deiminated residue(s) and adjoining protein 
sequence as determinants of the specificity of SLE6 IgG (B).   
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H1 subtypes whose unique epitopes may represent additional autoantibody targets (296).  
In the following experiments, we used the SLE6 serum (303) whose binding was highly 
biased toward deiminated H1.2 and did not extend to citrullines in a heterologous protein 
(BSA; Figure 3-1B).   
 
 
Determination of Autoepitope in Histone H1.2 
 
Because SLE6 antiserum preferentially bound deiminated histone H1.2, we asked 
whether one of the 3 arginines in H1.2, if converted to citrulline, formed the SLE6 
binding determinant.  We addressed the question by using synthetic peptides as inhibitors 
of antibody binding.  To compete binding of SLE6 to the deiminated histone H1.2, we 
incubated the serum with either of two peptides (containing citrulline at position 32 or at 
position 53 of H1.2; Figure 3-2A) before reacting the serum against the intact histones 
on a Western blot (Figure 3-2B).  Dilutions of the 16-mer peptides were prepared and 
their effect on binding to the immobilized histones was compared.  The preference of 
SLE6 for deiminated H1.2 was maintained even after incubation with 1.0 ug of 
Competitor 1 (KKAGGTP-Cit-KASGPPVS), whereas, in a parallel incubation, 
preferential binding was eliminated with a ten-fold lower amount of Competitor 2 
(KAVAASKE-Cit-SGVSLAA).  Thus, we concluded that Competitor 2, containing 
citrulline in place of arginine 53, was more effective as inhibitor of SLE6 binding and 
therefore shared structural features with the authentic H1.2 autoepitope recognized by the 
SLE6 serum autoantibodies. 
 
 
Deimination of Recombinant H1.2 
 
To confirm that incubation of H1.2 with PAD4 converts arginine 53 to citrulline, 
we subjected the deiminated H1.2 to Lys C protease cleavage and analyzed the peptides 
by MS/MS.  We also asked if arginine 32 and 78 of H1.2 serve as substrates for PAD4 
deimination.  We observed multiple peptide fragments (including the b2 and y9 ions; 
Figure 3-3A) that were consistent with arginine deimination occurring within the amino 
terminal dipeptide of ER*SGVSLAALK.  In addition, we identified citrulline at position 
32 of H1.2 by performing MS/MS on the peptide AGGTPR*K (Figure 3-3B).  The mass 
determination using Q-TOF spectroscopy was consistent with the presence of citrulline 
(1130.70 Da for the LysC-derived peptide, compared to the theoretical monoisotopic 
masses of 1129.65 and 1130.63 Da for the unmodified versus the deiminated peptides).  
To estimate the uncertainty inherent in the measurements, the experiment was performed 
three times and each time the error was less than 62 ppm.  Thus, the mass measurements 
proved reliable and sufficient to discriminate between arginine and citrulline in this 
peptide. In contrast, we observed that the NNSRIK peptide was resistant to deimination, 
inasmuch as we did not detect citrulline within that peptide even after a 4 h incubation 
with recombinant PAD4 (Figure 3-3C).    
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Figure 3-2: Peptide inhibition of SLE6 binding to deiminated H1.2 
The preferential binding of SLE6 to deiminated H1.2 was assessed after a preincubation 
of the serum in the presence of either of two 16mer synthetic peptides (Competitor 1= 
R32Cit; KKAGGTP-Cit-KASGPPVS) and Competitor 2= R53Cit; KAVAASKE-Cit-
SGVSLAA). The peptides were designed to match H1.2 with citrulline residues 
substituting for arginine 32 or 53 (A).  Equal amounts of deiminated (C) and non-
deiminated (H) H1.2 were analyzed by SDS-PAGE (Coomassie) or blotted and probed 
with SLE6 serum. Panels below the horizontal line show results of Western blot 
performed following a preincubation in the presence of competitors 1 or 2.  The mass of 
the peptide is indicated beneath each panel. Competitor 2 (R53Cit) was more effective at 
blocking preferential binding of SLE6 to deiminated H1.2 (B). 
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Figure 3-3: MS/MS analysis of in vitro deiminated recombinant H1.2 
MS/MS spectra of doubly charged precursor ions of deiminated histone H1.2 treated with 
LysC protease to release peptides (A-C).   Fragmented ions (b series and y series) are 
marked on respective peptide sequences and on the MS/MS spectra. Two of 3 arginines 
in H1.2, peptide ER*SGVSLAALK (A) and AGGTPR*K (B) showed mass consistent 
with deimination to citrulline. We found no evidence for peptide NNSRIK (C) 
deimination during the in vitro PAD4 reaction.  
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Autoimmune IgG Preferentially Bind H1 Linker Histones in Activated Neutrophils 
and Neutrophil Extracellular Chromatin  
 
To assess the range of SLE6-reactive proteins on Western blots, we prepared total 
cell lysates from unstimulated and Ca-ionophore stimulated human neutrophils.  Lysates 
were resolved on SDS-PAGE, blotted onto nitrocellulose membranes and probed with 
SLE6 serum (Figure 3-4A).  Antibodies bound numerous proteins from both Ca++ 
ionophore treated and untreated neutrophils, with notably little to no detectable binding to 
core histones. Binding of SLE6 to lysates showed that a protein in the molecular weight 
range of histone H1 along with few other proteins became more immunoreactive 
following treatment with Ca++ ionophore (Figure 3-4A). 
 
To examine the distribution of SLE6 antigen targets in cells, we stimulated 
neutrophils with LPS, an inflammatory stimulus that induces deimination and chromatin 
release from neutrophils (202), and used them for confocal microscopy.  LPS-treated and 
untreated cells were incubated with SLE6, as well as a rabbit antibody to deiminated H3 
and the DNA stain sytox orange (Figure 3-4B-D).   SLE6 IgG binding increased in LPS-
treated neutrophils with decondensed chromatin (Figure 3-4C), whereas unstimulated 
neutrophils maintaining a lobed nuclear architecture showed minimal IgG binding 
(Figure 3-4B).  In contrast, SLE6 IgG colocalized with deiminated H3 in decondensed 
intracellular chromatin (Figure 3-4C) and in some neutrophil NETs (Figure 3-4D).  
Intense granular SLE6 staining was observed in the cytoplasm of activated neutrophils, 
suggesting segregation of immunoreactive epitopes from the nuclear compartment before 
chromatin release (Figure 3-4D).  
 
 
Neutrophils Express Multiple H1 mRNAs and Proteins 
 
To obtain a more complete view of H1 subtype expression in neutrophils, we 
isolated total RNA from blood neutrophils and examined the representation of different 
H1 mRNA by hybridization to expression microarrays (Figure 3-5A).  H1.4 was the 
most actively transcribed linker histone, followed by H1.0 and H1.2.  In contrast, H1.1, 
H1.3 and H1.5 expression was near background levels (Figure 3-5A).  The expression 
levels of the house-keeping gene, HGPRT were similar in magnitude to histone H1.2 
(Figure 3-5A).  These data indicate that mature neutrophils express a limited set of linker 
histones and that the bulk of newly made histones is comprised of H1.4.   
 
Next, we asked whether the RNA present in mature neutrophils reflects the H1 
protein complement that is present in neutrophils.  For that purpose, we compared 
untreated human neutrophils to neutrophils stimulated with A23187 calcium ionophore 
for 2 h.  The H1 proteins were isolated from treated and untreated neutrophils by 5% 
perchloric acid extraction, separated by gel electrophoresis and probed with anti-citrulline 
antibodies (Figure 3-5B).  H1 isolated from ionophore-treated cells reacted with the 
antibodies, indicating the presence of citrullines.  In addition, the purified H1 resolved 
into a set of similar-sized proteins, suggesting the expression of different H1 subtypes. 
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Figure 3-4: Neutrophil activation increases SLE6 reactivity 
Lysates of unstimulated (U) and Ca++ ionophore-treated (S) neutrophil were probed with 
SLE6 serum (A).  Enhanced binding of IgG to a doublet of proteins migrating to a 
position near the 37kD marker is indicated (arrow). SLE binding (red) to unstimulated or 
LPS treated neutrophils was compared to the binding of anti-deiminated H3 antibody 
(green) and the DNA binding dye, sytox orange (blue) (B-D).  Faint SLE6 binding to the 
cytoplasm of untreated neutrophils (B). SLE6 binding is increased in LPS-treated 
neutrophils that have lost the integrity of nuclear membrane (C) and show increased 
reactivity with the anti-deiminated H3 antibody (C). SLE6 bound to NETs that reacted 
with the anti-deiminated H3, although prominent cytoplasmic clusters of SLE6 binding 
were also observed (D).   
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Figure 3-5: Analysis of linker histone transcripts and proteins from neutrophils 
Relative mRNA levels of different H1 subtypes were determined from total mRNA 
extracted from neutrophils. cDNA was prepared by reverse transcription and expression 
levels were measured on an Affymetrix Whole-Transcript Human Gene 1.0 ST Array. 
Relative fluorescence intensities were plotted for each H1 subtype (A).   Whole cell 
lysates and perchloric-acid-extracted linker histones from unstimulated (U) and Ca++ 
ionophore-stimulated (S) neutrophils were analyzed by SDS-PAGE (coomassie). 
Extracted H1 histones were blotted, chemically modified and probed with anti-Cit 
(modified) antibody.  Only H1 from activated neutrophils reacted with the antibody (B).  
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MS/MS Analysis of H1 Histones from Activated Neutrophils 
 
Following LysC digestion of H1 from activated neutrophils, mass spectroscopy 
identified the ER*SGVSLAALK peptide that may derive from H1.2, H1.3 or H1.4 (296).  
To confirm that the deimination of arginine to citrulline is consistent with the predicted 
peptide sequence, we performed MS/MS of the product-ions exclusively on the precursor 
ER*SGVSLAALK peptide (Figure 3-6A).  The MS/MS spectrum contained a series of 
y-ions (y1-y9) that did not contain R*.  However, the b-series ions (b2-b10) exhibited 
masses consistent with citrulline: the b2# (b2-NH3), b4@ (b4-H2O), and b10 ion were found 
at m/z 270.11, 413.21, and 985.60, respectively.  The mass errors were 0.02, 0.03, and 
0.07 Da, respectively for an average error of 0.04 Da.  Therefore, the masses of all the b-
ions closely matched the masses that are predicted by the presence of citrulline instead of 
arginine at position 53 of H1.2 (Figure 3-3A).  Similar arguments apply to the 
homologous peptide that was derived from histone H1.5 (ER*NGLSLAALK, Figure 
3-6C), in that masses corresponding to the b3, b7, b8, b9 and b10 ions closely matched 
those that are predicted if citrulline replaces arginine.   
 
Interestingly, the H1 histones that were purified from activated neutrophils also 
yielded peptides that were identical to the ones described above except for the presence 
of arginines (Figure 3-6B and D).  There, the b and y series ion masses were consistent 
with the presence of arginine, indicating that a 2 h treatment of neutrophils with 
ionophore does not completely convert histone H1 arginines to citrullines.  Moreover, we 
observed the deimination of arginines in unique peptides derived from histone H1.0: 
GVGASGFR*LAK (Figure 3-6E) and R*LVTGVLK (Table 3-1).  In contrast, we found 
no evidence for deimination of the arginine in NNSRIK that is part of the third helix in 
the globular domain (Figure 3-6F).  Our results suggest that several arginines in the 
globular DNA binding domain of H1, including R53, the most conserved arginine in H1 
histones, are converted to citrulline following neutrophil activation (Table 3-1). 
 
 
Summary of Histone H1 Expression in Neutrophils  
 
The mass spectrometry experiments provided evidence supporting the expression 
of at least 5 different H1 proteins in neutrophils.  We identified peptides whose sequences 
unambiguously matched unique sequences in each of 5 different H1 subtypes (H1.0, 
H1.2, H1.3, H1.4 and H1.5; see Figure 3-7).  It is interesting that we detected a peptide 
matching H1.3 (VAGAATPK) and two peptides matching H1.5 (KPAGATPK and 
KPAAAGVK), despite very low mRNA for H1.3 and H1.5 (Figure 3-5A).  Overall, 
protease cleavage and mass spectrometry yielded a sequence coverage of 30-44% for 
each of the H1 proteins, although some peptides were shared between the most closely 
related H1 subtypes (Figure 3-7). 
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Figure 3-6: MS/MS analysis of H1 peptides from activated neutrophils 
MS/MS spectra of peptides yielding doubly charged precursor ions of H1 histone from 
Ca++ ionophore treated neutrophils (A-F).   Fragmented ions (b series and y series) are 
marked on the peptide sequences or spectral peaks. Both  peptide ER*SGVSLAALK (A) 
and ERSGVSLAALK (B) were observed, with a +1Da shift resulting from deimination 
of  arginine in evidence in b2 and b10 ions. The peptide ERSGVSLAALK is conserved 
between H1.2, H1.3 and H1.4 subtypes. Both ER*NGLSLAALK (C) and its 
non-deiminated form ERNGLSLAALK (D) derived from H1.5 were identified. Again, 
the mass shift of corresponding b ions is consisten with arginine deimination.  Arginine-
containing peptide GVGASGFR*LAK (E) from H1.0 was also identified, whereas 
peptide NNSRIK (F), conserved in subtypes H1.1-H1.5 was only found in its 
non-deiminated form.   
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Table 3-1: Arginine containing peptides detected in H1 extracted from activated 
neutrophils 
 
Deiminated Peptides Non-modified Peptides Corresponding H1 Isotype 
ER*SGVSLAALK ERSGVSLAALK H1.2 – H1.4 
ER*NGLSLAALK ERNGLSLAALK H1.5 
GVGASGFR*LAK - H1.0 
R*LVTTGVLK - H1.0 
- NNSRIK H1.1 – H1.5 
* Indicate deimination of arginine to citrulline. 
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Figure 3-7: Summary of mass spectrometry with linker histones from activated neutrophils 
Sequences of somatic linker histone H1 subtypes were aligned to maximize homology. Arginine residues are indicated in red. Peptides 
identified by mass spectrometry highlighted in yellow, and H1 subtype-specific peptide sequences are in black and underlined.  The 
globular domain of H1 is indicated by a broken line above the sequences. Brown boxes represent the 3 helices of the H1 winged helix.  
Residues contributing to DNA binding residues are indicated with arrows. 
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Discussion  
 
Evidence mounts that NETs participate in the induction of autoimmune responses.  
Because NETs are released at sites of inflammation (306-309) and NET chromatin 
intimately associates with bacteria (194, 310), NETs were predicted to contribute to 
autoimmunity (285).  Recent observations support this prediction.  Autoantibodies from 
patients with systemic autoimmunity recognize innate immune defense proteins that 
associate with NETs.  This is the case for the major NET components, including the 
granule proteases elastase, cathepsin G and proteinase 3 (235, 236, 238), as well as for 
various bactericidal peptides that are stored in granules and co-purify with NETs, such as 
neutrophil defensins and the LL37 peptide (239, 240).  Therefore it is relevant to further 
characterize mechanisms involved in the release of NET chromatin. 
  
NET release depends on PAD4 (213, 302).  Although PAD4 deiminates a variety 
of substrates (283, 303), it is plausible that histone deimination plays an important role in 
the unfolding of nuclear chromatin into the extended structure of NETs.  Consistent with 
this role, treatment of a nucleosome array with PAD4 decreased its capacity for 
compaction in the presence of linker histone H5 (311).  Our studies have revealed that 
NETs contain deiminated histones (202).  Deiminated histones thus can be considered as 
markers of NET chromatin (312, 313).  
 
In that light, our recent studies support the idea that NETs induce autoantibody 
responses in susceptible individuals.  We screened sera from patients with SLE, RA and 
Felty’s syndrome and found examples of sera that preferentially bound to deiminated 
histones (303). 
 
Our current results confirm that human autoimmune IgG react with the 
deiminated form of human H1.2.  Autoantibodies to deiminated histone H1 provide 
support for the hypothesis that NETs induce autoantibodies.  However, only a small 
fraction of the tested sera (5%) had antibodies with a marked preference for the 
citrullinated form of H1.  Antibodies to linker histones H1 are considered as important 
marker SLE as dsDNA. Detection of antibodies against H1 by ELISA yield a sensitivity 
of about 45% with a specificity of 98% in diagnosing SLE (314).  H1 antibodies show a 
strong association with disease activity such as lupus nephritis (314) and neuropsychiatric 
lupus (315).  H1 is also an important autoimmune target in Sjögren's syndrome as binding 
of purified IgG against an immunodominant epitope of La/SSB antigen was completely 
inhibited by H1 (316).   Involvement of H1 in lupus is not limited to being an 
autoimmune target.  PBMCs co-cultured with H1 from lupus patients, but not healthy 
controls, induced increased production of TNF-alpha (317).  Whether antibodies to 
deiminated H1 derive from a subset of patients with particular clinical features is 
unknown. 
 
Our results identify the complement of H1 subtypes expressed in human 
neutrophils.  Although the H1.4 gene encodes the majority of mRNA in mature 
neutrophils (Figure 3-5A), neutrophils contain at least five H1 subtypes (Figure 3-7), 
including H1.3 and H1.5 for which very little if any mRNA could be detected.  This 
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observation suggests that H1.3 and H1.5 may be synthesized during neutrophil 
development but that they are replaced with H1.0, H1.2 and particularly with H1.4 as 
neutrophils mature.  Because H1 histones play important regulatory roles in chromatin 
compaction (296), it is likely that changes in H1 subtype expression reflect changes in 
chromatin conformation, condensation, or nuclear morphology.  A shift in subtype 
expression may alter global chromatin properties because different H1 subtypes differ in 
their DNA binding and/or protein interaction potential.   
 
The binding of SLE6 serum IgG to an epitope containing citrulline at position 53 
of the H1 winged helix was surprising because the arginine at position 53 was considered 
to be a DNA binding residue (318).  DNA bound to arginine 53 may shield this domain 
of histone H1 from antibody binding.  Moreover, arginine 53 is conserved in all human 
H1 subtypes and is located within the structurally conserved globular region of H1 
(Figure 3-7).  However, the involvement of R53 in DNA binding was deduced from 
mutagenesis of this arginine in histone H1.0 (318).  A recent study which examined this 
residue in H1.2 found only a negligible effect of an alanine substitution on DNA binding 
(319).  The authors suggested that the 53 position is not part of the DNA binding site and 
that their result may explain why H1.0 binds more tightly to DNA than H1.2 (319).  This 
result may imply that H1.2 has only two DNA binding sites, whereas H1.0 has three.  
 
If that conclusion holds true, then R53 must have another function that is highly 
conserved in evolution.  It could be that R53 contributes to one or more of the protein 
interactions that have been identified for H1 histones.  These range from interactions with 
core histones in chromatin (320) to interactions with RNA polymerase (299) and various 
transcription factors (321, 322).  Because the two main H1 subtypes that are expressed in 
mature neutrophils, H1.2 and H1.4, may not use R53 for DNA binding, it may be that this 
residue has an important role in the specific nuclear chromatin changes that take place in 
neutrophil activation.  
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CHAPTER 4.    DEIMINATION REDUCES REACTIVITY OF HISTONES WITH 
MURINE LUPUS AUTOANTIBODIES  
 
 
Summary 
 
Deimination of histones, a posttranslational modification of arginine to citrulline 
by peptidylarginine deiminase 4 (PAD4), is associated with neutrophil extracellular traps 
(NETs) and may compromise tolerance of self-antigens.  The aim of this study was to test 
whether spontaneously autoimmune mice react preferentially with deiminated or non-
deiminated histones. 
 
IgG Ab binding to deiminated histones and non-deiminated histones were 
determined by ELISA and Western blotting, and splenocyte proliferation was analyzed in 
spontaneously autoimmune mice.  We measured levels of deiminated histones in tissues 
from C57BL/6.Sle1.Sle2.Sle3 (B6.TC) and control mice, to search for putative 
tolerogens.  Serum IgG from autoimmune (NZBxNZW)F1, NZM2410, and 
C57BL/6.Sle1.Sle3 mice consistently bound non-deiminated histones with preference 
over deiminated histones.  In contrast, splenocytes from (NZBxNZW)F1 proliferated with 
no bias for either antigen.  In addition, the bone marrows and spleens of B6.TC mice 
contained increased amounts of deiminated histones as compared to control C57BL/6 
mice. 
 
Our study demonstrates that sera of autoimmune lupus prone mice react less 
strongly against deiminated histones than non-deiminated histones.  We note that 
deiminated histones, presumably derived from NETs, are available at increased levels in 
primary and secondary lymphoid tissues of autoimmune mice relative to littermates.  The 
deiminated histones may function as tolerogens to suppress production of anti-deiminated 
histone IgG. 
 
 
Introduction 
 
Connections between the innate and adaptive immune system are intriguing and 
often surprising.  This is particularly true with regard to mechanisms that distinguish self 
from non-self (323).  A special challenge for adaptive immunity arises during neutrophil 
responses to infections.  Neutrophils respond to bacterial infections by ejecting nuclear 
chromatin from the confines of the cell (194).  The chromatin is associated with various 
bactericidal substances and it forms a mesh that immobilizes infectious organisms (324).  
These structures are called neutrophil extracellular traps (NETs).  NETs serve to capture 
bacteria and fungi.  It is important to efficiently clear NETs, as they can promote 
intravascular thrombosis (307). 
 
The challenge for the adaptive immune response is to use the NET-ted bacteria as 
antigens, while maintaining tolerance to the structural components of NETs.  A possible 
confounding factor in the recognition of NETs may be that their release is accompanied 
 67 
by a particular post-translational modification (PTM).  Neutrophils exposed to 
inflammatory stimuli, or the physical proximity of microbes, induce the enzyme 
peptidylarginine deiminase 4 (PAD4) which converts arginines to citrullines (202). 
 
Deimination of histones appears to play a special role in the release of NETs, as 
mice deficient in PAD4, the enzyme that deiminates histones, fail to make NETs and 
suffer more serious infections (213).  Deimination may have broader physiological roles 
and yet several deiminated self-proteins are targeted by autoantibodies.  Deimination of 
keratin and filaggrin occur during terminal differentiation of keratinocytes (209, 210, 
325) yet deiminated filaggrin is a target of antibodies (Abs) associated with rheumatoid 
arthritis (RA) (214).  Generally, anti-citrullinated protein antibodies (ACPA) serve as 
reliable diagnostic markers for RA (326).  Deimination of vimentin, a member of the 
intermediate filament family of cytoskeletal proteins, generates the target of anti-Sa 
autoantibodies in RA (264).  It is not clear whether normal levels of deimination generate 
autoepitopes in RA or whether the deimination in RA is enhanced and produces unusual 
“neo” epitopes. 
 
PAD4 is the only PAD that has a nuclear localization signal and deiminates 
histones H2A, H3, and H4 (268, 327).  In a genetic study, a link between PAD4 and RA 
was observed: Haplotypes linked to increased RA susceptibility produced PAD4 mRNA 
that was more stable than mRNA from non-susceptible haplotypes (228).  The increased 
mRNA stability may lead to increased expression of PAD4 in individual carriers of these 
susceptibility haplotypes.  The association between deiminated proteins and various 
autoimmune diseases strongly suggests that deimination generates novel epitopes that are 
able to break tolerance and initiate autoimmune responses.  However, it is not known 
whether deimination of histones is sufficient to break tolerance to nuclear autoantigens. 
 
Recently, it has been suggested that NETs are responsible for inducing 
autoimmune reactions (242, 328, 329).  Type 1 IFN, involved in lupus pathogenesis, has 
been found to prime neutrophils to release NETs (328).  Consequences of NET release 
are exposure of DNA-peptide complexes (242) that cause further release of Type 1 IFN 
from plasmacytoid dendritic cells (329).  Also, the structural components of NETs and 
various associated proteins and peptides have been recognized as autoantigens in lupus 
patients (260, 330, 331).  Based on these facts and our observation that chromatin 
released in NETs consist of deiminated histones, we investigated the hypothesis that if 
NETs are induced by inflammation, as is typical of autoimmunity, and if NETs are 
immunogenic, then anti-deiminated histone antibodies should be prevalent in lupus-prone 
mice. 
 
IgGs from (NZBxNZW)F1 mice and their recombinant derivative strains, 
including NZM2410 and B6.Sle1, B6.Sle1.Sle3 or B6.TC congenics, showed strong 
preference for non-deiminated histones over deiminated histones by ELISA and Western 
blot.  Thus, even after tolerance to histones was broken and autoantibodies to non-
deiminated histones were expressed, autoimmune-prone congenic strains remained 
tolerant of deiminated histones.  B cell binding to deiminated histones relative to non-
deiminated histones was reduced.  Therefore, autoantibody binding focused on PAD4 
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substrate arginines.  No such bias was observed with autoreactive splenocytes from 
autoimmune (NZBxNZW)F1 mice.  These splenocytes responded differentially to 
deiminated histones versus non-deiminated histones and the responses developed 
simultaneously with serum anti-DNA autoantibodies.  The splenocyte response was 
idiosyncratic in preferentially targeting either deiminated histones or non-deiminated 
histones.  The B cell bias against deiminated histones argues that deiminated histones 
remain effective tolerogens in autoimmune mice.  In support of this possibility, we 
observed elevated levels of deiminated histones in bone marrows and spleens of 
autoimmune B6.TC mice.  Our observations suggest that, even in overtly autoimmune 
lupus mice, tolerance mechanisms inhibit B cells that react with a deiminated variant of 
an important nuclear autoantigen. 
 
 
Methods 
 
 
In-vitro Histone Deimination 
 
Calf thymus histones (US Biochemicals) were dissolved in PAD4 reaction buffer 
(100 mM Tris-HCl at pH 7.6, 50 mM NaCl, 2 mM DTT and 10 mM CaCl2) to a final 
concentration of 0.1 mM total histones.  The reaction mixture was incubated for 10 min 
at 37°C and then PAD4 enzyme was added to a final concentration of 0.2 µM to start the 
reaction.  Sixty µl aliquots were taken at different time points and the reaction was 
quenched with liquid nitrogen.  Amounts of deiminated proteins were estimated by 
colorimetry as described (332) using L-citrulline (Sigma) as a standard.  Deimination was 
also confirmed by Western blot using anti-deiminated histone antibody from Abcam  
(Cat # ab5103) that recognizes citrullines at positions 2, 8, and 17 of histone H3. 
 
 
Immunization of Mice  
 
Experiments were performed on 4-6 week female BALB/c mice housed in the 
animal care facility of the University of Tennessee Health Science Center, Memphis 
USA.  All experimental protocols were reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC).  BALB/c mice were divided into different 
groups for immunization.  Four mice each were immunized intraperitoneally with 100 µg 
of non-deiminated histones or deiminated histones.  Two mice were immunized with 100 
µg of ovalbumin (OVA) as a positive control.  Initial immunizations were done with 
emulsified proteins in complete Freund’s adjuvant (CFA) and one subsequent 
immunization was done in incomplete Freund’s adjuvant (IFA).  Mice were boosted 10 
days after the first immunization, and sera were collected 7 days later and used for 
comparison in ELISA.  In addition, two mice each from the deiminated histone and non-
deiminated histone groups were boosted with 100 µg of deiminated histone or non-
deiminated histone and 20 µg of Imiquimod (Invivogen), a TLR-7 stimulant, along with 
IFA.  The remaining two mice from each group were boosted with 100 µg of deiminated 
histones or non-deiminated histones in IFA.  One mouse from the OVA group was also 
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boosted with 100 µg of OVA along with 20 µg of Imiquimod in IFA.  Sera were analyzed 
seven days after each immunization.  
 
 
ELISA 
 
Sera were obtained from (NZBxNZW)F1, NZM2410, B6.Sle1, B6.Sle1.Sle3 and 
B6.TC mice at 7 months of age when these mice produce autoantibodies.  The treatment 
and care of animals were in accordance with the guidelines of the IACUC of UTHSC, the 
University of Florida and the Norwegian Ethical and Welfare Board.  Deiminated 
histones for ELISA and Western blot were prepared in vitro.  Deimination of non-
deiminated histones (Calf thymus histones, US Biochemicals) was done by recombinant 
PAD4 as described above.  Flat bottom, 96 well microtiter plates (Immulon 4HBX; 
Thermo Electron Corp.) were coated overnight with 5 µg/mL of deiminated histones, 
non-deiminated histones, OVA (Sigma) or coating buffer alone (control).  Plates were 
washed 3 times with 0.05% Tween-20 in PBS and blocked with 2.5% BSA in 0.02% 
NaN3 and PBS for 2 h.  A 1:200 initial dilution of primary sera along with 5-fold serial 
dilutions in 1.6% Tween-20 and 1% BSA in PBS were incubated for 2 h in plates.  Then, 
serum dilutions were removed and wells were washed with 0.1% Tween-20 in PBS.  
Alkaline phosphate-conjugated goat anti-mouse IgG (γ-chain-specific; Southern Biotech) 
was added at 1:1000 dilution in 1% BSA with 0.05% Tween-20 in PBS for 1 h.  
Phosphatase substrate (Sigma) was used to develop the ELISA and OD values were read 
at 405 nm on a Multiskan Plus plate reader (Labsystems). 
 
ELISA with the sera from immunized BALB/c mice was done with the same 
protocol as described in methods with a modification such that the initial serum dilutions 
tested were 1:100 with 1:3 serial dilutions, whereas as initial serum dilutions for 
autoimmune mice were 1:200 with 1:5 serial dilutions. 
 
Serum antibodies against dsDNA were detected by ELISA exactly as described 
(333, 334).  In short, calf-thymus dsDNA (10ug/ml in PBS) was coated on microtitre 
plates (MaxiSorb; Nunc, Copenhagen, Denmark).  Sera from mice were diluted 2 fold 
from 1:100 to 1:3,200 in PBS containing 0.02% Tween-20 and incubated in wells.  
ELISA readings were obtained with peroxidase-conjugated rabbit anti-mouse Fc-γ 
antibodies. 
 
 
Western Blot 
 
For Western blot analysis, proteins were resolved on 15% SDS-PAGE and 
transferred to nitrocellulose.  Membranes were blocked in 5% BSA in 0.1% Tween 20 in 
TBS (TBST) overnight at 4°C.  Subsequently, the membranes were incubated with sera at 
1:500 dilution in TBS containing 2.5% BSA, 0.5% NP-40 and 0.05% SDS.  After 2 h of 
incubation, membranes were washed with 1% NP-40 in TBS.  Anti-mouse IgG–HRP 
(H+L-chain-specific; Millipore) was used for detection at 1:10,000 dilution in TBST for 
1 h and blots were developed using “Western Lightning” chemiluminescence 
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(PerkinElmer).  Separately, autoimmune sera were treated with DNase1 prior to Western 
blotting.  Briefly, 400ul of a 1:200 dilution of sera were incubated with 20 units of 
DNase1 (New England Biolabs) for 1 h at room temperature before adjusting the sera to a 
1:500 dilution in Western blot binding buffer.  To probe for deiminated histone H3 in 
B6.TC and C57BL/6 mice, equal amount of tissue lysates were resolved on 12% 
SDS-PAGE and transferred to nitrocellulose.  Membranes were blocked with 5% BSA in 
TBST for 30 min and incubated with anti-deiminated histone H3 rabbit antibody (Abcam, 
ab 5103) overnight at 4°C.  Membranes were washed and incubated with HRP-
conjugated goat-anti-rabbit secondary antibody for 1 h at room temperature, washed three 
times in TBST and twice in TBS alone.  The HRP activity was detected as above. 
 
 
Splenocyte Proliferation Assay 
 
BALB/c mice were boosted twice with 100µg antigen (deiminated histones, 
non-deiminated histones or OVA) 14 and 2 days prior to the splenocyte proliferation 
assay.  Ninety-six well tissue culture plates (Corning Incorporated) were filled with 100 
µl aliquots of 100 µg/ml (or 3 fold serial dilutions) of deiminated histones, non-
deiminated histones, or ovalbumin in RPMI 1640 (Mediatech Inc.) supplemented with 
10% FBS.  Splenocytes were isolated and resuspended in RPMI with 10% FBS at 1x106 
cells/ml.  One hundred µl of cell suspension was added to each well and plates were 
incubated at 37°C in 5% CO2 for 72 to 96 h. Tritiated thymidine (1 µCi/well) was added 
for the last 17 h of incubation.  Plates were harvested onto glass fiber filters and 
thymidine incorporation was assessed by scintillation counting. 
 
Splenocyte proliferation assays for autoimmune mice used splenocytes from 
female (NZBxNZW) F1 mice of different ages purchased from the Jackson Laboratory 
(Bar Harbor, ME).  Following RBC lysis, splenocytes were resuspended in DMEM-10 
media with 10000 U/ml penicillin and 10 mg/ml streptomycin.  One hundred thousand 
cells were incubated with deiminated histones or non-deiminated histones (20ug/ml of 
protein) in triplicate wells.  Tritiated thymidine incorporation (1 µCi/well) was measured 
after 20 h, 3 days or 6 days by liquid scintillation, as described (335, 336). 
 
 
Ex-vivo Tissue Lysate Preparation 
 
Seven-month-old B6.TC female mice and age-matched control C57BL/6 IgHa 
were dissected.  A portion of spleen, bone marrow, kidney and liver was cut, minced with 
scissors and crushed between two sterile frosted glass slides.  Dissociated tissues were 
washed in PBS (without Ca++) and centrifuged at 5000g for 5 min to pellet cells.  Cell 
pellets were mixed with lysis buffer (65mM Tris pH 7.2, 2%SDS, 10% Glycerol), 
containing protease inhibitors.  To test for deiminated histones and total H3 in tissue 
lysates, equal amounts of total protein were analyzed by Western blotting, as described 
above. 
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 Results 
 
 
In-vitro Histone Deimination 
 
For the immunization and immunochemistry experiments, we prepared calf 
thymus deiminated histones by using recombinant PAD4 (274).  The deimination 
reaction reached completion by 24 h (Figure 4-1A), as addition of more PAD4 enzyme 
to the reaction at that time did not increase deimination (data not shown).  We measured 
the generation of 1.67 moles of citrulline per mole of total histones.  Because histone 
H2B is not a substrate for PAD4, we estimate that about 2 citrullines were introduced into 
each modifiable core histone.  Quantitation of citrullines was performed by colorimetry 
(Figure 4-1A).  We confirmed histone deimination by Western blot using antibodies that 
recognize citrullines at the histone H3 amino terminus (Figure 4-1B).  The starting calf 
thymus histone preparation had no detectable citrullines (Figure 4-1B, time = 0). 
 
 
Spontaneously Arising Anti-histone Autoantibodies Bind Non-deiminated Histones 
 
To assess the production of anti-deiminated histones autoantibodies in mice that 
spontaneously develop anti-nuclear autoantibodies (ANA), we tested sera from 
(NZBxNZW)F1 and their recombinant inbred derivative strain NZM2410 for binding to 
non-deiminated histones and deiminated histones.  In addition, we tested the contribution 
of lupus-predisposing genetic intervals Sle1 and Sle3 that were back-crossed from the 
NZM2410 onto the C57BL/6 background (B6.Sle1 and B6.Sle1.Sle3).  Sle1 is a locus 
that breaks tolerance to chromatin, whereas Sle3 affects functions of myeloid cells (53).  
We also tested B6.TC mice, a triple congenic strain that in addition to having the lupus-
predisposing genetic intervals Sle1 and Sle3, also carries the Sle2 interval that results in 
the spontaneous activation and hyperactivity of B cells.  The parental strains, NZB and 
NZW, have distinct MHC, H-2d and H-2z respectively.  The lupus-predisposing H-2z was 
maintained in the NZM2410 mice, whereas the congenics have the H-2b from C57BL/6.  
Antibody binding to deiminated histone and non-deiminated histone was assessed by 
ELISA (Figure 4-2) and Western blot (Figure 4-3 and Table 4-1).  As controls, sera 
from age- and sex-matched C57BL/6 mice were used. 
 
By ELISA, (NZBxNZW)F1 (Figure 4-2A), NZM2410 (Figure 4-2B), B6.Sle1 
(Figure 4-2C), B6.Sle1.Sle3 (Figure 4-2D) and B6.TC (Figure 4-2E) sera showed 
preference for non-deiminated histones over deiminated histones.  This preferential 
binding was statistically significant for (NZBxNZW)F1, NZM2410, and B6.Sle1.Sle3, as 
assessed by a paired, two tailed T-test.  The strength of binding differed for different 
mice and serum dilutions but binding to non-deiminated histones was equal or greater 
than the binding to deiminated histones in all except one B6.TC mouse.  We also 
confirmed the additive effect of Sle1 and Sle3 loci, as the B6.Sle1.Sle3 combination 
resulted in greater absorbance values relative to the B6.Sle1 mice.  In parallel assays, sera 
from C57BL/6 mice (Figure 4-2F) showed no reactivity to histones.  Both deiminated 
histones and non-deiminated histones were present in equivalent concentrations on the  
 72 
 
 
 
Figure 4-1: In-vitro deimination of histones by PAD4 
Calf thymus histones (0.1 mM) were incubated with 0.2 µM PAD4 up to 24 h and 
deimination (in nmoles) was measured by colorimetry at 595nm using a citrulline 
standard solution.  B) Western blot showing deimination of calf thymus histones at 
different time points in a 24 h in-vitro PAD4 reaction using anti-deiminated histone H3 
antibody. 
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Figure 4-2: Binding of IgG from autoimmune prone and control mice to non-
deiminated histones and deiminated histones 
Sera from (NZBxNZW)F1 (A), NZM2410 (B), B6.Sle1 (C), B6.Sle1.Sle3 (D), B6.TC (E) 
and control C57BL/6  mice (F) were tested for IgG binding to non-deiminated histones 
(nH) and deiminated histones (dH).  Complete binding curves were obtained and OD 
values for a single dilution were plotted in panels A to E.  We plotted data from 1:1000 
dilutions in all other than B where data is from 1:200 dilution.  Absorbance values for 
each serum corresponding to IgG binding to dH and nH are shown and are connected by 
a line indicating the pairs of data for the binding of each serum to the two antigens.  
Significance of the readings was tested by paired, two-tailed T-test.  Binding to dH was 
significantly less than to nH for (NZBxNZW)F1 (p<0.0001), NZM2410 (p=0.031) and 
B6.Sle1.Sle3 (p=0.032).  The binding of B6.Sle1 IgG (p=0.203) and B6.TC (p=0.278) 
tended to be lower to dH.  In comparison, control B6 mice showed negligible binding to 
either form of histones (F). 
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Figure 4-3: Western blot of IgG to deiminated histones and non-deiminated 
histones 
Equal amounts of deiminated histones (dH) and non-deiminated histones (nH) were 
resolved on SDS-PAGE, transferred to nitrocellulose, and stained with Ponceau red 
(upper left panel).  The stained bands migrating with the mobilities of core and linker 
histones are indicated along the margins.  Strips of membrane containing nH or dH were 
probed with (NZBxNZW)F1, NZM2410, B6.Sle1, B6.Sle1.Sle3 and B6.TC sera at 1:500 
dilution and developed with anti-mouse IgG-HRP.  Autoimmune prone mice sera bound 
nH in preference to dH.  The experiments were performed at least three times with 
consistent results.  One experiment is shown and was used to derive data for Table 4-1.  
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Table 4-1:  Summary of Western blot analysis 
 
Histone 
Subtype 
(NZB X 
NZW) F1 
(n=7) 
NZM2410 
(n=8) 
B6.Sle1 
(n=8) 
B6.Sle1.Sle3 
(n=8) 
TC 
(n=7) 
Total 
(n=38) 
H3 7 : 1 8 : 4 5 : 0 8 : 4 7 : 0 35 : 9 
H2A 2 : 0 1 : 0 5 : 0 6 : 2 7 : 0 21 : 2 
H4 2 : 0 4 : 0 2 : 0 4 : 0 6 : 0 18 : 0 
H1 1 : 0 1 : 1 2 : 1 5 : 4 6 : 5 15 : 11 
Total 12 : 1 14 : 5 14 : 1 23 : 10 26 : 5 89 : 22 
Results are listed as a ratio of IgG binding to non-deiminated histones: deiminated 
histones.  We set 120% of background intensity as threshold for positive bands. 
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plates, as seen by the nearly identical binding of the LG2.2 mAb (data not shown) whose 
epitope corresponds to first 13 amino acid residues of histone H2B (337). 
  
To examine the preferential binding to non-deiminated histones, we used Western 
blotting.  The stringency of binding was increased by including both SDS (0.05%) and 
NP-40 (0.5%) in the binding buffer.  Indeed, under these conditions, many of the sera 
bound exclusively or with preference to non-deiminated histones relative to deiminated 
histones (Figure 4-3 and Table 4-1).  A variety of binding patterns were observed, 
including exclusive binding to one or two core histones.  Binding to histone H3 was 
observed most often, whereas binding to H4 and H2A were rare.  In addition, binding to a 
band with the mobility of the linker histone H1 was observed in several blots.  Overall, 
binding was biased toward non-deiminated histones over deiminated histones (Table  
4-1), although some IgG binding to deiminated histones was also observed.  To assess the 
possibility that DNA-anti-DNA complexes present in sera contribute to the observed 
histone binding, we treated sera with DNase1 prior to incubation with the histone blots.  
None of the sera tested altered their preferential binding to non-deiminated histones 
following treatment with DNase1, and the immunoreactivity of DNA-depleted sera was  
indistinguishable from untreated sera (data not shown).  Therefore, anti-DNA antibodies 
did not measurably contribute to the observed results. 
 
 
(NZBxNZW) F1 Splenocytes Respond to Deiminated Histones or Non-deiminated 
Histones 
 
To investigate whether splenocytes from autoimmune (NZBxNZW) F1 mice, are 
capable of responding to deiminated histones or non-deiminated histones, we measured 
the proliferation of splenocytes from (NZBxNZW)F1 mice of different ages.  At 6 to 10 
weeks of age, prior to any measurable anti-DNA reactivity, the splenocytes did not 
proliferate in response to either form of histone (Figure 4-4A and B).  At 20 to 21 weeks 
of age, anti DNA autoantibodies could be detected in the sera, and splenocytes 
proliferated in response to non-deiminated histones and deiminated histones (Figure  
4-4C and D).  Thus, splenocyte responses to histones arose in parallel with humoral 
responses to DNA.  Twenty-five-week-old (NZBxNZW)F1 mice with established 
autoimmunity showed splenocyte proliferation in response to deiminated histones and 
non-deiminated histones (Figure 4-4E and F), suggesting the presence of histone-
reactive T cells in the spleens of autoimmune mice.  Although some mice showed a 
tendency to preferentially respond to deiminated histones, others preferred non-
deiminated histones.  Notably, preference could switch, depending on the length of 
stimulation (Figure 4-4E and F), suggesting that growth characteristics of some 
splenocytes may be influenced by deimination.  This suggested that T cell help for B cells 
with receptors to non-deiminated histones and deiminated histones should be available 
following the development of autoimmunity in these mice.  Interestingly, splenocytes 
from BALB/c mice immunized with deiminated histones proliferated vigorously in 
response to deiminated histones yet failed to respond to non-deiminated histones (Figure 
4-5).  Yet, B cells from BALB/c mice immunized with either non-deiminated histones or 
deiminated histones, with or without aTLR7 agonist, showed no response after multiple  
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Figure 4-4: Proliferation of splenocytes from (NZBxNZW)F1 mice 
Splenocytes derived from (NZBxNZW)F1 mice of different ages were tested for dsDNA 
binding by ELISA (A-F).  In parallel, splenocytes were stimulated with deiminated 
histones (dH) or non-deiminated histones (nH) in vitro, as indicated.  Proliferation was 
assessed following 20 h, 3 days and 6 days in culture, and the response was determined 
by [3H] thymidine incorporation.  The results are presented as stimulation indices (SI) 
that were calculated from mean cpm values of triplicate wells.  The significance of 
differences between samples was determined by unpaired T-test and the p values are 
indicated. 
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Figure 4-5: Proliferation of splenocytes from immunized BALB/c mice 
Splenocytes from mice immunized with deiminated histones (A) or non-deiminated 
histones (B) were tested for proliferation in response to deiminated histones (dH) or 
non-deiminated histones (nH).  Two mice were immunized with OVA (C) as control.  
The results are presented as stimulation indices (SI) that were calculated from mean cpm 
values of triplicate wells incubated with respective antigens for 72 -96 hours.  A good 
proliferation response to deiminated histones was seen in splenocytes from mice 
immunized with deiminated histones, whereas splenocytes from mice immunized with 
non-deiminated histones showed low to negligible proliferation. 
  
 80 
immunizations (Figure 4-6). 
 
 
Spleens of Autoimmune Mice Have Increased Levels of Deiminated Histones 
 
In autoimmunity, the chronic inflammation may be expected to induce PAD4 
activation and histone deimination.  To test for the presence of deiminated histones in 
tissues of autoimmune mice, we dissected tissues from B6.TC mice and littermate 
controls.  Lysates of bone marrow, spleen, liver and kidney were probed for deiminated 
histone H3 and total H3.  Out of the 7 B6.TC mice tested, 6 showed detectable amounts 
of deiminated histone H3 in their bone marrow and spleen (Figure 4-7A and B, see box).  
The spleens of B6.TC mice had markedly increased levels of deiminated histone H3 as 
compared to C57BL/6 controls or control cell lysate (Figure 4-7).  The overall amounts 
of histone H3 were similar in all samples, as indicated by the equivalent 
immunoreactivity of an anti-H3 antibody that does not discriminate deiminated histone 
H3 from non-deiminated histone H3.  Therefore, the bone marrow and spleens of 
autoimmune B6.TC mice contained increased quantities of deiminated histone H3.  In 
addition, the kidneys of one autoimmune mouse exhibited increased levels of deiminated 
histone H3 (Figure 4-7C, #12).  Unexpectedly, the bone marrow, spleen and kidney of 
one C57BL/6 mouse showed elevated levels of deiminated histone H3 (Figure 4-7A, B 
and C, #2).  Yet, this C57BL/6 mouse showed no binding to either non-deiminated 
histones or deiminated histones on ELISA (data not shown).  
 
 
Discussion 
 
In this study, we observed that in autoimmune mice, B cells readily produce IgG 
autoantibodies to non-deiminated histones (Figure 4-2 and 4-3), suggesting the 
availability of T cell help.  However, autoimmune mice exhibited a striking B cell bias 
for non-deiminated histones over deiminated histones.  Of all the mice tested by ELISA, 
only one B6.TC showed preferential binding to deiminated histones (Figure 4-2E).  On 
Western blot this serum differed from most others in that it showed equal binding to 
deiminated and non-deiminated H1 while the binding to core histones was reduced.  In 35 
of 35 mice that made anti-histone H3 IgG, preference was invariably in favor of non-
deiminated histone H3 (Figure 4-3 and Table 4-1).  In 19 animals, we failed to detect 
antibodies to deiminated histones by immunoblotting, whereas antibodies to non-
deiminated histones were readily observed (Figure 4-3).  Strongly biased binding to non-
deiminated histones indicates that autoantibody epitopes often (or exclusively) depend on 
arginines that are substrates for PAD4.  This is surprising, as other, non-arginine 
containing epitopes should also be accessible for antibody binding.  These results indicate 
that, even in overt autoimmunity, IgG binding to deiminated histones is suppressed, and 
autoantibody binding is focused on arginine-containing epitopes that are absent from 
deiminated histones.  Deimination itself is unlikely to interfere with antibody binding to 
deiminated histones because autoantibodies to deiminated histones are prevalent in 
patients with Felty’s syndrome (303).  One possible explanation for binding to non-
deiminated histone epitopes in preference over deiminated histones is that deiminated  
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Figure 4-6: B cell response after 3rd immunization using Imiquimod, a TLR-7 
agonist as adjuvant  
Sera from pre-immunized mice (A, D, G) as well as sera after the third immunization 
with imiquimod (C, F, I) or without (B, E, H) were tested against the antigens in the 
legend.  Reactivity to antigens was unchanged before and after immunization in mice 
immunized with deiminated histones (A and B) and non-deiminated histones (D and E).  
With imiquimod as adjuvant, the response to deiminated histones or non-deiminated 
histones was not enhanced, but the binding to poly-L-lysine increased (C and F).  The 
response of ovalbumin (OVA) immunized mice to OVA increased after immunization, as 
expected (H and I). 
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Figure 4-7: Western blot detection of deiminated histones H3 in mouse tissues 
Equal amounts of freshly prepared lysates from bone marrow (A), spleen (B), kidney (C) 
and liver (D) of autoimmune B6.TC and control C57BL/6 mice were blotted onto 
nitrocellulose membranes and probed with anti-deiminated histone H3 (dH3) antibody.  
A total of 12 mice were analyzed in two separate blots and same tissues are grouped 
together for presentation.  Lanes corresponding to B6.TC tissues are highlighted in box.  
As control Jurkat lymphoma cells were used (B).  The same blots were also re-probed 
with an antibody that recognizes total histone H3 (Pan H3) to confirm equal loading of 
lysates.  Bone marrow and spleen of 6 out of 7 B6.TC mice showed presence of 
deiminated histone H3. 
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histones remain effective tolerogens even after development of autoimmunity.The 
striking bias toward non-deiminated histones binding was particularly evident in animals 
containing the lupus susceptibility locus Sle3 (Figures 4-2 and 4-3).  As established by 
Mehrad et al. (53), neutrophils from Sle3 congenics respond more vigorously to bacterial 
infection and release MPO by degranulation.  In response to bacteria or other 
inflammatory stimuli, neutrophils release deiminated chromatin from the cell to the 
extracellular milieu (202, 203).  Deimination indeed may be required for chromatin 
decondensation that accompanies extracellular chromatin release (213).  It has been 
argued that microbes become entangled in this released chromatin and that they are killed 
by MPO and other bactericidal enzymes that associate with the chromatin (201).  
Therefore, this chromatin may act as a neutrophil extracellular trap (NET) that serves to 
contain and destroy microbial pathogens (194).  These findings suggest that NETs are 
important adaptations of innate immunity and that NETosis represents a specific form of 
programmed cell death that is morphologically, mechanistically and functionally distinct 
from apoptosis (196).  The data of Mehrad et al. (53) suggest that genes in the genetic 
interval of Sle3 favor neutrophil activation and subsequent NET chromatin release. 
  
To test the hypothesis that deiminated histones act as tolerogens in autoimmune 
mice, we prepared lysates from tissues of B6.TC and control mice and analyzed them for 
deiminated histone H3.  Spleens and to a lesser degree the bone marrow from 7-mo-old 
female B6.TC mice generally exhibited elevated levels of deiminated histone H3.  The 
kidney from these mice, as well as tissues from control mice, had reduced or background 
levels of deiminated histone H3 (Figure 4-6).  Interestingly, kidney lysates from one of 
the autoimmune mice showed elevated levels of deiminated histones, although it is not 
known whether the increase in deiminated histones was correlated with any aspect of the 
pathogenic process in this mouse.  
 
Our observations suggest a tolerance mechanism that may operate in the spleens 
of autoimmune mice.  Autoimmune mice may generate a chronic inflammatory milieu in 
which neutrophils are more likely to become activated.  In these mice, neutrophils may 
induce histone deimination and become sequestered in the spleen.  The clearance of 
activated neutrophils through the splenic reticuloendothelium is consistent with the 
observed migration of neutrophils to the light zone in the spleen of LPS-treated mice 
(338).  Detection of deiminated histone H3 in the spleens of autoimmune mice is 
consistent with the release of NETs (202).  Should chromatin containing deiminated 
histones be externalized in the spleen, serum nucleases such as DNase1 may degrade it 
into separate nucleosomes.  The effect of the solubilized nucleosomes may be to tolerize 
splenic B cells that express receptors for anti-deiminated histone epitopes.  The only anti-
histone reactive B cells escaping this tolerogen would be those that bind non-deiminated 
histones epitopes, as was observed in our study.  
 
Induction of splenic tolerance by soluble antigen is consistent with earlier studies 
demonstrating the induction of tolerance in germinal center B cells (339, 340).  Mice 
harboring anti-hen-egg-lysozyme B cells respond to an injection of soluble antigen by 
rapid apoptosis of centrocytes (340).  The presence of deiminated histones in the spleens 
of autoimmune mice together with the B cell response targeting non-deiminated histones 
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suggests that deiminated histones act as effective tolerogens in the spleens of 
autoimmune mice.  If so, the ability of soluble nucleosomes to establish tolerance may be 
beneficial in immune responses to microbial infections.  Because NET-ted microbes may 
be engulfed by antigen presenting cells, it may be vital for the organism to respond to 
bacteria that become entangled in NETs, while repressing a response to NET/chromatin 
Ags.  Therefore, it is meaningful to predict that NETs act as signals to enhance the 
immune response to infections, and that effective tolerance mechanisms exist to prevent 
“collateral” responses to NET chromatin.  If peripheral tolerance to deiminated histones 
is preserved in autoimmune mice, our results may suggest ways to re-establish tolerance 
in overt autoimmunity. 
 
 
Conclusion 
 
Autoimmune disorders are associated with ongoing inflammation.  Our results 
show that autoantibodies from lupus prone mice preferentially recognize non-deiminated 
histones over deiminated histones.  Consistent with inflammatory stimuli causing histone 
deimination in neutrophils, we found high levels of deiminated histone H3 in bone 
marrow and spleen of lupus prone mice.  We conclude that the biased autoantibody 
response to non-deiminated histones seen in lupus mice, in spite of the availability of 
deiminated histones antigen indicates effective tolerance against deiminated histones. 
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CHAPTER 5.    DISCUSSION 
 
 
Despite decades of intense research, we do not know the stimuli that trigger the 
production of autoantibodies in systemic autoimmune diseases (341).  The autoantibodies 
themselves have been studied and found to be useful as diagnostics for different 
autoimmune diseases.  For example, autoantibodies reacting against nuclear antigens, 
most notably DNA and histones, are a distinguishing feature of systemic lupus 
erythematosus (SLE), whereas autoantibodies to a citrullinated cyclic peptide (CCP) are a 
reliable diagnostic for rheumatoid arthritis (RA).  A plausible prediction is that the 
careful analysis of autoantibodies will lead to a better understanding of their origins. 
 
The structure of autoantibodies argues that they are selected for improved binding 
to autoantigens.  The genetic mechanisms that give rise to autoantibodies argue strongly 
in favor of this conclusion.  Autoantibody sequences indicate that even though diverse V 
genes code for anti-DNA and rheumatoid factor (RF) autoantibodies in murine models of 
SLE and RA, junctional diversity and somatic mutations make essential contributions to 
binding (342-344).  In consequence, only few B cell clones secure conditions for 
expansion.  The expanded autoreactive B cell clones participate in antigen presentation, 
given that T cell help promotes antibody H chain isotype switching and selects for 
mutations that improve antibody binding to autoantigens.  As result, autoantibodies 
acquire all of the molecular hallmarks of affinity maturation, just as antibodies to foreign 
antigens do (345).  Therefore, the identification of molecular features of autoantigens that 
drive systemic autoimmune diseases holds the key for understanding the pathways that 
stimulate the production of autoantibodies.  
 
 
Post-Translational Modification of Autoantigens  
 
Autoantibodies frequently target post translational modifications (PTM) in self-
antigens (64, 65), including PTM that are introduced during apoptotic cell death (346, 
347).  Thus, PTMs may provide a mechanism for converting innocuous self components 
into targets of an autoimmune response.  PTMs generate “neo- epitopes” that alter 
antigen processing and presentation (348).  One such PTM is the enzymatic conversion of 
arginines in a polypeptide chain to citrullines.  Citrullination, also called deimination, is 
the work of peptidylarginine deiminases (PADs).  PADs are Ca++-dependent enzymes 
that are conserved in all vertebrates (204, 205).  The conserved nature of PADs implies 
an important physiological role.  Indeed, citrullination regulates zygotic development, the 
myelination of neurons, and properties of the epidermis. 
 
PAD4 is the only PAD that has a nuclear localization signal and deiminates 
histones H2A, H3, and H4 (268, 327).  A link exists between PAD4 haplotypes and risk 
of RA.  Alleles linked to an increased susceptibility to RA encode a more stable PAD4 
mRNA than alleles that are neutral for RA (228).  The increased mRNA stability may 
lead to increased expression of PAD4 in individuals bearing the susceptible haplotype.  
An association between deiminated proteins and autoimmune diseases strongly suggests 
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that deimination generates novel epitopes that are able to break tolerance and initiate 
autoimmune responses. 
  
 
PAD4 Action in Neutrophils 
 
PAD4 is most abundantly expressed in granulocytes (349), monocytes (350) and 
mast cells (310).  PAD4 may associate with cytoplasmic granules, but it also enters the 
nucleus where it may participate in gene regulation by deiminating histones (268).  
Deimination transforms a positively charged amino acid (arginine) into a neutral amino 
acid (citrulline), resulting in the net loss of one positive charge per modified residue 
(206).  Therefore, deimination changes not only the primary sequence of a protein but 
also its net charge.  During the reaction, the guanidino group of arginine is attacked by a 
Cys residue of PAD4, resulting in the formation of a tetrahedral adduct (351).  A 
nucleophilic attack by a water molecule then cleaves the adduct to form the keto group of 
citrulline, while releasing ammonia and regenerating the Cys residue of the enzyme (206, 
207).  The net result is the conversion of arginine to citrulline with a mass shift of +1 Da. 
 
The activation of PAD4 in neutrophils is exquisitely sensitive to inflammatory 
stimuli, such as f-MLP, LTA or LPS (202).  In contrast, the induction of neutrophil 
apoptosis blocks PAD4 activation (202).  Whereas senescent neutrophils that were not 
needed to fight an infection die by apoptosis (352, 353), neutrophils faced with 
microorganisms in the course of an infection perform an elaborate form of cell suicide.  
Those neutrophils die by ejecting nuclear chromatin in order to capture, or “trap”, 
microbial pathogens (194).  PAD4 activity precedes and facilitates the release of 
chromatin from neutrophils (203).  In fact, PAD4 is essential for neutrophil extracellular 
trap (NET) release and, in the absence of PAD4, the innate response to bacterial 
infections is impaired (213).  Since the discovery that neutrophils release chromatin in an 
innate response to infections (194), NET release has been reported in responses to 
bacterial and fungal infections.  NET release is triggered by neutrophil encounter with 
Staphylococcus aureus (194) or Mycobacterium tuberculosis (354) and in response to 
exposure to Candida albicans (195) and Aspergillus fumigatus (355, 356).  NETs 
function in trapping and damaging microorganisms and this explains how extracellular 
nucleases produced by bacteria function as virulence factors (309).  The release of NETs 
is linked to various clinical complications of infectious diseases, including bacterial 
sepsis (357, 358) and the increased risk of thrombosis (196).  Interestingly, more serious 
infections and blood clots are known as complications in a number of autoimmune 
disorders (359).  These complications could be linked, in part, to the inopportune release 
of NETs from autoimmune patient neutrophils.  
 
Clearly, NETs deserve wider experimental scrutiny because, in infections (285), 
or in response to adjuvants (312), NETs connect citrullinated histones with strong 
immune stimuli.  This feature of NETs could be instrumental in breaking tolerance and 
inducing an autoimmune response to chromatin antigens. 
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Neutrophil Extracellular Traps and Autoimmunity 
 
That NETs may stimulate autoimmunity follows from discoveries that 
autoantibodies target various NET components.  Autoantibodies from patients with 
systemic autoimmunity may recognize innate immune defense proteins that associate 
with NETs.  This is the case for the major NET components, including the granule 
proteases elastase, cathepsin G and proteinase 3 (235, 236, 238), as well as for various 
bactericidal peptides that are stored in granules and co-purify with NETs, such as 
neutrophil defensins and the LL37 peptide (239, 240).  Separate studies indicate an 
increased abundance of activated neutrophils and increased serum levels of neutrophil 
granule contents in patients with more advanced disease (235, 287).  In addition, the 
severity of lupus may also correlate with the levels of autoantibodies to NET components 
(243).  Thus, lupus autoantibodies target NET-associated proteins in addition to the 
NETs’ structural scaffold, DNA and histones. 
 
Other studies directly point to neutrophil activation as a key factor in the 
stimulation of autoantibodies.  Notably, SLE patients possess neutrophils that are prone 
to NET release (241).  The exacerbated response of neutrophils to lupus autoantibody 
complexes was discovered in studies that used cells from juvenile lupus patients (241).  
In turn, NETs may persist for a longer time in autoimmunity, as SLE patients’ anti-DNA 
antibodies protect NETs from degradation by nucleases (243).  Together, these findings 
suggest that, in SLE, the release of NETs may be more easily triggered by stimuli, NETs 
may induce the production of anti-NET antibodies, and the NET antigens may persist in 
tissues because they are protected by autoantibodies.  Thus, NET antigens and anti-NET 
autoantibodies may be linked in a pernicious pathogenic cycle. 
 
 
Autoantibodies to Deiminated Histones 
 
To initiate our search for autoantibodies to deiminated histones, we collected sera 
from patients with SLE and RA.  In addition, we obtained sera from patients with Felty’s 
syndrome (FS), a disorder that shares features of SLE and RA and is defined by the triad 
of severe arthritis, splenomegaly and neutropenia.  FS arises in 1-3% of RA patients after 
an extended period of incompletely mitigated disease (254, 360).  FS patients experience 
severe destructive arthritis and develop extra-articular manifestations including rheumatic 
nodules and vasculitis (361).  Neutropenia is thought to be associated with an intense and 
ongoing autoimmune reponse to neutrophil surface antigens. 
 
Experiments suggest that neutropenia in FS follows from autoimmune etiology 
rather than a production defect.  In mice infused with the sera or isolated immune 
complexes of FS patients, neutrophil counts drop precipitously, suggesting autoimmunity 
as the mechanism (362).  Both immune complexes and soluble antibodies from FS 
patients bind neutrophils and mediate their sequestration in the spleen (363).  The spleen 
of FS patients exhibits an expansion of red pulp, sinus hyperplasia, macrophage 
infiltration, and prominent germinal centers (364).  These hallmarks of increased splenic 
activity indicate that clearance of activated neutrophils by the spleen may promote FS.  
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Interruption of the self-sustaining autoreactivity by removal of the patient’s spleen 
restores neutrophil counts, arguing that the spleen provides a sink for neutrophils in FS 
(364).  Thus, it is reasonable to argue that autoantibodies against neutrophil antigens in 
FS drive neutropenia by splenic sequestration of neutrophils.  To understand FS, it will be 
important to identify the neutrophil targets of autoantibodies. 
 
There are three observations that suggest histone deimination during neutrophil 
activation as a possible pathogenic mechanism in FS.  First, FS patients score positive for 
binding to the cyclic citrullinated peptide, a screening test that identifies 77% of FS 
patients (365, 366).  Second, a remarkably high percentage of FS patients have 
autoantibodies to histones, and reports indicate that over 80% of FS sera contain anti-
histone IgG (246).  Third, there is sequestration of activated neutrophils in the spleen that 
may, over time, induce autoantibody production against neutrophil antigens.  Because we 
hypothesized that stimulation of neutrophils in FS would lead to PAD4 activation and 
histone deimination, and because FS patients make anti-histone antibodies, we decided to 
test FS patient sera for IgG to deiminated histones. 
  
To test for the presence of antibodies to deiminated histones, we reacted histones 
from calf thymus with recombinant PAD4 to completion.  To compare sera from different 
autoimmune disorders (FS, RA and SLE), tests were performed at equal IgG 
concentrations.  ELISA for deiminated and non-deiminated histones revealed that 
majority of FS sera contained IgGs that bound deiminated histones with preference over 
non-deiminated histones.  In contrast, all 37 RA sera, except 2, showed nearly equal 
binding to deiminated and non-deiminated histones.  Using Western blots, we probed the 
binding of antibodies to individual histones.  Deiminated H3 was the major target 
autoantigen, although binding to other core histones was also observed.  In some cases, 
IgG preferentially bound non-deiminated H2A, H4 and linker histone H1.  
 
Overall, ELISA and Western blot results were in agreement, although some serum 
samples showed preferred binding to deiminated histones by only one of the methods.  
The difference arose because of strong binding of antibodies to both antigens on Western 
blot was recorded as preferential binding by ELISA.  In addition, multiple reactivities 
could be distinguished by Western blot that could cancel each other by ELISA (e.g. 
antibodies against deiminated H3 and non-deiminated H4).  In one case, an SLE serum 
showed remarkable preference for deiminated linker histone H1 by Western blot, yet 
ELISA showed no preferential binding because H1 was only a minor component of the 
calf thymus core histone preparation used in coating the plates.  Western blots also 
detected slight preference for deiminated H3 in several RA samples.  We concluded that 
this weak binding was due to cross-reactivity between antibodies to CCP and citrulline 
residues on deiminated H3 (367). 
 
The difference between FS and RA samples is remarkable and argues that 
neutropenia in FS may be activation-induced neutropenia.  Neutropenia is also a known 
complication of SLE [85], suggesting why some SLE sera showed preference for 
deiminated histones.  Autoantibodies to deiminated histones, an antigen that is produced 
during neutrophil activation represents strong evidence that NETs contribute to 
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autoimmunity in FS.  As neutrophils are involved in responses to infections, our findings 
suggest a novel path whereby sustained infection may lead to autoimmunity.  Neutrophil 
activation and NET formation are also induced by inflammatory cytokines, suggesting 
how one might arrive at a positive feedback loop that is the hallmark of autoimmune 
disorders. 
  
 
Lupus Mice Do Not Make Antibodies to Deiminated Histones 
 
As (NZB X NZW)F1 mice make anti-chromatin autoantibodies and have higher 
levels of Type 1 IFN (368) that predispose for NET formation (241), we tested sera from 
(NZB X NZW)F1 mice and the recombinant inbred New Zealand Mixed NZM2410 
strain for the presence of anti-deiminated histone antibodies.  We also tested sera from 3 
congenic strains that were derived by backcrossing lupus predisposing genetic intervals 
of NZM2410 mice on a B6 background (369).  Studies have shown that the Sle1 genetic 
interval promotes production of anti-chromatin antibodies (49, 50) while the Sle2 interval 
is responsible for a defect in B cells and renders them hyperactive (51).  The Sle3 genetic 
interval results in hyperactivation of myeloid cells (53).  Neutrophils from B6 mice 
harboring the Sle3 interval respond vigorously to bacteria by degranulation (53).  We 
intended to establish if these autoimmune mice make autoantibodies to deiminated 
histones by screening sera from these autoimmune mice for reactivity to deiminated 
histones.  The comparison between different mouse sera also could reveal which genetic 
element, if any, contributes in autoimmune response against deiminated histones.  Both 
ELISA and Western blot demonstrated that spontaneously arising autoantibodies in the 
autoimmune mice we tested recognize non-deiminated histones over deiminated histones.  
The preference for non-deiminated histones became more evident on Western blot where 
almost all the mouse sera bound histones with preference over non-deiminated histones.  
In 24 out of 35 sera no binding to deiminated histones could be detected, whereas 
antibodies to non-deiminated histones were easily observed.  This argues that B cell 
responses in autoimmune mice are preferentially targeted against epitopes that contain 
arginines.  For the majority of these sera, deimination of arginine to citrulline reduced 
binding to histones. 
 
 
Splenocytes of Autoimmune Mice Respond to Both Deiminated and Non-deiminated 
Histones 
 
Splenocytes from (NZB X NZW)F1 autoimmune mice of an age when 
autoimmunity manifested as indicated by the emergence of anti-dsDNA antibodies 
proliferated in response to deiminated and non-deiminated histones.  Splenocyte 
proliferation in individual mice was biased to either non-deiminated or deiminated 
histones indicating that deimination of arginine to citrulline affects recognition of 
proteins by splenocytes.  In individual mice, the proliferation was stimulated more by 
non-deiminated histones but in some the response later switched to deiminated histones.  
This suggests that the growth characteristics of some splenocytes may be influenced by 
deimination.  Possibilities for a biased response to deiminated vs. non-deiminated 
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histones may include differences in processing and presentation of the two antigens.  
Proteolytic processing of proteins is a prerequisite for MHC loading.  Though many 
proteases of the lysosomal compartment have overlapping activity, certain proteases are 
specific for digesting and presenting specific proteins.  For example, tetanus toxin C 
fragment (TTCF) is specifically cleaved by asparaginyl endopeptidase (248).  
Consequently, APCs treated with inhibitors of asparaginyl endopeptidase, and not other 
protease inhibitors, have reduced presentation of TTCF antigen (248).  With regard to 
deiminated histones, cleavage by neutrophil proteases may shift position relative to non-
deiminated histones.  Neutrophils express cathepsin H (249), a lysosomal cysteine 
proteinase involed in antigen presentation (250).  Cathepsin H recognizes arginine as its 
major cleavage site.  Neutrophils also express trypsin, a protease that cleaves proteins at 
carboxy terminal of arginine.  Thus, by deiminating arginine to citrulline, the loss of a 
cleavage site on histones may result in different peptide fragments.  Differences in 
presentation may influence T cell central tolerance and B or T cell activation in the 
periphery.  As splenocytes from (NZB X NZW) F1 mice proliferated in response to both 
deiminated and non-deiminated histones, we suggest that MHC presentation of 
deiminated histones is intact in lupus prone autoimmune mice. 
 
The paucity of antibodies to deiminated histones despite the presence of 
splenocytes that respond to deiminated histones suggests that B cells are tolerant of 
deiminated histones even in autoimmune mice.  Theoretically, the B cell repertoire is 
very large.  It is estimated that B cells can make receptors of more than 1011 specificities 
(370).  Thus it is highly likely that B cells from (NZB X NZW) F1, NZM2410 and 
congenic autoimmune mice have B cells that can recognize histone epitopes with 
citrullines.  The fact that such B cells either fail to develop or are not activated by 
deiminated histone antigens, or fail to respond even in an inflammatory environment 
where autoantibodies to non-deiminated histones are readily produced, argues for B cell 
tolerance to deiminated histones.  
 
B cell tolerance to self-antigens is induced either during development or in the 
periphery (371).  During development, B cells that express self-reactive BCRs undergo 
receptor editing which has an increased likelihood of a change in affinity of binding to 
self-antigens (372, 373).  B cells that still express a self-reactive BCR are deleted from 
the repertoire, although notable exceptions have been observed (374).  As result of 
tolerance, a majority of self-reactive B cells can be prevented from populating the 
periphery.  Some self-reactive B cells that escape to periphery are kept in a state of non-
responsiveness or anergy.  Essentially contact with self-antigens in absence of 
engagement by helper T cell or TLR ligands results in B cell anergy (375). 
 
 
Presence of Deiminated Histones in Lymphoid Organs of Autoimmune Mice 
 
In search of putative tolerogens, we probed tissue lysates from primary and 
secondary lymphoid organs of B6.TC congenic with an antibody to deiminated H3 and 
compared the results with control C57BL/6 mice.  We found that both bone marrow and 
spleen of B6.TC mice have higher levels of deiminated H3 than the controls.  This 
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suggests that B cell tolerance to deiminated histones may be maintained by presence of 
deiminated histones both at developmental stages and in the periphery.  Since we have 
used whole tissue lysates for our analysis, we do not know the cellular source of 
deiminated histones or how they are presented to B cells.  Overall, our results indicate 
that high levels of deiminated histones in autoimmune mice negatively influence B cell 
responses to deiminated histones.  How deiminated histones induce tolerance or what 
precise mechanisms are involved in tolerance to deiminated histones need further 
investigation.  
 
 
B and T Cell Responses in BALB/c Mice Immunized with Deiminated Histones 
 
Immunization with deiminated fibrinogen in DR4-IE transgenic mice was able to 
induce arthritis characterized by synovial hyperplasia and ankylosis (376).  BALB/c mice 
immunized with deiminated fibrinogen in presence of Freund's complete adjuvant 
produced an antibody response to deiminated fibrinogen but not to non-deiminated 
fibrinogen (377).  By immunizing BALB/c mice with deiminated histones in the presence 
of different adjuvants, we tested whether deimination itself is sufficient in inducing 
antibody responses against histones.  Immunization with both deiminated and non-
deiminated histones failed to induce antibodies to histones even after multiple 
immunizations.  That either form of histones failed to induce any B cell response in the 
presence of adjuvants like LPS or Imiquimod, a TLR7 agonist, suggest active tolerance to 
histones with or without deimination. 
 
The splenocytes of BALB/c mice immunized with non-deiminated histones when 
incubated with either form of histones showed poor proliferation response similar to that 
observed with media alone.  The splenocytes from mice immunized with deiminated 
histones showed increased proliferation in response to both deiminated and non-
deiminated histones.  Previously Hill et al have found that deiminated peptides are 
presented better by MHC molecules of DR4-IE transgenic mice (224).  Similarly, we 
found increased proliferation response in presence of deiminated histones suggesting that 
deimination influences antigen processing and presentation to T cells.  The fact that mice 
immunized with deiminated histones, in spite of having splenocytes that may respond to 
deiminated histones, still showed no B cell response to histones indicate strong B cell 
tolerance to histones that is not affected by deimination. 
 
 
Deiminated Linker Histones in Neutrophils 
 
Linker histones bind linker DNA at entry and exit points of nucleosomes, thus 
condensing chromatin into a compact structure (378-380).  H1 has multiple isoforms all 
of which have similar structural features; they are composed of a central globular domain 
flanked by a long lysine rich C-terminal domain tail and a short N-terminal region (381).  
PTMs, particularly phosphorylation on the C-terminal tail of H1 during different stages 
of cell cycles are important for chromatin remodeling (382).  The globular domain of H1 
also binds chromatin and is involved in protecting it from nuclease digestion (383, 384).  
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Specific interactions of this domain with nucleosomes may influence the structural 
geometry of chromatin as well as gene expression (385-387).  The globular domain of H1 
contains positively charged residues that interact with nucleosomes through two distinct 
binding sites.  Strong contribution to binding at the first site in histone H1.0 comes from 
residues: His 25, Arg 47, Lys 69, Lys 73, Arg 74 and Lys 85, whereas for second smaller 
site contribution to binding was by Arg 42, Arg 94 and Lys 97 (318).  In all these 
positions introduction of a negative charge by replacement of one of these residues with 
glutamic acid reduced binding, while introduction of residues with a positive charge 
resulted in near similar or higher binding (318).  All somatic subtypes of H1 have 
arginine residues in or near the DNA binding region of globular domain (297).  With 
conversion of positively charged arginine to neutral citrulline deimination results in a net 
loss of charge that may affect its interactions with linker DNA.  Formation of NETs 
during neutrophil activation requires rapid changes in chromatin structure.  Deimination 
of histones is considered essential for release of NETs as neutrophils deficient in PAD4 
are also deficient in making NETs (203).  That the primary function of linker histones is 
to keep chromatin condensed, that deimination is essential for NET release, and that 
deimination may alter interaction between H1 and DNA, prompted us to investigate if 
linker histones in neutrophils are deiminated. 
 
By extracting total RNA from circulating neutrophils we assessed mRNA 
expression for different H1 subtypes on a microarray chip.  Among the different subtypes 
H1.4 was highly expressed in neutrophils and its expression levels were about 4-5 fold 
more than H1.0 that has the second highest expression levels.  The expression levels for 
H1.1, H1.3 and H1.5 were low and below the housekeeping gene HGPRT used as control 
whereas H1.2 was expressed at intermediate levels between HGPRT and H1.0.  We 
chemically extracted H1 from neutrophils treated with ionophore in presence of Ca++ 
and found deimination of H1 both by probing it with Anti-Cit (modified) Ab by Western 
blot and also by Q-TOF Mass Spectrometery followed by MSMS where we identified 
peptides with characteristic +1 Da mass shift of arginine converting to citrulline.  We 
identified deiminated peptides that are unique to H1.0 and H1.5 or shared between H1.2, 
H1.3 and H1.4.  We also identified peptides with unique sequences corresponding to 
H1.0, H1.2, H1.4 and H1.5 indicating the presence of these H1 subtypes in neutrophils.  
With these results we identified linker histone H1 as a substrate for deimination.  How 
deimination of H1 affects its interaction with DNA and what role, if any, deimination of 
H1 plays in NET formation will require further studies.  
 
 
Autoantibodies to Deiminated Linker Histones 
 
As antibodies to H1 are present in large number of SLE patients, we tested SLE 
sera for the presence of anti-deiminated histone H1 antibodies by using in-vitro 
deiminated recombinant H1.2.  Only 2 of 24 SLE samples showed preferential binding to 
deiminated histone H1.2 over non-deiminated H1.2 with Western blot.  One of the SLE 
serum sample, SLE6, showed more than 8 times preference for deiminated H1.2 over 
non-deiminated H1.2 by Western blot and we further used this serum to characterize 
autoepitope on H1.2.  Two synthetic 16mer peptides containing citrulline in the position 
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R32 and R53 of H1.2 were prepared for competition with deiminated H1.2 to binding to 
SLE6 autoantibodies in Western blot.  The assay showed that the peptide R53Cit 
competes more effectively for binding to deiminated H1.2 than R32Cit, indicating that 
deimination of Arg53 occurs within the SLE6 epitope.  Arg53 of H1.2 shows sequence 
homology with Arg42 of H1.0, which is known to be a DNA binding residue.  Mutation 
of Arg42 to glutamic acid on H1.0 which shares sequence homology with Arg 53 of 
H1.2, decreased DNA binding (318).  A similar effect can be deduced for its conversion 
to citrulline that is also neutral in charge. 
 
We also tested serum samples from 20 patients each of Sjogren’s syndrome, 
Scleroderma, and RA for presence of anti-deiminated H1 antibodies.  We also included 
samples from FS patients that have earlier showed some preferential binding to 
deiminated calf thymus H1 in our survey.  The FS sera showed slight preference to 
deiminated H1.2 over non-deiminated H1.2 (binding ratio of deiminated histones/non-
deiminated histones: 1.2-1.3) but this was much less than expected from the Western blot 
using calf thymus histones.  This may be due to the fact that antibodies are reacting more 
to calf thymus histones recognize a H1 subtype other than H1.2 or perhaps different 
adjoining sequences of calf thymus and human H1.2 are responsible for difference in 
binding.  While testing other autoimmune disorders for the presence of anti-deiminated 
histone antibodies we found only 1 out of 20 Sjogren’s syndrome patients’ samples that 
showed preferential binding of autoantibodies to deiminated H1.2.  Rest of the Sjogren’s 
syndrome samples and also the samples from Scleroderma and RA patients did not 
discriminate between binding to deiminated and non-deiminated histone H1.2.  We 
conclude from our screening that antibodies to deiminated histone H1 occur rarely in 
systemic autoimmune disorders. 
 
 
Inferences from Human and Mice Antibody Response to Deiminated Histones 
 
Deimination of histones in neutrophils occurs in response to inflammatory stimuli 
(202) and consistent with this we found elevated levels of deiminated histones in 
circulating neutrophils of RA patients as compared to controls.  Increased neutrophil 
activation is also reported in SLE patients where increased levels of Type 1 IFN prime 
neutrophils to make NETs (240, 241).  Increased levels of neutrophil NETs in SLE 
patients are associated with release of immunostimulatory self-peptides and nuclear 
autoantigens (242).  When sera from patients with RA, SLE and FS patients were tested, 
we found that the majority of FS patients have antibodies to deiminated histones, whereas 
only a small minority of patients in RA and SLE make anti-deiminated histone 
antibodies.  Both RA and SLE patient sera bound histones on ELISA and Western blot 
but their binding was not much affected by histone deimination.  This implies that 
deiminated residues do not affect the binding of a majority of RA and SLE anti-histone 
autoantibodies.  The preference for deiminated histones by autoantibodies in FS, a 
disorder characterized by destruction and sequestration of neutrophils in the spleen (364), 
suggests that deiminated histones released from neutrophils may be involved in the 
autoimmune process of FS.  Although, the majority of RA sera recognize deiminated 
antigens, in our assay only a few sera showed higher binding to deiminated histones.  The 
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facts that FS occurs in patients who have long standing RA, that anti-deiminated histone 
antibodies are found in majority of FS rather than RA patients and that antibodies to other 
deiminated proteins arise early in RA patients, suggest that while deimination enhances 
immune reactivity to many proteins, a response to deiminated histones is not easily 
induced.  
 
Our results from the study of various lupus prone and control mice support the 
idea of strong tolerance to deiminated histones.  On screening sera from lupus prone mice 
that readily make autoantibodies against chromatin including histones, we found that 
autoantibodies in these mice have much higher preference to non-deiminated histones 
than deiminated histones.  We found increased levels of deiminated histones in bone 
marrow and spleen of autoimmune B6.TC mice which come presumably from 
neutrophils activated with higher Type 1 IFN levels (241, 368) together with ongoing 
autoimmune injury seen in these mice.  Although the exact mechanisms of tolerance to 
deiminated histones are unknown, the fact that we found antibodies to deiminated 
histones only in FS, a severe variant of arthritis occurring in patients with long standing 
RA, suggests that unusual circumstances are needed to elicit such autoantibodies.  The 
inability of BALB/c mice to make antibodies to deiminated histones when immunized 
with excess of deiminated histones suggests that this is indeed the case.  There can be 
serious consequences for health in case tolerance of deiminated histones is compromised, 
a component of NETs released during innate neutrophil response to infections (194, 285).  
This is evident in case of FS where we found antibodies to deiminated histones and 
which differs from RA in having severe arthritis, extra-articular manifestations and a high 
susceptibility to infections due to lower neutrophil counts. 
 
 
Model of Autoimmune Pathogenesis in Felty’s Syndrome 
 
We propose the following model of FS pathogenesis based on the biological 
properties of neutrophils, our data on the high incidence of autoantibodies to deiminated 
histones, and the disease progression in FS (Figure 5-1).  The diagram connects the 
clinical observations that characterize FS, for example the pre-existing arthritis, 
neutropenia, splenomegaly and an increased incidence of infections, with the neutrophil 
response to infections and inflammation.  In these circumstances, neutrophils induce 
histone deimination and expel chromatin from the cell.  NETs containing deiminated 
histones, in complex with bacterial adjuvants, are the most likely antigenic trigger to 
account for the production of autoantibodies to the modified histones.  These 
autoantibodies, similar to other ANCA, may further stimulate neutrophils, thus 
completing a cycle that is self-sustaining and drives depletion of mature neutrophils.  
Clearly, our model is simplified and incomplete, as our data from other autoimmune 
disorders imply.  Even though SLE patients may exhibit increased neutrophil activation 
and neutropenia, we failed to detect a high incidence of antibodies to deiminated 
histones.  Thus, one might suspect that tolerance mechanisms prevent the development of 
autoantibodies to deiminated histones and only sustained immune stimulation breaks this 
tolerance.  What factors break tolerance to deiminated histones in FS remains to be 
determined.  Nevertheless, the increased severity of FS as compared to RA, with its 
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Figure 5-1:  A model of autoimmune pathogenesis in Felty’s syndrome 
Diagram shows proposed relationships between clinical manifestations and disease 
mechanisms.  For details, see text. 
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rapidly progressing arthritis, extra-articular manifestations and life threatening 
neutropenia, clearly indicate the need to identify the pathogenic mechanisms of FS. 
 
 
Future Directions 
 
An increased expression of PAD4 mRNA is observed in RA patients and they 
have increased titers of anti-CCP antibodies.  Our results that antibodies to deiminated 
histones are predominantly present in FS patients, a severe variant of RA with 
splenomegaly and neutropenia; and only infrequently in RA and SLE patients highlight 
how autoimmunity against deiminated histones contributes to progression of RA to a 
more severe and crippling form.  Anti-deiminated histone antibodies are the first in the 
group of known ACPAs where the process of deiminated antigen release can be assumed 
to be activated neutrophils (202).  Further research needs to be done to better understand 
the relationship between neutrophils, PAD4 and autoimmunity.  A detailed study is 
needed to understand how and when these antibodies arise; and how they contribute to 
disease manifestations.  Many studies have found ACPA to be associated with increased 
severe arthritis in RA.  As FS mostly occurs in patients with long standing RA (254, 
360), further studies aiming to correlate the emergence of anti-deiminated histones 
antibodies with onset, duration and progression of FS in RA patients will help to 
understand autoimmune responses against this deiminated antigen. 
 
Certain MHC haplotypes such as HLA-DRB1*04 associate with ACPA positive 
RA (388) and studies have shown that deiminated pepties preferentially bind such MHC 
molecules (224).  Research into FS MHC haplotypes associated with anti-deiminated 
histone antibody response will provide further insights into the development of 
autoimmunity to deiminated histones.  If an association exists between the development 
of anti-deiminated histone antibodies and particular MHC haplotypes, then it might be a 
good screening test for identifying RA patients at risk for developing FS.  A standardized 
anti-deiminated histone IgG ELISA may be developed to monitor such patients and RA 
patients making anti-deiminated histone antibodies might be ideal candidates to for 
therapeutic intervention with PAD4 inhibitors.  
   
Clinically related to FS is LGL leukemia, in which patients suffer from 
neutropenia and arthritis similar to, seen in FS (389, 390).  Such similarities have led 
many to believe that FS and LGL belong to the same spectrum of diseases and share 
common pathological mechanism (255, 390, 391).  Because we found that anti-
deiminated histone antibodies are predominantly present in FS patients, we propose that 
screening LGL patients for these antibodies will be a good way to test whether etiology 
of LGL is as similar to FS as its clinical features.  A key difference between LGL and FS 
is in the mechanism of neutropenia.  In LGL neutropenia is supposed to occur due to 
production defect as bone marrow become infiltrated by leukemic lymphocytes (392, 
393) that outcompete myeloid cell precursors or induce apoptosis during development 
(394).  On the contrary neutropenia in FS is due to sequestration of mature activated 
neutrophils in the spleen (363, 364, 395).  As deimination of histones in neutrophils is 
seen on activation, we hypothesize that anti-deiminated histone antibodies will be present 
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in FS but not in LGL patients.  Thus, simple ELISA and Western blot for the presence of 
these antibodies in LGL patient sera will provide useful information to discriminate 
between these two disorders. 
 
Another important area of potential research is to investigate and understand the 
role deimination of histone plays in neutrophil biology.  So far the only role suggested for 
histone deimination is in facilitating neutrophil NETs (203).  Yet the mechanism how 
deimination plays a role in unraveling chromatin is not understood well.  With conversion 
of positively charged arginine to neutral citrulline there is a possibility of decreased 
interaction between DNA and histones.  Careful characterization of interactions between 
DNA and histones is needed to understand whether this mechanism is involved in the 
release of NETs.  We have also identified that linker histones, responsible to maintain 
compact chromatin structures in cells, are substrate of PAD4 induced deimination in 
neutrophils.  We identified deimination at Arg 53, a residue reported to interact with 
DNA.  Future studies on the effect of deimination on interactions linker histones and 
linker DNA will be important in elucidating the mechanism of NET formation. 
 
A related role of deimination in loosening chromatin might be seen while 
transmigration of neutrophils to the site of inflammation.  Neutrophil influx into inflamed 
sites is preceded by rolling, adhesion to vessel endothelium and then diapedesis through 
the cell junctions (396).  The ability of neutrophils to squeeze themselves through tight 
junctions of endothelium requires highly plastic nuclei.  One possible way to achieve this 
is by deiminating histones so as to loosen chromatin.  The fact that arthritic joints of RA 
patients are infiltrated with neutrophils (397) and that neutrophils of RA patients show 
high expression of PAD4 mRNA (228) support this thought.  It is possible that increased 
PAD4 activity allows for increased neutrophil infiltration in joints of RA susceptible 
individuals and cause increased inflammation in response to even minor trauma.  
Whether this is true could be ascertained by in vitro transmigration experiments with 
human donor neutrophil in presence of PAD4 inhibitors or by comparing neutrophil 
influx after inducing sterile peritonitis in PAD4 deficient and control mice.  Presently, 
neutrophils are known to deiminate histone to make NETs in response to inflammatory 
stimuli (202).  If deimination indeed helps in transmigration of neutrophils then an 
important question will be to identify a stimulus that induces just sufficient deimination 
of histones in neutrophils that facilitates transmigration and yet allows normal neutrophil 
function rather than NET formation.  Other interesting questions like what role do 
deiminated histones play in NETs needs to be investigated in future.  Recently, NETs and 
excess of histones have been shown to promote thrombosis (307).  What role deimination 
plays in increasing thrombosis has not been investigated.  As deiminated histones are 
released during neutrophil activation, it is important to investigate how they interact with 
other self-proteins.  
  
Numerous reports of autoimmune responses against deiminated non-nuclear 
proteins have strengthened the notion that deimination, a PTM that accompanies 
inflammation or differentiation, might lead to autoimmunity by generating ‘neo-
epitopes”.  In our attempt to understand the contribution of deimination in promoting 
autoimmunity we found that autoimmune responses against deiminated histones occur 
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rarely.  Screening of sera from FS SLE, RA, SS, Scl and ANCA vasculides patients 
revealed that only FS patients have anti-deiminated histone autoantibodies.  Other studies 
have pointed to increased levels PAD4 enzyme and deiminated proteins in RA.  Also, 
SLE patients have preponderance of anti-histone autoantibodies and lupus pathogenesis 
promotes neutrophil activation and NET formation.  Still, our results show that the sera 
from SLE, RA and many other autoimmune patients do not prefer deiminated histones.  
Consistent with human studies, sera of autoimmune lupus prone mice preferred non-
deiminated histones.  While deimination promotes antigen recognition for many non-
nuclear proteins, the rarity of autoantibodies against deiminated histones suggests that 
development of autoimmune responses against important nuclear antigens is protected. 
 
As FS is considered to be a severe variant of RA, the work in this dissertation 
opens up several interesting questions relevant to understanding of autoimmune process 
in FS and RA.  Studies to identify RA patients at risk of developing FS will help in 
understanding autoimmune responses against deiminated histones.  Our results show 
robust tolerance to deiminated histones in RA and SLE patients as well as lupus prone 
mice.  Future studies might identify mechanisms of tolerance to deiminated histones 
which can be applied to modulate autoimmune response against other autoantigens.  Our 
current study also provides opportunities to further investigate neutrophil function of 
transmigration and NETosis, so that these important mechanisms involved in innate 
defense can be understood better.  Detailed understanding of neutrophil function in health 
and disease is required to devise better strategies for fighting infections while preventing 
potential adverse consequences of uncontrolled neutrophils activation such as thrombosis, 
sepsis and autoimmunity.  
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